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CHAPTER I
INTRODUCTION
It is the purpose of this thesis to develop a course of
study for pharmacy schools on drug regulation by the Food
and Drug Administration (FDA).

A summarization of the

history of the development of the Food and Drug Administration
(FDA) and of pharmacy education reveals a lack of interface
· between the two.

The necessity for the interface of phai·-

macy education and the agency which has significant control
over the products forming the basis of the pharmacy profession will be made apparent.

A period of residency through

which the course of study on drug regulation by the :F.DA was
to be developed, will be described.

This description details

the responsibilities and functions of the various segments
of the FDA involved in the regulation of drugs as acquired
through discussion with agency officials during the residency.
It is intended to be used as the textual material for the
didactic portion of the course of study to be offered at
schools of pharmacy.

Based upon the experience, recommen-

dations will be made regarding the applicability of the course
of study to include possible residencies for pharmacy students
at the agency.
Development of the Food and Drug Administration
Affecting every American, the Food and Drug Administration

1

2
(]'DA) has broad responsib:Lli ties e.s a consumer protection
agency.

The FDA furwt:i.on'3 to protect the public health

llnd welfaxe by insuring that:

.food is safe, pm:-e, and

wholesome; human and animal d:eugs, biological prc,d:c:.cts and
therapeutic devices are safe ru.1d effective;

eor,me~;:i.cs

harmless; radiological products and their use do not

are
re~1ult

in unnecessary exposure to radiation; any food, drug, device,

or cosmetic that :Ls adulterated or misbranded is prohibited
from introduction into interstate commerce (1).
The FDA 1 s mission is an important one, but the absolute
enforeement of the above is almost impossible, considering
the nwnber of food, drug, and cosmetic products ·that are on
the

rrt8J:•J!.~~';.;i:;

today,.

IJ•o augment its X'Ggula.i;c•:ey Eieti yj:t;i6S ~

e.gen.cy vJor}\:s· to as;;}ure that the

mai-J.LLfc:tctuT~.trs

i;ht~~

have g<jocl

quality control measures so that they will hasc

tiv~

<<b:Uity

to ·identify problems that may occv.x·. _ 'l'he. e:;cpQilsi,o:Q of the
industry han led to continual increases :i.n the size of' the
J!'DA and rramber . of ree;ulations.

In the thirty-four years

beh1een 191J.O m1d 1974, the number of employees has increHs&d
from seven hundred to over six thomwn.d.

To obtain better

pm·spec.tive as to the fm1ct.j.ons performed :t;odc.-1y by the D.gcncy,
au

u.~d,,,rs1;anding

of the development of leg:lslat;:lon C3:·ea:i;:i.ng

At the turn of the t\rJentieth centm:oy, the p:c·edecessci'
of the ]'ood and Drug Administration came into existence,
~'he

formation of the agency was prompted by the industriaJi ...

zation of thi.s cotmtry, bringing with it the mass production

3
of foods and drugs.

Their wide distribution,_ coupled with

the f'act that many people were moving from the farm to the
.cities end becoming de1)endent upon processed foods, accen.,tuated the inadequacies in their formulation, production,
and handling (~:).

Much of the legislation concerning the

-FDA was written in attempts to correct totally intolerable

situations - even tragedies - exemplifying the lack {)f concern for food and drug regulation in the past.
The d.l:'iving f'orce behind the legislation creating the
agencJ's predecessor came from the chief of the Bureau of
Chemistry in the U.S. Department of Agriculture at the time,
Dr. Ha.rvey Wiley.

Dr. viiley was an advocate of pure and

wholesomf' food ;.md became ve:ey interested in the problems
"
0 ,;..

fc>co'
,
'1 '·

cer·tair.~.

011
t·tl',
.
. "'

..

•

·u"":.~,
't .r.u.. ,\:'-_-e-~I'l~c
lo .; .(.;4 E::;: ~

Tr1
--

19('J"h··\:,;: 1:)l.:;.,~_,t.:.....
~,:)···:t·n
·• l:.. l

1 -~+J. ':1'"--''t·-~·..-.a
-·--1-~~~
.L!.
'f ,-_.~.--;.
~~ -t:_Jc~ •-l.l..to

acldi ti:'ire.s in commo:n usC1 for food p:r-ese.r:vation to

determine their ef'fects on humans.

His group oi' young,

heeJ.t;hy malo volunteers were fed a normal diet containi:ng

the preservative 1.n question.

Tho :press became int;erested

in the experiment, labeling the group "The Poison Hquad",
aiJd printing in.fo:rm;;rtion
basis :in f'act;.

~lhich,

fo:P the most: ptou:t, had little

This created problems bet1·1een Wiley and the

Secretary of Ag:ricul twre, J"ameH \vilscm, who ordered the
projec.-t; to be discont:inued.

The Congress and PreB:i.den-G TheodorE'

Hoosevelt; also 11e.re concerned over the publicity and
e:>..'1Jeriments should be discontinued.

Dr. Wiley,

fel-~

ho~Tevex-,

t;he
still

very much concerned over the health hazard, continued the
studies.

He took the press into his confidence, releal>ing

reports as they became available (3).
In 1906, Congress developed stronger interest in Wiley's

experiments and held_hearings on the subject.

The

revealed that many foods and drugs were misbranded
adulterated.

hea~ings

~~d

Additionally, the hearings revealed that many

of the chemical preservatives used were unnecessary, except
in the transportation of perishable foods.

This information

prompted the introduction of the Pure Food and Drug Act of
1906, one of the earliest measures by the Federal government
to regulate interstate and foreign commerce for the specific
purpose of the protecting the consumer's health.

There was

some question as to whether the approach was constitutional
since it did not attempt to regulate .commercE>

~ri thin

the

proper definition, that is to protect the economic rights
of the consumer.

However, it was argued that Congress, fer

consumers, should "not only protect their pocket books, but
protect their lives (4)."
The Pur.e Food and Drug Act o.f 1906 provided jurisdiction
over foods and drugs and although this jurisdiction was rather
limited, it provided a basis for the regulation of foods and
drugs.

The 1906 Act defined the terms "drug", "food",

"adulteration", ·and

"misb~·anding",

standards for quality.

thus establishing minimum

The term "drug" included all medicines

recognized by.the .United States Pharmacopeia and National
Formulary, and any.subs.tance intended for the "cure, mitigation, or prevention, . of disease in either man or other animals".

An . adulterated d-"Ug was one which, if marketed by a

5
name recognized in the official eompendia, did not meet the
official standard.

However, an exception was allowed in

that the official standards \-.rould not have to be met ii' the
drug met its own purity, quality, and strength specifications
which were clearly marked on the label.

Drugs were considered

misbranded if the label bore false and misleading statements;
the drug offered for sale was an imitation of another article
(false name), or contents had been deleted, added or changed
(false contents); or the label did not bear the quantity of
alcohol, narcotics, and certain other specified ingredients.
Food was defined as all articles used for food, drink, confectionary or condiment by man or other animals.
considered

Food was

adulterated if any substance 'tras mixed \'lith it

to lower quality or strength, was substituted wholly or inpart
for the article, or if the food was treated in such a way as to
conceal damage.

Additionally, if the food contained poisonous

ingredients or contained filthy or decomposed animal or vegetable material, it

~ras

adulterated.

Misbranding of .food

included any imitation of the food that

~ms

not labeled as

such; misleading labels or packaging; replacement of contents
with other than the indicated ingredients; and the failure to
include certain ingredients on the label (5).
The authority for enforcement of the Act was delegated
to the Bureau of Chemistry of .the. Department of Agriculture.
The formation of regulations was assign.ed to the Secretaries
of Agriculture, Commerce, and.Treasury.

Dr. Wiley headed the

enforcement of the regulations,· appoint.ing Mr. Walter Campbell

6

as his chief inspector, a man who would later be a prominent
figure in the agency's development (6).

The jurisdiction of

the 1906 Act enabled the Bureau to upgra.de the quality of
foods and drugs to some extent.

Additional pieces of legis-

lation such as the Sherley Amendment of 1912, banning therapeutic claims which were false and fraudulent, the Filled
Milk Act of 1923, and Caustic Poison Act of 1927 increased
the scope of their regulatory powers (7).
In 1927, the Bureau of Chemistry was replaced by the
Food, Drug and Insecticide Administration.

Then, in 1931,

the name was changed to its current one, the Food and Drug
Administration.

Walter Campbell became the first head of

the agency (8).

About that time, the inadequacies in the

1906 Act were evidenced by the prevalence of unsafe medicines
sold with false claims.
stronger legislation.

Mr. Campbell began to push for
The battle was not

eas~ly

won.

Opposi-

tion arose to the agency's setting tolerance limits for pes"t;ic.ide.s on fruits..

Some .members .from Congre.s.s fe.lt the burden

of proof that large levels were dangerous should be placed
on the agency (9).

However, other influences worked to out-

weigh the opposition.

Books such as 100 Million Guinea Pigs, a

Buyer 1 s Beware, b and The Tragedy of \vaste, c along with Franklin

a- Kallet, A., and Schlink, F. J., "100 Million Guinea Pigs,"
Vanguard Press, New York, 1933.
b - Lamb, Beatrice.,· "Buyer's Beware," The National League of
Women Voters, Washington, D. c., 1935.
c- Chase, Stuart, "Tragedy of Waste," Finch Press, Ann Arbor,
f.'Iichigan, 1929.

7
Roosevelt's wish to surpass Theodore Roosevelt's legislation,
created a favorable atmosphere in the early 1930's to push
for a new food and drug act.

Hov1ever, the sponsorship of

the bill, coupled with additional opposition to the FDA's
activities in the regulation of foods, caused it to be delayed
for several years (10).
In 1937 1 a tragedy occurred that gave the needed impetus
to get the new legislation passed.

A cbemist, in trying to

find an adequate solvent for sulfanilamide, used diethylene
glycol without testing the chemical for human toxicity.

As

a result, there were 107 deaths from the Elixir Sulfanilamide.
This episode convinced Congress of the need for-stronger legislation and, in 1938, the Federal Food, Drug and Cosmetic Act
(F.D.&C. Act) was passed{ll).
significance.

The new 1938 Act was of vital

As stated by Franklin Depew, it "can be ranked

as the commercial law of greatest social and economic importance in the land because it regulated food and drugs- our
two most vital consumer products (12). 11

The 1938 Food, Drug

and Cosmetic Act, although it has been amended many times,
still serves as the basis for the regulatory action of today's
Food and Drug Administration.
The Act is composed of a series of compromises that had
developed in five years of hearings and four major revisions.
The main provision is to "prohibit the introduction or delivery
for introduction across state lines of· any food, drug, device,
or cosmetic which is adulterated or misbranded (13),"·and is
similar to the main provision of the 1906 Act.

The basic

8
principles that guided the development of. the new legislation
were that it must not. we ?-ken existing la11s, but rather
strengthen and extend the law's .p1:·otection of the consumer,
ru1d that it must impose no unnecessac·y or unjustified hard···

ship on. honest. industrial enterprise (14). · The Act streugt;h-.
ened the lm11 by (15):
1.

requiring premarket clearance fol' the safety
of drugs;

2.

covering cosmetics and devices.

3.

requiring the labeling of drugs to have:
adequate direct:i.ons for use, wru:'nings against
unsafe use or habit formation; the official
drugs packaged and labeled according to the
official compendia.

lf..

providing for the esta.blishment of food
stBndar·ds for identity, qual:\.tyr or con-·
· t,ainer fill.

5.

prohibiting the addition of poisonous .S\ubstences to fQod.
·

6.

authorizing factory insvections and injnrwtions to restrain violations.
·

In 1940, the FDA was transferred out of the Department
of .Agriculture into the ]'ederal Security Agency which, in

1953, became the Department of Health, Education, and Welfare
(HEW).

'l'he agency is, today, a part of

EEW (8).

As the

years passed, the legislation tightening controls on the
food, drug, cosmetic, and device indust'l'ies inereaBed.
In l9LJ-l, legislation required all insulin products to
be batch certified, as the dose of the drug is critical.

At

the same time, antibiotics (i.e., the penicillins) had just
been developed and were coming into more frequent use.

9
Variations in potency of these. life-saving natural products ·
became a pro'blem.

CongreSl:1 enacted several laws during

those years to require that each batch qf penicillin,
streptomycin, chlortetracycline, bacitracin, chloramphenicol,
and their derivatives be batch tested and certified by the
Subsequently, the 1962 Drug Amendments added a.ll

agency.

other antibiotics to the list (16).
Tighter control over potent medications was obtained
in 1951.

The HUmphrey-Durham Amendment divided drugs into

two categories:

Prescription, those drugs restricted to use

on the physician's recommendation only; and Over-the-Counter
(OTC), those drugs '<JMch can be purchased without a physician 1 s

r~u.thorizat:i.on.

The prescription drugse.were further

subdivided into three groups:

hypnotic or habi.t·-forming;

were limited to prescription use by the Nev1 Drug Applieation
(NDA) which contained information on the safety of the drug, .

and was approved by the agency.

T'ne amendment also provided

for improved labeling of OTC drugs requiring adequate directions for s€:.fe. use (17).
Under the 1938 Act, questions on the agency's authority
to inspect manufacturers arose.

A 1952 Supreme Court ruling

stated that the Act did I).ot clearly permit mandatory facto.ry
inspections.

Congress alleviated the problem by passing .the

1953 Factory Inspection Amendments allowing the agency, ei'ter
written notice to the owner, to inspect the place of manufacture without warrant or permission (18).

10
Two other sets of amendments to the Act, the Food
Additives Amendments of 1958 and the Color Additives
Amendments of 1960 gave the agency additional power by
requiring premarket clearance of chemical additives whose
safety was not generally recognized and by allowing for the
conditions for the safe use of a co.lor additive to be established by regulation (19).
In the late 1950's and early 1960's, Congressional
committees began to study the excess cost of the drug industry.

The studies also reviewed inadequate competition, price

controls, and patent protection, thought to be inherent in
the business.

The Kefauver hearings of 1962 were intended

to· study just that, the business aspects of the drug industry, until another tragedy occurred that changed their emphasis.

Thalidomide, an investigational ne\'r drug being tested

in clinical trials as a sedative for pregnant women,

\~as

found to cause phocomelia, a birth defect in which the limbs
do not develop in their offspring.

The hearings then became

more concerned with new drug requirements:

the animal toxicity

tests; c.linical trials .and the distribution and use of the
investigational drugs; removal· of drugs of questionable safety
from the market; and prescripti.on drug advertising.

The

changes brought about by the Kefauver-Harris Drug Amendments
of 1962 expanded the agency's regulatory authority, and established (20) :
1.

current good manufacturing practices

. 2.

yearly manufacturer registration.

(QG~W's) •

11
;.

drug factory inspections at least once
every two years.

4.

marketing of new drugs only after approval
for safety ~nd efficacy.·

5.

control over labeling suc)l that it could
not be false or misleading in a:n.y \my.

6.

suspension of new drug approval by the
Secretary of Health, Education a:n.d Welfare
if. a hazard ~as suspected.

7. ·. Yiolations for \vhich the a.pproval of a new
d.ru.g could be withdra\m:

a.

false or misleading labeling.

b.

new eYidence showed satet7 and ·
efficacy not supported.

c.

CGJVJP's not adhered to in production.

d.

inadequate records or reporting to
the ]'DA.
,.

8.

adverse reactions o:r: other ini'orrnatio11 relating to the safety and efficacy o:f' the drug
must be reported promptl;>' to FDA by the
ruanufacturer.

9<

specified safety conditions to be met bef'ore .
human trials.

10~

informed consent of patients required in clinical trials.

11.

all human antibiotics to be batch tested an.d
certified.

12.

labeling requirements which·listed the qurocitti t:y
of active ingredien'bn ru1d some, specified
inactives.
prescription drug advertising must sb.mv the
established name along with the trade ne.m~;.

'rhe efficacy requirement greatly increased the revi.e\v work
required for the approval of nev1 drugs for marketing.

:c;•:w

manufacturers were required to submit "substanti.al evidence"

12
o:f . .the

efficacy of the new drug through clinical trials ·on

the drug.

These clinical trials sometimes involve thousands

of patients; thus creating many case reports for the agency

to evaluate.

The efficacy requirement not only affected

new drugG, but extended to those drugs thatwe:r:e on the
marketprior to 1962.

Determination.of whether these drugs

were effective presented. special problems to the agency, both
·.in the system of evaluation and the manpower required to carry
out a program.

The decisj_on 1t1as made by the agency to contract

the work; and the National Academy of Sciences (NAS)/the
National Research Council (NRC) was chosen in 1966 to evalu.s:te

the

1938~1962

drugs for efficacy.

When the reviews were coru-

pl'Gted., the agency developed a prop;.ram to in.i tiatc action on
tb.e

e.:f.':tect:i.ve, probably eff'eoti ve, possibly ·1<ffective,

:i.ncff'ElC"tivG

llli.ttees.

recomm.endations .made

by

<ll"!d

the· NAS/NRC revic>W cDm-

The program, entit:led the Drug Effieacy Study

Implementation (DESI) program, is still in progress.
~'he

agency's jurisdiction in the ea.rly 1960·'s covered

foods, drugs,· devices, cosmetics, and product safety.

In the

late 1960's and early 1970's shifts in the responsibilities
. crune

abo·ut \d:trh the formation of the separate Product Safety

Gommif;s:i.on,

the passage of the Radiation Control for Health

a:n.d. Sa.fei;y Act of 19'71 for FDA to protect the con;;umer against

mmeeessary exposure to radiation, and the 1972 Public Health
Service .Act.

In the latter, the :I!"DA gained control over bio··

logical products which were previously held by the National
Institutes of Health (NIH).

Today, the agency's regulations
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cover eli verse areas of. consmner protection to include:

the

use oi' impact--resistant lenses in eyeglasses· and sunglasses,·
antibiotics in food producing animals, the interstate ship·•
ment of pet tui·tles to reduce the incidence of salmonellosis,
and performance standards of laser products.

These regula-

tions are in Title 21 (l!'ood and Drugs) of the Code of Federal
Regulations, with Chapter I being devoted entirely to the
Food and Drug Administration.
From its formation as the Bureau of Chemistry in 1906,
the. FDA has undergone multiple restructu:t:ings due to emphasis
shifts o:f the changing agency leadership, and to expansion
of the agency's functions-through legislation.

Today, the

agency is subdivided into eight major m•ea£: ..Bureau of Foods,
Bureau of Itrugs, Bureau of Veterinary ·Med:Lcine, Bux·Erau of
Biologics, Bu:r:eau of Radiological Health, Bureau of l'1edica1
Devices and Diagnostic Products, National Genter for
Tox:Lcolog:ical Research, and the Executive JJirector for
Regional Operations (Figure 1).

Each of those areas has

its own defined functions and structure that contribute to
the implementation of the legislation passed by the Congress
:i.11

the a:reao of foods, drugs, cosmetics, devices, diae,nostic

products, biologicals, and radiologieal product;s.

Bm·eau of Foods
The Bureau of J!'oods plays a major role in the
·of the consumer

\~ith

protect~_on

its responsibility for the assurance of'

safety, quali t;y, and proper labeling of foods., food and color
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additives, and cosmetics.

The Bureau adminis·ters its

. prograrus and regulations through standards development,
good manu_facturing practices (GMP's), review of food add.:itive petitions, analysis of' I·Ggulatory samples, and

strr~

veillance through inspections of the industry (21).
Three major areas are focal points for the Bureau of
Foods activities:

]'ood Safety, Food Economics, ar1d Cosmetics.

Food Safety, utilizing about 90% of the Bureau 1 s menpower and
budget, includes a number of programs to assure safety,
quality, nutritional adequacy, and integrity of the nation's
food through programs in such areas as:

.food sanitation con-

·trol, chemical contaminants, mycotoxins and other natural
poisons, shellfish safet;')', and the generally recognh;ed az
sai'e ·(GRAS) food additive list;

revim~.

Food Economics

i\mctions to protect ·the consurner from economic I·isk that
could be incurred

~>Ji th

lov: fill containers, . substandax·d ·.

foods, and packaging and labelin.g violations.

Cosmetics

assures the sai'ety of cosmetic products (22).
Bureau of Drugs
A major sector of the FDA, the Bureau of Drugs aims
to assl.Lt'e that d.:;:·ugs are both safe and effective, and of
good quality.

This is accomplished through the :Peview and

evaluation of investigational ne'll drugs (IND 1 s), new drug
applica·t;ions (N.DA's), and labeling, as well as the development of good manufacturing practices (Gl'lP's) in indus·i;ry
with surveillance to check compliance.

The Bureau operates
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a nUJilber of

progr~ms

to accomplish its mission.

The ad.verse

drug reaction reporting system a.ssetn'bles data concerning
adveJ.•se reactio.ns that occur with marketed drugs to detect
side. effects not seen :i.n the clinical trials on the drug.
The drug product defect reporting system receives reports ·
from practicing pharmacists concerning problems they have
had with the produc.ts they dispense,· thus aiding the agency
to identify manufacturing problems.

The Bureau also handles

all of. the antio'biotic .and insulin certification, as

\~ell

as

the monitoring of' all·methadone that is dispensed through
its methadone monitoring program (23).
As the principle content of this study was accomplished
·Within thEl B1:.reau of Drugs., a more comprehensive d:l.scuss:i.on
of the Bureau follows in Chapter III.
Bureau of Veterinary Medicine
The tvm major concerns of the Bureau of Veterinary
Medicine are the. assm'rulce .that veterinary medications a:re
se.fe and effective for their intended use, and that the
refd.dues in food-producing animals clo not cause harm to
humans.

\Vorldng closely

1~i th

t)le Bureau of l!'oods, Bureau.

o:f Dru.gs, m.1d the Department of Agt·icul tu.re, Vete:t·imn"Y
Hedicine coordinates inspection and investiga.tional programs.
It plans, directs, and evaluates the areas of animal drug
safety, antibiotics in animal feed, drugs residues, and
animal feed safety (24).
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Bureau of Biologics
The regulation of biologicals and blood products to
provide protection to the consumer was transferred to FDA
from the National Institutes of Health in 1972, and falls
Uilder the jurisdiction of the newly created Bureau of
Biologics.

The major source of legislative authorit;y for

this bureau is Section 351 of the Public Health Service

..

Act rather than the 1938 Federal Food, Drug, and Cosmetic
Act.

Through registration and inspection of blood banks

and firms colJ.ecting source plasma (human); testing of
blood and blood products; review of bacterial, viral, and
rickettsial vaccines; development of compliance prograrns
fol' biologie.s; and

revie~rl

of lice11.sing and control of

c<J.r~

rent good ma."lu.facturing practices (CGMP 1 s), the B'tll'eau 8.ims
to assure that biologics are pure, safe, effe cti v.e 1 a:nd of
the proper potency (25).
Bureau of Radiological Health
Various aspects of radiation are controlled by the
Bureau of Radiological Health.
radi.a:t~i.on

Controlling unnecessary

exposure of man, coupled tvith the srJ.fe and ef:fec-

tive use c,f potentially hazardous ionizing and noionizing
radiation constitutes a majority of the Bureau's frmctions.
The major legislative base for this bureau is the Radia·Gion
Control for Health and Safety Act of 1968.

The control of

radiation exposure by the Bureau involves the following:
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surveillance and compliance to limits, reeeare;h into health
effects,. and. development of· perfo:rmance standards of radi.a..
tion emissions from electronic prorltlctn (26).
Bureau of Medical Devices and Diagnostic Products
~'he

Bureau of Medica1 Devices and Diagnostic Products,

"lhose a(Jtions were previously delegated to the Bureau of
Drugs, was created in ]'ebruary,

197L~,

as the agency 1 s ne>vest

Bureau d1.1e to the increased workload in this s.rea.

The

safety, efficacy and proper labeling of medical devices and
in vi.EQ diagnostic products, along with the er;tablishment
of standards for these procl.ucts is the responsibility of ·!;his
bureau~

Surveillance of the industry to assu.re compliance

\'lith the regulations and the collection arFl evaluation of
datil on hazards of medical devices ancl di.r...grwstics adds to
the nev1ly created Bureau's respon.sib:Ui ties (27).
tion d.ee.ling

'~ith

I"sgis1a-

medical devices is found in the adultera-

. tion ancl. misbJ.•anding sections of the Federal Food, Drug, and
Cosmetic Act; hO\vever, there is no premarke·!;ing cll3arance
provi~.i.on.

.New legislation to provide for prema:eket clearance

of diagnostic products and medical devices is r.mrrently. "()ending in the Congress.
:National Center of Toxicological Research
In Pine Bluff, Arkansas, what once \vas a part o.f the
Army's biological warfare production complex, is now the
J!';DA' s National

C~nter

of Toxicological Research.

The
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laboratories .have been established to determine the health
effects of chemicals and toxins, in both E!CUte studies and
long-term low-level exposure (i.e. small quantities of
chemical toxins in the environment).

The P:in.e Bluff facility

is the largest of the FDA laboratories (28).
Executive Director for Regional Operations
The "front-line" FDA employees, the investigators or
':

..

consumer safety officers, are scattered throughottt the Ii~tion
in district offices and resident posts within the ten Department
of Health, Education, and Welfare regions.

They are coordi-

nated through the Executive Director for Regional Operations
(EDRO).

EDRO has authority over all FDA field operations and

directs the Regional and District Food and Drug Directors.
In addition, EDRO coordinates the FDA

~lith

state and local

agencies 1 policies and programs in the food. and drug· areas·
to assure that the pure food and drug effort is not being
duplicated or ignored in any way.

EDRO provides each of the

FDA Bureaus with field support for the Bureaus' compliance
programs (29).
As part of the study of FDA, a 111eek was spent in this
area to determine EDRO's relation to the programs of the
Bureau of Drugs.

A more detailed discussion of EDRO is con-

tained in Chapter III.
Development of' Pharmaceutical Education
Around the turn of the

t~entieth

century, when the
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problems with .the

nation'~~

food and drugs. reached such

proportions as to generate the 1906 Pure Ji'ood and Drug Act,
pharmacy education commenced some of' its most rapid and
significant changes.

From its begirmtng e.i; the Ph:i.ladelphia

College of Pharmacy in 1821, formal fJd.uc:ation in pharmacy
served merely as an optional; and not too frequently
utilized, supplement to the informal and unorga."lized
apprenticeship systenJ of learning the trade.

However, in

1900, although apprenticeship i·las· still the most coril.1non
method used to train the pharmacist, advances were made in
pharmacy education which included:

ai:t elementary school

education requirement for entrance into pharmacy school, a
t1~o

yeru:· course of study (although some forty".week program3

were iJt:i.ll offered), e.nd a new four year cou:rse offered by
· tl1e Un:i.vsrsi ty of l'iichigan (30).

A grm•ling <Jmph(ls:i.s o:n the

value of the basic science.s in pharmacy, in the late 1800's,·
established the trend towards increased college traini:ngas
opposed to appren·t:iceship (31).
The fifty-three colleges or depa:r.'tments of pharmacy

. that 1:1ere in existence in 1900 were of highly va:dable
quality.

This problem disturbed many pha"Cma.cy educators

enci prompted the formation of a group, the American Confer0mee
of Phe_rmaceu.ticc.l ]'a01.1l ties (ACP:I'!') • which has effected gre<J.t

changes in pharmacy education.

In 1925, the name of thiEl

organization was chru1ged to the presen'l; American Association
of Colleges of Pharmacy (AACP).

Through the establishment

of minimum national standards for admission to the schools,
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length of s-tudy, and .type of degree conferred, the AACP was
effective in elevating the quality of pharmacy education (32).
The standards for entrance into pharmacy· school and the

length of study set by the AACP increased rapidJ.y from 1900
to 1925.

Fromvirtl.ially no admission prerequisites in 1900,

i;he organization was successful in the.establishment of a
minimum of a grammar school education in 1904, one year of
high school in 1908, two years in 1918, end finally in 1923,
only high school graduates could be admitted to the colleges
of pharmacy.· Due·to the desire to incorporate ever-increasing
amounts of material into the curriculum, the required length
of study increased from forty weeks in 1904 to· tv1o years i:r1
1907, three years in 1925, i'ow: yea:Nl in 1932'; and to five
years in 1960 (32).

Currently, some schools off'er a six

yea~'

program.
In 1906, representatives from the AACP, Nat·ionnl
Association of Boards of Pharmacy (N.A:i3P), and the American
Pha't'macent:i.cal Association (A.PhA), joined to form the
Pharmaceutical Syllabus Corumi ttee to provide some standardi··
zation t:o the curricula in pharmacy schools.
lished

!flf2l~€.C1:.m.g,£s:u~J-El S;z:J),~,

dations ±'or subjects to be includeQ.
ricuhllll, from 1910 ur1til

19'-~6,

t~hen

The group pub-

which contained
\'li thin

the pharmacy cur-

the task

by the Committee on Curriculum o:f AACP.

rec~lnunen,

~Ja.s

taken over

The recommendations

in the §;ylla1?.l:!.§. during that time period for subjects to be
contained in the pharmacy curriculum were:
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theoretic and applied pharmacy, biological
sciences (including bacteriology, botany,
pharmacognosy, pharmac.olo[;y, pb;ysiology,
zoology, public health, and first aid), basic
and applied chemistr;r,. physics, commercial
subjects, English, :modern :for.eign languages,
mathematics, and ot:her eultural subjects,
particularly th<:; hhd;o:qr of civilization and
history of pharmacy (33).
Through the encouragement of the same· organizat5.or,,
i.e. AACP, NABP, and .APhA, the states began to require
pharmacy education as a prerequisite to licensure.

In 1904,

the state of New Yoi•k became the first to pass a law that
all applicants for regist;ration as licensed pharmacists
should be graduated in pharmacy.
precedent in 1906.

Pennsylvania followed this

By January 1, 1921, seventeen states had

passed such legislation, providing the pharmacy schools vlith
a solid fo•-lndation for existence (34-).
In the eady 1900 1 .s, the compoundj.ng a,rld dispensing of
pharmaceuticals \1as, .fox·. the most part, the basis for the
pharmacist' .s education.

About that time, when the trend

developed towards incorporating the private schools of pharmacy into colleges and. universities, pharmacy

\~as

frequently

associated with the chemistry departments (Arts and Sciences),
rather than the .medical departments.

T.hus the pharmacist

received no clinical practice.· The manipulative skills of
the pharmacist, his expertise in the preparation aJ1d dispensing of pharmaceuticals, were considered hls prima:r•y role
as a professional

(35).

The change in the direction of pharmacy from the rnsld.ng
of drug products to therapeutic ·counseling of patients about
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their drug therapy began. in the early 191!.0' s, as the
manipulative skills of the pharll!aci.st were .used less
frequently due to the growing number of
pharmaceuticals (36).

nm~,

pre made

However, the:ce •vas the feeling

in some schools that the four year program was too short
for students to learn the aspects of therapel.J_tic counseling and, at the same time, to have a sound scientifi·c
knowledge of drugs.
. phasized.

This

\1as

Therefore, the cotmseling was deem-

.partially becam;e it was considered

unethical as it was thought to·be solely the physician's
duty. · 'l'he physical-chemical aspect of assuring a quality
drug product was held to be the main consideration (35).
Just si·tei· World \Var II, the objectives of pharmacy
were studied by a corumi ttee composed cf specialists in ea.ch
of the various aspects of pharmacy.
i.n 19'J-8,

~~'1LRe~:L.Q!

Their report, published

the PharmacELgtical fur£ve;y.,,

contained fundamental statements about pharmacy practice,
objectives of pharmacy education, and specific recommendations for the pharmacy curriculum.

The objeetives that were

established by the Survey were (37):
1.

Selecting, .screening, a..r1d g'eaduating those
students possessing t:b.e technical abilities,
persona~ character, and social outlook
required .for the practit::e of the profession
of pharmacy.

2.

Preparing student:s to procure, develop, prepare, preserve, standardize, test, and dispense substances and articles used in the
diagnosis, treatment, and prevention of
disease.

4.

Grounding students in the principles and.
·practices of organizing end administering
a pharmacy.;

5.

Making students fully conscious of the
.
ethical standards to be met by the pharmacist.

6.

Qualifying students to cooperate with members
of the othe:r• health professions a.n.d to consult
with them; to furnish accurate, objective, and
scientii'ic information to physicians and members of other health professions concerning
drugs and the_ir action.

'1·

Preparing students to provide professional
services to the public appropriate to the
basic functions of ph<u•macy in its role as
a health profession.

8.

Equ::i.ppin;:; and stimulating students to cont·ribute to -the profession by .}!B.:Ctic:1-pating
in its various organizatione.l, literary,

teaching, resoarch, and other activities.

9,. Providing students >1ith an adequai;e foundation for graduat~J WJrk in the various subjects
of the curriculum.
10.

Preparing students to· assume the resporwi"oilities of citizenship befitting profess:i.onals.

:n. Enriching the life of the students through

greater understanding and. appl'eciation of the
culture; values, and problems of our civilization.

'l!o achieve these objectives, ge11eral and spec:ific curriculum

reqnh:ements 11ere outlined.

A strong foundation in the basic

sciences of chemistry, physics, and biology was recommended.
~'he

technical skills of the pharmacist were to be included

with emphasis on the qualitative accuracy and consultation
aspects :rather than manipulative skills, and the economics
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of the operation of a phax·macy was to be explained.

'!!he

importance of the :phc;:rma.cist as a consultant to other
-health professions.ls and _the psychological and sociological understanding of the patient v;as to. be stres8ed.

Addi-

tionally, a broad, general education to provide an assortment

of general ideas and aesthetic appreciation completed the
education of the well-rounded pharmacist (38).

Tho specifics

of' the curricula \vere recommended in the 191~8 Survey as

follows

(39):
l.

Pharmacy (22 hours): orientation cour·se
and courses in calculations, general
pharmacy, . dispensing pharmacy, and manufacturing pharmacy.

2.

Physical sciences and math (57 hours):
general chemiabry, inorganic pha:emaceutical
chemistry, organic chemj_st:ry, :i.ni::rodx.ct:.:i.on
to colloids, qumrt:Ltati ve ana1ys:Lc, 'oio·-"
chemistry, chemistry and pharmacy in mea.:\-·
,cinals, mathematics (algebra <m.d td.gnometry),
and physics.

3.

Pharmacology _and related (2lJ· Jwurs); general
biology, vertebrate anatomy, histology, physi.:..
ology, pha:emacology.

4.

Hicrobiology and public health

5.

Pharmacognosy (8 hours).

6.

Pharmacy administration (15 hours): economics,
pha:emacy accounting, drug marketing, pha.rmacy
mmlag,ement, ru1d phs.rm.acy law.

(9 hours).

Following the 1948 Pharmaceutical Survey, pharmacy
education

\-las

headed in the direction of today with emph<,sis

in education on the therapeutic care of the patient and m0.dication counseling by the pharmacist.

With the new social

health legislation and increased concern for the quality of

.
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health care, coupled with the laxge number of new drugs

developed, it 'lias felt that the pharmacist should be
relied upon for his knowledge of the action of drugs, in
addition to his dispensing sltills.

then adjusted to .fit this new role.

Pharmacy education was

According to Swintosky

(35) in the early 1970's, Brodie stunmarized that the pharmacist should be trained to be:
1.

A manager of all drug-related resoux·ces ••

2.

A professional responsible for

drug

counseling and adv-ising persons 11i thin
the community,

:?.

A drug consultant; this means tha\~ the
pharmacist needs to be kno\vledgeable of
di.seaso procesBes and the appro:priate

treatment, e.d.minif;i;ra:tion, b:i.oayailability,

interactions, s:1.de effects &nd p:r·oper dose
adjustment oi' dr-ugs.
4.

(,'hi·ef responsibility for maint:emmc.;, care
·o:r chronically ill patients i'.fhose medical
condition if.> stabilized but whcs!3 welfare
is dependent upon conti:::med proper use eli'
medication.

5. Primary health care:

intermediary between
the patient BJJ.d ph,ysieian vn outpatiEm·t;
situations.

In the past decade, this new concept of the role of the
pharmacist has been dubbed as clinical pharmacy.
The incro.asing number of n<:M ·drugs on the market, . the
incidence of hos:pi tal admission:3 duo to ·adverse drug reac-tions, and the decreased amount of pharmacology taught in
medical schools will necessi tc,te the pharmacist's becoming

increasingly involved in the patient's therapy as the drug
expert on the health care team (40).

There have been numerous

2'7
definitions of clinical pha:rm.<Jcy.

The Advisory Commission

on Pharmacy to the Cal.:i.i'ornia State Legislature chose the
following for its report;:
A pharmacis1; who has received advanced training
in the application of' drug therapy in a clinical
environment (hospital wards, outpatient or community clinics, etc.) or who, by actual practice
in a clinical environment, has mastered the concepts of drug therapy and who applies them (or
advises in their application) to the drug .therapy
of·patients (41). ·
·
The Committee on Cut'riculuro of the AACJP chose its official
definition to be:
Clinical pharmacy is that area within the pharmacy curric:ulum which. cleaTs with emphasis on
drug therapy. Clinical Pharmacy seeks to
develop a patient-oriented attitude. The acquisition of new knm•rledge is secondary to the
attainment; of skills in :i.nterprcfessional a:nd
pC\t:i.(mi; co!llllluni cations ( lJ-2) •
:f.lhe goal of training pharmacists in a clin:Lcal setting 1dtb.

emphasis on patient

C!il'e

education stand.B today.

Err1d

In order to achieve this goal, i.:he

AllCP Corm:r,:i.ttee on CurriculuJ11

objectives.

drug therapy is where pb.armacy

ch!ll'8.(~ter:i.zed

the educational

Tl1ese objectives are ('J.2):

1.

To acquaint the student \d·l;h cJ.in:i.ca.l applications of pharmacologic and pharmaceutical
principles;

2..

~'o help· make the stt1dent more avmre of the
general methods of dias~:1osis Emd pat:i.E';nt Cc{I'<l
sped.fically as they x·eJ.ate to drug therapy;

3.

To develop in the student; a facility for
eff'ecti ve interaction with the patient <cnd
w:i. th practitioners of' other health professions;

4.

To help the student; develop a patient awa:ceness
in providing pharmaceutical services;
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5.

'.l!o enable the stud.ent tc jntegrate the
knowledge acquired. in preclinical yea.rs
and·to apply it to the solution of real
problems; end

6.

To develop in the stu.dent an a1rmreness of
his responsibility in monitoring drug
utilization.

It is remarkable that, even at this point in time,
no mention of FDA drug regulation responsibilities is made.
~g_rfacing

of Pharmaceutical Education and the Food and

P-~1g Admin~ptration

Throughout the development of pharmacy education, there
\'las little mention of inclusion within the curricula of some
information on FDA drug regulatory procedures.;

The system

developed from teaching the basic sciences wi'ch emphasis on
the physice.l-chemical characteristics of drugs, to the
therapeutic nature and consulta.tion about drttgs.

IJi ttle

attention \vas given to the governmental agency \'Those responsibility it is to regulate the drugs pharmacists dispense.
The common goal of both the FDA and pharmacy of achieving
safe and effective drug therapy has, \vi.th the increased
ree;ulatory po\vers of the agency, created sit-uations where
the FDA is having significe..nt effect on the practicing pharmacist.

Some of the regulations v1ritten by the agency that

direci;ly affect the pra.ct:i.tioner include those requiring
that nitroglycerine be dispensed in its original container,
and. methadone may be dispensed only in specially licensed
facilities.

Additionally, the agency controls the labeling

of drugs which has a direct effect upon the pharmacist in
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both dispensing and therapeutic counseling functions.

As

the i.nteractions increase, there exists a need. for the. FDA
.and pharmacy educ.ation to open lines of communication to
avoid situations of misinterpretating one another's actions.
The understanding of the mutual goal will aid in assuring
that drugs are safe, effective, and used properly.
The agency, in the past few years, has.become aware
of the pharmacist and his value to its mission;.

Several

programs have been conducted by the FDA that have been both
educational to the pharmacist .and benefiCial to the agency.
Two such programs are the Commissioned Officer Student
Training and

~~ternship

Program (COSTEP} offered through

the Commissioned Corps of the Public. Health Se;r.'vice, end.
the Drug Product Defect Reporting System offered in conjunction vri.th.the U.S.P.
The COBTEP's were utilized i'irstin 1966.

As the agency

was in need. of additional professionals to execute the efficacy
requirements or the 1962 Drug Amendments, Dr. Goddard, the
Commissioner of FDA at the time, arranged to have approximately 20 COSTEP':s work for 2 years in the Bureau of Drugs.
Many o! these CO:STEP' s were graduate pharmacists, and assisted.

· the agency in its review oi' nevl d:rugs :for e!!icacy, and the
iru:plementat.i.on oi" the NAS/NRC review panel recommendations.
After this, C'.OSTEP within FDA remained dormant.

Early in

1974, the Bureau of Drugs of the FDA became interested in
participating in the COSTEP again.

Although most assignments

within COSi'EP are to government hospitals or clinics oi' the
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Public Health Service,

17 students from 13 colleges of

pharmacy were selected to work.in various areas within
.the Bureau of Drugs.

Their assignments included:

Drug

Listing, Drug Product Surveillance, Drug Information
Services, Over-the-counter Drug
and

Biopharraaceutics~

ReviEn~,

Ne~;

Drug Evaluation,

Assignment to the program was for a

period of time not to exceed 120 days.

~he

students took

part in a variety-of FDA activities that not only aided
their understanding the f1.mctions of the agency, but did an
excellent· job in providi.ng the FDA with the additional manpo\~er

needed for some of its projects.
The types of activities in which the COSTEP'S'tookpart

included review of investigational new drug applications to
determine i:f the information includedmet the requirements
prior to assignment· to a revie\qer.

'I'hey ansv1erecl consumer

inquiries abm<t drugs and researched records to prepare_
memoranda :for Senate drug investigations.

Further, they

1r1ere involved in evaluation and coding of· information for
the computer follo"1-up sys.tem of the d:r11g product defect
reports.

In addition they were given responsibility for·

catego:rizing the ing-redients in the over-the-counter drugs,
so as to identify what ingredients were being studied by the·
_. variou.s panels, and for obtaining reference material from
the library for use by the over-the-counter drug review
panels.

~lost

significantly, in response to Congressional

inquiries, the COS'l'EP's researched and collected data on the
so-called "drug lag" problem to determine if the FDA was

·indeed hindering the introde1ction of useful, possibly
life-saving drugs to the American marketplace through
·its lengthy new drug approval procedures.
ll. second program, bringing pharmacists in closer communication \'lith the FDA, is the Drug Product Defect Reporting
System.

Through a contract VIi th the

u.s.P.' the FDA has

initiated a system whereby pharmacists can report any defects
o~

problems they have found \vith products on the market.

The

Drug Product Defect Reporting System, initiated in 1972 by a
pharmacist \forking in the FJJll., has served as an invaluable
source of information for the agency in the detection of·
problems occurring with marketed drugs.

This interaction

oi' the pharmacist, the dru:g dispenser, '-'lith the FDA, the

drug regulator, has done a great deal to strengthen the ties
between the tt•o and the reccgni tion that they are interdependent.·
· It appears evident,

hO\~ever,

that colleges of pharmacy

must estp.blish some major: course of study in the area of
governmental drug regulatory procedures if they !ll'e to support the needs of the health professions and, ultimately, a:
ful~er

responsibility :for the health care-of the nation. ·rt

· :i.s sad to note that, from the inception of the l<,DA, pha:rma·Ceutical education has given only token attention to this
agency \vhich is .responsible for the approval and regulation
of' those substances, the principal raison
prof'ession.

~~

for the

This allegation can be supported by a perusal

of the catalogues from the schools of pharmacy.

At best,

.7. ")

,')c..

there are only a few whi::h lh:t minOJ' survey courses in the
cl.esign and functions of the

]'J)A

but these are usually incor-

porated into the pharmacy la.vl courses.

Also, one might

suspect that tho lack of advancement; possibilities for the
pharmacist classificatj_on within the agency, so as to force
pharmacists to seek other titles such as Consumer Safety
Officer, reflects the absence of any :real pha"C'maceutical
cla:i.m for responsibility within FDA.

Therefore, if the

pharmacy profession is to contribute to the

contl~ol

and

rational use of its basic materials, drugs, it must begin
to assume responsibility for educatinf; its practitioners
appropriately to maximize the benefits of mutual support
of the professions and the Food and Dl'ug Administration.
'l'he J!'DA has

alr,~ady

acknowledged the value of ed.uca:t:ional

programs in ·t;ho agency for students of the b.ealth professions
through the graduate studies and the Commissioned. Officer
Student 'l'raining and E'A:ternship Program (COSTEP).
It is, therefore, the objective of this study to expand
cooperative ecluca·l;ional programs for pharmacy students thx·ough
the development of a course of stu.dy in FDA dxug regulatory
procedures for schools of pha:r•macy,.

JVJore specifically 9 :i.t is

the intent of this project to design e. formal course or
courses which may be offered for on-campus study and, because
it is preclic-tecl to be a necessity for comprehensive un.derBi;and··
ing of FDA drug regulatory procedures and their application and
:i.mpl:Lcat:ions, to make recommendations for a peri.od of :::·eside!J.cy
within the l'DA.

CHAPTER II
EXPERIMENTAL METHOD
Early in the fall of 1972, representatives of the
University of the Pacific School of Pharmacy met with
representatives of the Food ru1d Drug Administration,
expressly the Bureau of Drugs, to discuss the feasibility
of establishing a cooperative experimental program designed
to provide training for graduate pharmacists in governmental
drug regulatory procedures.

The proposed program was to

utilize the '\•;ork,;,study technique and to be

..

j,ri

partial ful:-

f:i.llment of the require!Jlents for .i;he Master of Science degree
in Pharmaceutical Scien.ces.

Based on the interest e:x"Jlressed by the agency, a syllabus (Appendix A) was prepared.

The syllabus contained the

School 1 s projected representation of a basic framevrork which
would provide a broad experience within the agency and allow
the student to learn its functions.

The goals; as set forth

in the Syllabus vrere: ·

,••

to provide background research material
as part of a graduate degree program.

2.

to develop an efficient and meaningful
program which may be utilized on a continuing basis for senior or graduate
pharmacy students.

3.

to create a resource pool of professionals
trained in governmental drug regulatory
procedures.
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To accomplish these goals, the st)ldent would rotate
through the several Offices of the Bureau of Drugs to gain
a first-hand working imowledge of the structure .and f.unctions of each. aud ho1r1 these interrelate to accomplish the
Bureau's mission.

Although the duration of each rotation

.

\'/aS

.

-

.

established rather arbitrarily, they 'tlere thought to

be reasonable estimates.

Modification of the syllabus would

1;ake place, with regard to time frames, assignments, metho-'
dology, and even·objectivesas the student began to gain
experience•

Continuous input from the student, preceptors

\'lithin the agency, and supervising faculty were·encouraged
to provide for revisions of the original document that would
.

.~

.

put it into a final form >vhich would be suitable for subse..o.
quent students.
The syllabus described the duration of the residency
within the agency as being from 4-6 months.

It was divided

into six units which included rotations to various areas
\'li thin the Bureau of Drugs.

Each of the unit descriptions

was composed of objective, methodology, a..Tld assignment sections to give the student and the supervisor some guidelines
on the purpose of the

progr~~.

The schedule of rotations

included:
I.
II.
III.
IV.

FDA:

Organization and F1mctions

Bureau of Drugs:
and Functions

Organization

(1 week)

(l week)

O:rfice of Compliance

(1

Office of Pharmaceutical Research
and Testing

(TBA)

~;eek)
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v.
VI.

Office of Scientific Coordination

(1-2

~reeks)

Office of Scientific Evaluation

(4 months.)

The syllabus was viewed as a flexible document and
it served its purpose well for this program in that it
was used as an introductory piece of information for those
·in FDAwho became involved in the program's implementation:
Although most of the methodology and the series of rotations were adjusted to accommodate some practical concerns
of the student and her supervisor (e.g. extra time in the
division for adjustment to the agency's routine and allowance for contribution to the workload, and changing the
areas of rotation to parallel the Rureau's reorganization
in September 1974), the objectives delineated~in the introduction a11d under each of the unit headings were achieved.
The student assigned to this project was expected
to submit periodic reports to the faculty advisor and
agency preceptors.

These were to describe in some detail

the functions of the division& and the experiences gained .
within each; to recommend improved syllabus content; and
to serve as a record f.rom which this thesis \vould be
prepared.
It \>/as in August 1974, that arrangements were finalized
· for the author to be appointed to the FDA as a temporary
employee for a period not to exceed one year· (Appendix B).
Specific assignment vlas within the Bureau of Drugs, Office

of. Scientific Evaluation,'" the area. of the agency
corresponding to the student's main interests.

Assigned.

as the Assistant to the Assistfmt Director for Ohemical
Review, Dr. Charles KumkUJJiian, the student was charged
with the responsibility of "providing him with scientific
and technical•expert:i:£e in the pharmacy area necessary to
accomplish the program's mission" (Appendix C).
\vas directed by Dr. Kurnkumian to

a specific

The student

area i1ithin the

Office, the Divisionof Surgical-·Dental Drug Products.
Under the guidance of Dr.· Robert Jerussi, . supervisory
chemist in the Division, the student was provided with a·
working knowledge of the organization, functions, and regulations of the agency through participation in the Division's
responsibility for reviewing data submitted on ne-...; •::l.rugs to
substantiate their safety and efficacy· and. special asGignments pertaining. to the drugs handled by tile division.

In

addition, Dr. Jerussi arranged the rotations to other areas
within the Bureau of Drugs and the Executive Director of
Regional Operations.

Memos with a syllabus attached were

sent to the various directors of. other areas
agency.

~1i thin

the

The memos contained a brief summary of the purpose·

of the program, the need for rotations to their area, and a

--·-*The organizational title in effect at the initiation of this
program is used here. After the reorganization in the fall of
1974, the Office of Scientific Evaluation became the Associate
Director for New Drug Evaluation and the Office of Scientific
Coordination became the Associate Director for Biometrics ~md·
Epidemiology. The other areas.headed by Associate Directors
include Compliance, Information Systems, Drug Monographs, fu~d
Pharmaceutical Research and Testing (Figure 2).
·

37
request that the student be allowed to work in their at'ea
for a limited amount of time.

These were sufficient to

introduce the student to the other area directors, ru1d a
rotation schedule was established.
September 30-0ctober 4, 1974

Office of Scientific
Coordination*

October 29-November 4

Drug Product Defect
Reporting

November 18-22

Pharmaceutical
Research and
Testing

February 3-7, 10-14, 1975

Compliance

March 10-14

Executive Director
for Regional
Operations

May 21, 22, and 26

Drug Monographs

'!'he com:prehensi ve understanding of each rotational area's
drug regulatory functions \<Ias acquired ,through a series of
discussions Hith the officials in eao.h of the divisions.
In the morning of the first day of the rotation, the director
of the area questioned the student to identif'y what aspects
of the area's f'unctions would be of' most interest.

The

plromed rotational experiences then were directed towards
providing information within the scope of this expressed
interest.
-------~--------

*See f'ootnote, p. 36.

CHAPTER III
RESULTS:
Followin~

REVIEW OF RESIDENCY

the approach outlined; the \vork-study residency

. experience, ;from vlhich recommendations for curriculum were to
be designed, was comprised of several rotations through
various units of the agency.

Although principal assignment

and service responsibilities were in the area of New Drug
Evaluation, the inclusion of short term experience in several
other areas permitted.gaining a comprehensive understanding
of the l'esponsibilities and functions· of the 1lureau as a
whole.· An in-depth

~Jerking

1Gl.owledge of New Drug Evaluation,

t.he author's chief interest:, was provj_ded by. responsibi1i ties
assigned in. that unit and complr,ted under the guidance of that
staff •
. The. presentation which follov!S describes in some detail
the functions of the several units included, the regulations
under which they operate, and
mission.

ho~1

they articulate in a total

These descriptions a;t'e inte11ded to serve as part of

the textual me.terial for the curriculum recommended in
Chapter·IV of this report.

The sequence of presentation

here is not int:ended to suggest a chronologie approach to
the topic, but starts, logically, with a brief description
of the Bureau of Drugs as a whole, followed by a lengthy
exploration of New Drug Evaluation.
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Those units iri which

·I
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shorter rotations were completed follow in random order.
Bureau of DrU5£
The Bureau of Drugs is responsible for the enforcement
of those sections of the Federal Food, Drug, and Cosmetic
Act which pertain to old, new, and investigational drugs;

.

antibiotics, insulin and ho.rmones; prescription, nonprescr·iption, and habit-forming drugs; as well a.s those
which may be misbranded or adulterated.

The definitions

of these are.contained in Chapters II and V of the Act.
Overall, the Bureau's. functions within the FDA include
the development of policy with regard to the safety, effectiveness, labeling and quality of all drugs for human use.
:I:t is responsi.ble for reviewing and evaluating ne'IJ drug
applications U!'"ld claimed exemptions for imrestigational new
drugs, as well as operating. drug experience and poison con;..
trol monitoring and reporting systems.

In addition, it plans,

coordinates, al'ld evaluates FDA surveillance and compliance
programs relating to drugs.

The provision of scientific and

technical support for regulatory work in drug biology and
drug chemistry are also within its functions, as is development of regulations covering drug-industry .practices·(current
good manufacturing practices).

Finally, the Bureau ha.s

responsibility for coordinating, directing, and reviewing
the FDA antibiotic and insulin certification program

(L~3).

To accomplish these functions effectively, the Bureau
is organized into a number of Divisions, as indicated in
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Figure 2.

~Che

relationship.

grouping of the Divisions is by functional
Each of the Divisions in an area has a leader

reporting to an Associate Director in the Office of the
Bure.au Director.

In addition to the delegation of respon-

sibilities of the Bureau according to the divisions, the
agency utilizes the Program l'ianagement System (PM.S). ·The
system was introduced around 1969-1970 to provide for an
interface between the agency's responsibilities and the
agency's budget.

It describes the objectives of.the agency

in terms of projects to be accomplished for the year rather
than through func.tional descriptions of organizational units •.
This allows. for more effective planning from budget category
to program to project to compliance progrrun, and provides an
interface between the Bureau and the E'xecutive Director for
Regional Operations (tho field force).
include:

The Bureau's programs

Drug Quality Assurance, Over-the-Counter Dn1g

Evaluation, Drug Application .Evaluation, Clinical Investigation
Evaluation,Biopharmaceutics, Drug Efficacy Study Implementation,
Drug Experience and Trends Analysis, Mathadone Honi to ring, Drug
Listing, Poison Control, and Prescription Drug Advertising.
Ne,..; Drug l!.'valuation

-Introduct:i.on
r--The Associate Director for New Drug Evaluation has the
responsibility of enforcing those sections of the Federal
Food,. Drug and Cosmetic Act pertaining to new drugs.
Act defines a

"ne~l

drug" in Section 201 (p) to be:

The
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1.

any drug the composition of which i.s such
tb.at such drug i.s not generally recognized,
among experts qualified by scientific·training and experience to evaluate the safety
and effectiveness o.f drugs, as safe and
effective for use under the conditions prescribed, recommended, or suggested in the
labeling thereof, except that such a drug
not so recognized shall not be deemed to be
a "new drug" if a·!; any time prior to the
enactment of this Act it ~las subject to the
Food and Drugs Act of ,Tune 30, 1906, as
amended, <md if at such time its labeling;
contained the same representations concern~
ing the conditions of its use; or

2.

any drug the composition of which is fmch
that such drug, as a result of investigations to determine its satety and effectiveness for use under such conditions, has
become so recognized, but ~lhich has not,
otherwise that in such investiga.tions, been.·.
used to a material extent or for a matei';Lal
time under such conditions.

Several points in this definition have required clari-·
fication through court decisions.

!'lost specifically, the

decisions have dealt wi-t;h the. app1ication of the "grandfather
clause", which pertains to those drugs subject to the Food,
and Drugs Act of 1906.

In a 1972 case, United States vs.

An article of drug, "Bentex Ulcerine", the claimant contended

that because the drug had previous1y been marketed, from
1958-1963, it fell under the provisions of the· grandfather
clause Hnd therefore 111as uot co:lsidered to be a "ne\'i drug".
FDA, however, made the decision that Ulcerine did not meet:
the requirement of being "generally recognized as safe and
effective" and was to be considered a new drug.
was supported in the court decision (45).

This decision

The generally

recognized as safe and effective statement leaves the new
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drug definition open to the FDA's own interpretation.

Based

upon this court decision and others, the FDA has been given
·broad authority over what constitutes a new drug.

Thus

through FDA's interpretation, the definition can include an
added indication in the labeling, change in dosage, or a
new combination of old drugs.

The decision is primarily

admin:i.strati ve.
When a drug is considered to be a "new" drug, the
Associate Director for New Drug Evaluation has the responsibility over itslicensing as dei'ined in Section 5.05(a) of'
the Federal Food, Drug and Cosmetic Act.

This section

states that no person shall enter a new drug into interstate
commerce unless an approved application is in"· effect for th0
drug.

For a new drug application to be approved, according

to Section 505 (b), it is required to conte.in:

(46)

L

clinical data showing the
and effective.

2.

components of the drug.

:;.

composition of the drug.

4.

methods, facilities, and controls for manufacturing, processing and packing oi' the drug.

5·

samples of the drug.

6.

labeling for the drug.

This requirement for the filing

ne~l

drug is safe

of a nm; drug application

for approval '>las initially introduced in the 1938 Act.

At

this time, the application dealt primarily with the safety
testing towhich the drug had been subjected.

The 1962 Drug

Amendments greatly increased the requirements for the approval

of the application by the addition tb.at the ne•v -drug must
be proven to be efficacious.

The efficacy requirement

·substantially increased the workload of the agency.
To define the. new drug application requirements better,
regulations which at•e included in Title 21 Code of Federal
Regulations (21 CFR) have been promulgated.

Two sections,

21 CFR 312 and 21 CFR 314 are the most direct interpreta-

tions of the Section 505(b) statements.

These sections

describe the two principle application forms listing the
requirements to be completed for the approval of a new drug:
Form 1571 Notice of Claimed Exemption for an Investigational
Ne\v Drug (INTI) and Form 356H New Drug Application (NDA)
.(Appendixes D and E).
The ·responsibility for the evaluatior, and approval of
the Itm 1 s ·and -~mA 's submitted to the agency resides in the
six drug rev'iev: divisions 1r1hich report to the Associate
Director for New Drug Evaluation.

The revie\-1 divisiol1s have

responsibility over the c.ategories of drugs as follows:
I.

II.

III.

IV.

Division of Cardio-Renal Drug Products:
cardiac, antihypertensive and gastrointestinal drugs.
Division of Neuropharmacologic Drug Products:
ne11rology-ana,lgesic ·and psychopharmacologic
drugs, and the drug abuse staff.
Division· of JVJetabolic and Endocrine Drug
Products: fertility, anti··fertili ty,
metabolic, and endocrine drugs.
Division of Al1tiinfecti ve Drug Products.:
antiinfective systemic and vagina,l, dermatologic, opthalmologic, and otologic drugs.
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V.

. VI.

Division of Oncology and Radiopharmaceutical
Drug Products: oncologic, radiopharmaceutical, and antiinflammatory drugs •
Division of Surgical-Dental Drug Products:
respiratory, surgical and dental drugs.

Although the primary function of these divisions is
the

revie~r

of IND 1 s and NDA 1 s, there are additional respon-

sibilities which each accepts for its particular drug
·products. ·These include the assurance that the drugs with
approved NDA 1 s have the proper labeling.

The continued

surveillance of annual reports to pick up trends in adverse
drug effects which could lead to changes in the labeling or
possible withdrawal of the approval of the NDA is an important function of the divisions over marketed drugs.
divisions supply all information to other areas

Further,

of ·the agency

for each of their respective drug classes to inclt1de the
statns of NDJ,' s, policy, regulatory actions, freedom of·
in:formation

req·C~ests,

and prOduct development (43).

A seventh division in New Drug Evaluation is Drug
Advertising.

This division does review work, but not that

of IND's or NDA 1 s.

Instead, it evaluates

pr~scription

drug

promotional material, advertisements, and other labeling.
The Division establishes policy and regulations· on prescription drug advertising for the agency, and recommends action

.

to be taken when viGlations have been fom1d (43).
The Process of New Drug Evaluation

The FDA is intimately involved in the process of new
drug development.

Through the provisions of the Act, it has
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the power to license nev1 drugs by approving new drug
applications thus influencing what drugs will be marketed.
This important function of the agency greatly affects the·
pharmaceutical industry.
Typically, new drugs are generated in one of two ways.
A need for the treatment of a certain disease may be identified, causing a firm to instruct its synthetic chemists to
construct a molecule to meet the need.

Or, through basic

research, a new chemical entity with potential pharmacologic
activity is discovered.
with the

u.s.

The new molecule is then patented

Patent Office for seventeen yea-rs, after which

others may test, use, or market the chemical.

Firms generally

patent many more compounds that will ever been seen bythe
]'DA.

As examples, it

~ras

reported that, in 1974, :S:oe(!hst-

Dynachem filed for 101 patents, !'lerck for 66, Sandoz for 61,
Squibb for 56, Ciba.,-Geigy for 52, Bayer for 49 and HoffnianLa Roche for tJ:5 (47), however, the .number of applications
submitted to the agency \vas well below these· figures.
The compound goes through initial pharmacological screening for activity and, i f found to be active, will be subjected
to further animal and chemical testing for refinemE!nts in the
characterization of the molecule.

The testing includes:

toxicology·--subacute and chronic; pharmacology--absorption,
metabolism, distribution, excretion, and specific activity;
and chemistry--synthesis, identification, purity, and stability.
If the chemical is thought to have potential for use in man,
the firm must do the necessary tests, e.g. safety in animals,

'+7
\'lhich are required by· the FDA in their Notice of Claimed
Exemption for an Investigational New Drug (IND).

The firm

is required to file an IND for the interstate shipment of
any new drug without an approved new drug application and
provide information which ;justifies the use of the drug in
man.

The data that are required in the IND to fulfill its

requirements includes (48):
1.

2.

descriptive name, chemical name, and
structure {if kn01-m).
complete list of components, including
·reasonable alternatives .for the inactives.

3.

complete statement of the quantitative
composition.

4.

description of the source and preparation
of the ne;.1 drug substance.

5.

statement of the methods, fa.cilities, and
. controls used for the manufacturing, ·
processing, and packing of the nz:·lr{ d1,ug ·to
establish e.nd maintain appropriate stande.:erls
of identity, strength, q1.tality, and pu.ri ty
as needed for safety and to gi'IJe significance to clinical. investigations made 1vith
the drug.

6.

statement coveringall information available
to the sponsor from preclinical investiga~ .
tions and any clinical studies ru1d experience
t'li th the drug:
a.
b.;

c.

7•

studies on laboratory animals
if marketed commercially or investigated outside the United States,
complete information about such distribution or investigatio:;l
.
if the drug is a combination of
previously investigated or marketed
drugs, a summary of preexisting
information

a copy of all informational material, including label and labeling which is to be supplied
to the investigator.
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8.

scient:\.f:i.c training end experience that
the sponsor considers to qualify the
investigators as suitable experts to
investigate the safety of the drug.

9.

names· allCl. a summary of the training and
experience of each investigator and monitor.

10.

11.

outline of the phase or phases of planned
investigations and a description of the
institutional review committee as follows:
a. clinical pharmacology
b. clinical trial
c. institutional review committee.
statement that the sponsor wiH. notify the
. l!'DA i f the investigation is to be discontinued.

12. · statement that the sponsor will notify each
investigator if a new drug application is
approved, or if the·investigation is discontinued.

13.

i f the drug is to be sold, a fulJ. explanation
why sale is required and sl:iould not be regarded
as commercialization of a nevi drug for 1·1hi.ch an
NDA is not approved •.

.14. . statement that the· sponsor 1vill not i.niti£-te

clinical studies until 30 days after the date
of receipt of the notice by the FDA·and he will
withhold studies ii' requested by the :b'DA, · .
~/herein information on the deficiencies in the
IND willbe provided and a conference between·
the FDA and the sponsor will be held on request.

Additions are made to the IND throughout the investigation of
the drug as it proceeds through the three phases which describe
the stages of investigations in general terms.

Phase I

involves the use of healthy human volunteers for purposes
of characterizing the absorption, distribution, metabolism,
excretion, and toxicity of the new drug in man.

In

Phase II,

a small population of diseased patients is selected upon which
the new drug is used to determine efficacy.

Phase III is a

widespread study on diseased patients in order to characterize the safety and efficacy on a large number of patients.
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Triplicates of the

si~1ed

Form 1571 and the data generated

to fulfill the requirement.s are sent to the :I!'DA' s offices in
Rockville, Maryland.

l'ihen the IND arrives at the agency, a

receipt date is assigned.

From the,t date, the 30 day wait

for the firm, described in #14 of the Form 1571, begins.

The

document is routed through the Central Documents and Records
room where it is assigned a number (IND's and NDA's are numbered consecutively according to the receipt date), and to
Index and Aostracting for the coding of some of the. included
information.

It is then sent to the reviewing division

responsible for the therapeutic class of drugs to '1-!hich this
new chemical entity belongs.

The incoming INTI's are classified

by the divisions according .. to chemical type, therapeutic potent;ial, and sponsorship.

The chemieal types include:. ne.w. entity,.

nevi salt, ne·w ·formulation, new combination, one already

ma~r

keted by another firm, and one already marketed by the same
firm.

The th<;rapeutic potential gain is classified as:

impor-

tant, modest, little or none, significant for pediatrics use,
~d

DESI/OTC.

The sponsorship is either noncommercial

(individual or ins·!;:i..tute) or commercial.

The commercial

IND's are more lik:ely to give rise to NDA's.
The FDA, as its first effect on the sponsor of the ne1v ·
d:rug in its protection of the consumer hA.s kept the new dx•ug
off the market and prohibited its use in man prior to the
submitting evidence of its safety in the IND.

The agency's

second major impact·comes with.the 30 day safety review done
by the professional staff in the divisions of New Drug
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Evaluation.

The r·eviewerB, generally the chemist, the

pharmacologist, and the medical officer (the principle
members of the review team) survey the submitted data for
safety.
~'he

chemist must make certain that the sponsor has

properly identified the structure of thenew'chemical and
that the formulations listed in the manufacturing and control sections are logical and agree with those submitted in
the protocols for use in the clinical trials.

Further, he

checks that adequate quality control procedures are utilized
·to assure the proper strength, purity, and identify of the
molecule; and that the labeling contains the proper informa-

tia.

"
The ph?.xmacologist revievn1 the data ou the safety of

the mo1ecu.le in the aTJimal toxicity tests.

The dm'ation .of

the studies and the animal species in which these tests·are
to be performed varies 'tli th the route and duration of
administration of the drug anticipated for human administra'tion.

The firm must present adequate data that characterizes

the saf<,ty in animals of the drug before its use in hum:m
subjects.
The medical officer confers with the pharmacologist on
the an.imal data, and its relation to the dose that is to be
used initially in man.

The protocol, i.e. design of the

clinical trial, for Phase I, the initial studies of the molecule in man, is carefully evaluated so as to allow for the
greatest margin of safety possible.· The choice of the initial
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dose is a critical one, and is dependent upon the information
generated from the animal toxicity studies and possible
structural activit-y· relationships of the new compound tli th
known drugs.

It is a difficult decision, as the relationship

·of . animal data to man is not direct.
Together, the 30 day reviews are scrutinized and the
decision is made for human trials.
hu~an

The protection of the

research subject is the most important consideration

in making this decisi.on.

To achieve this, the adequacy of

the animal studies already completed and analyzed is ascertained.

The scientific merits of the research plan in addi··

tion to the qualifications of the investigator are determined.

Fu1?-ther, the proper. characterization of the. new drug ohenlically
is checked so that the investigator knows exactly what the new
compound is a..'ld thus the clinical tests vtill yield meaningful
data., (49).

I f any

question as to t;he· safety of the drug

arises, the division director can put a "clinical hold" on
the IND to prevent the proposed study
the matter has been cleared.

~rom

commencing until

Assuming no problem has arisen,

the firm ente:c's into the phases of clinical trials.
In testj_ng the new drug, the

~irm

must .keep in mind that

adequate, well-controlled· studies are required in order to
determine the safety and efficacy of the new drug.

Under the

provisions of Form 1571 lO(c), a reasonable clinical trial
shall contain (48):
l.

more than one independent competent
investigator to maintain adequatecase
histories of an adequate number of subjects.
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2.

observations and evaluations of ro.1y and
all discernable effects attributable to
the drug in each indj_v.idual with comparable records of' patients used a controls.

3.

records of adequate information pertaining
to each: age, sex, conditions treated,
dosage, frequency of adrn:i.nistrationof the
drug, results of all releve:J.lt elinical
observations and lab examinations made,
adequate information concerning ony other ·
treatment given, full statement of adverse
effects e:J.lrl useful results observed, ro.1d
whether such results or effects are attribut-able to the drug.

Phase I is ·the preliminary stage in the use of the

ne~;

drug in human beings, and involves a small number of healthy
volunteers.

It is conducted to determine such parameters as

toxid.ty, metabolism, absorption, elimination, prefe=ed
. route of administration, and safe dosage range (50).

The

FDA monitors the firm's use of the drug through periodic and
adverse reaction reports which are submitted to·tb.e

IND~

·The

idea of using normal human vol<mteers'who will derive no
benefit from the new drug has been criticized as introducing·.
an unnecessary risk, and leading to inaccu:rate results, as
some disease states could alter the pharmacological parallleters.
This criticism has some validity, but on the other hand, people
in diseased states are more difficult to control e:J.ld the
Phase I absorption, metabolism, excretion,·. and dose ranging
studies are critical.
"normal" periods.

In most disease states, there are

Because the diseased person is more debili-

tated, trueing him off medication in order to develop the
pharmacologic profile would not be advisable.
line for review is at 60 days.

A second dead-

This is an in-house deadline
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for the reviewers in which a detailed notation of the initial
deficiencies, not serious enough to
are cited.

~mrrru1t

a cli.nical hold,

The firm is sent a letter containing this ini'orma·-

tion so as to aid them

i~1

the development of the IND.

If the Phase I studies prove the new drug to be relatively safe, the clinical trials·enter into Phase II.

Some

additional animal data on the subacute and chronic toxicity
may be required, depending upon the duration of administra··
tion.

Additionally, some manufacturing and control data will

be added i f i;he firm has altered the :f'ormulation.

A limited

number of patients with the disease state the molecule has
been designed to treat are utilized in Phase II, after preliminary data on the efficacy of the molecule,.has peen
As in Phase I, the sponsor sends all protocols

generated.~

of the Phase II sh1.d:i.e:a to 1i'JlA for approval.

In general, a

good protocol should contain (51):
1.

clear statement of objectives.

2.

m~?thod

3.

explanation of the methods of observation and
recording of results.

4.

comparison of results of treatment with a
control to permit quantitative evaluation;
four types of comparison are recognized;
a. no treatment: where objective
measurements available and placebo
effect is negligible.

of selection of subjects.
suitable for purposes of study.
b. assigned to test groups in a way
to minimize bias.
c. assure comparability in test and
control groups (age, sex, severity,
or duration of disease, use of other
drugs).
~
a.
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b.
c.
d.

5.

placebo control: compare results
of new drug with those of inactive
preparnt:i.on.
active treatme11t control: compare
to an effectiv.;) regimen.
histol'ical control: in certain cir-·
cumsta:nces, sueh as withdiseases of
a high a11d predictable mortality with
signs and symptoms of predictable
duration, or in prophylaxis where
morbidity is predictable; new drug
may be compared with prior experience
derived from adequately documented
natural history of the disease.

summa.-ry .of methods of analysis and an evaluation · of' data.

At the end of Phase II, the molecule has been characterized for safety and efficacy.· T'ne extensive Phase III
c~linical

trials are then con.templated.

Consultations \vith

FDA perEJonnel sometimes termed pre-NDA confer13nces, are made
by

the .firm concerning the :protocol .for the H1ane III studies.

These st-udies utilize a large number of patie:ni;s ·,rith the
disease t:he drug is designed tq treat.

The large numbers

a.':'e needed for statistical support in the determination of
the safety, efficacy, desired·dosage range, and side effects
of the drug.

'l'his is generally by comparison to a group of

patients treated with a placebo.

The studies in Phase III

are generally of ·1;he double-blind and double-blind cross-over
tJ']?e.

T'ne "double··blind" refers to the fact that neither the

inve:::tigat<:•r nor the patient know v;hether active drug or
placebo is being administered.

Patients entered into the

studies are numbered, an.d then randomly assigned either the
active or the placebo.

If the study is of the cross-over

type, then the patient receives .the active drug for a period
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of time and switches over to the placebo for an equal amount
of tj_me.

The controls aid in the meaningful statistical

analyses by supplying data on some of the variables inherent
in most studies.

The spontaneous remission of .the disease

can occur and thus distort the results on efficacy.

The

"placebo effect", a phrase defining the amelioration of a
disease merely by the administration of an inactive dosage
. form to a patient can be significant in any patient populati.on, and thus the reason .for the widespread use of the
double-blind and double-blind cross-over studies.

Similarly,

with the "Hawthorne effect", patients may become better solely·
due to the special interest taken in their particular disease
state by entry into a clinical trial.

This effect is diffi-

cult to eliminate.
Thousands of patients are generall;y util:i.z,ed in these
trials.

The investigators use the drug similar to the wc.y

it would be used if marketed, which reguire·s extensive c:oordi-'
nation and inoni taring on the part of the sponsor. . As required
by the regulations, each study has a clinical monitor

;~ho

is

well-qualified (s1..\bmi ttcd curriculum vitae is reviewed by the
med:i.co.l or dental officer along with tllose of all investigators).

an.

'I·he purpose of t:he clinical monitor is to assure that

investigators are actually doing the study and are follow-

ing the

\~ritten

protoc:ol.

In addition, the clinical monitor

makes certain that the reports of the investigator are returned
according to schedule.
Additionally, the drug product formulation used in the
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Phase III trials should be the snme as that to be used on
the market.
tainer

f~r

Stability data on the formulation in its conmarketing should be generated.

If all has prog-.cessed well, and the firm feels the

results of its studies provide substantial evidence to
support the claims for safety and effectiveness from the
data in the various phases, the firm prepares to file a New
Drug Application.

The application, J!'orm 356H, by regulation

must contain (52):
1. · Table of Contents.
2.

Summary of all the data on the drug which
presents a sound basis for approval.

3. Evaluation of safety and effectiveness.
4.

Copies of label and labeling.

5. . Whether the drug is limited
professional supervision.·

6.

to use :.tnd.oP

Full list of components.

7• ]ull statement of the composition.
8.

l!'ull description of the methods used in,
and the facilities and controls used fOJ:·,
themanufacture, processing, a.nd packing
of tb.e drug.

9.

Se.mples of the drug.

10.

J!'ull reports of preclinical investigations .
that have been made to show if the drug is
safe and effective for use.

11.

List of investigators.

12.

Full reports of clinical investigations that
have been made to show if the drug is safe
and effective for use.

13.

If this is a supplemental application, full
information on each proposed change concerning any statement made in the approved application.
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14.

Environmenta.l Impact Statemen·t;.

The Form 356H and the data generated to fulfill the
requirements are submitted in triplicate by the method
described specially in 21 CFR 314.1 (3).

The NDA is sent

through Central Documents and Records room for numbering
and routing, to Indexing and Abstracting for coding and
abstracting, and then to the appropriate
The 180 day

revie~l

revie1~

division.

time allowed the agency begins when the .

document is received.

The team of reviewers:

the Pharmacologist, and the

~1edical

or Dental

the Chemist,
Officer~

~1ith

the possible addition of the Consumer Safety Officer, the
Microbiologist, the Statistician, and the Biopharmaceutics
specialist, now begin the. scrutiny of the submitted data in
their area of expertise and responsibility in order to determine if the drug .is indeed safe m1d ef:t:ective.

To prove

·efficacy, the sponsor must submit"substantial evidence" in
the application.

"Substantial evidence" is defined in

Section 505{d) as " ••• evidence consisting of adeque.te and
well-controlled investigations, including clinical investi_gations, by experts qualified by scientific training and
experience to evaluate the effectiveness of the drug involved,
on the basis of which it would fairly ar.td responsibly be concluded by such experts "!;hat the drug will have the effect_it
purports or is represented to have under the conditions of
use prescribed, recommended, or suggested in the labeling or
proposed labeling thereof (53)."
Within substantial evidence,- there are several specific
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parameters which are examined.

The number and t7Pe of

patients enrolled in the studies to test the drug are
checked for applicability to the questions about safety
and efi'icacy..

The measurements utilized to signal toxicity

are scrutinized for their adequacy to signal the reactiops.
Any adverse drug reactions are carefully studied. to note

their significance.

The long-term animal studies for

carcinogenicity at this point are complete and problems in
this area are noted.

The stability studies for the drug

product are now complete and any problems in this area which.
might invalidate some of the clinical studies due to an
unstable product are noted.

If all appears to be adequate

. with respect to the above, the ultimate decision as to whether
the drug is safe and effective involves the ·weighing of the.·
benefit'-t.:)-risk ratio.· ·The ratio is individualized for each
N:UA.

Drugs \'lhich cure some life· threatening disea!".e, but not

without a severe sj_de-effect may be approved, whereas the same
side effect in another drug treating a milder condition would
be considered too seYere to all.0\'1 its approval.
is delicate and,

-~i th

The balance

the massi Ye amounts of data to be

studied, can be a difficult one about which to. make a decision
in 180 days.
The reviewers are not entirely alone in the.weighing

of the benefit-to-risk ratio.

Since 1972, in response to the

increase in scientific knowledge and the complexity of new
drug development, the use of advisory committees in the

Bureau of Drugs has greatly increased.

The committees provide
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high levels of input from scientists outstanding in their
field, allowing the agency to make reg;ulatory decisions
advice and to open up the agency's decision-making.
Bureau now has

\~ith.

The

17 scientific advisory committees to aid in

the review of IND's and NDA's that need some special consideration, in the areas of:

antiinfective, arthritis,

.cardiovascular-renal, controlled substances, dental, drug
abuse, endocrine-metabolic, gastrointestinal, neurology,
obstetrics-gynecology, oncology, opthamology, psychophaTinacology, pulmonary-allergy, radioactive·pharmaceuticals,
respirato~·y-anesthesia,

and surgical.

The criteria for

IND's to be considered by the committee includes those

representing important therapeutic advances, n.t:>vel and
improved methods of drug administration, or have a potentially significant hazard, as well as those \'lith safety
problems or any other in which the committee .m11y be
ested.

inter~

For NDA's to be considered, the criteria include

those with important therapeutic advances or important ne\v
uses

\~i th

narrow benefit-to-risk or those representing drugs

of controversial efficacy.

In addition, those which may

need post marketing studies .and others representing drugs
being considered for Vlithdrawal from the market because of
safety or efficacy problems may be considered by-the committee.
Any others in

~1hich

the committee may be interested may· b 1.3 ·

brought for examination (49).
Once the reviews have been compiled and the. decision
has been made as to whether the NDA is to be approved, the
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letter is drafted.

I f the application fails to meet one or

more of the requirements of Section 505(b) of the Act, the
sections are .cited as reasons for its nonapproval.

If all

of the following conditions have been met, the application
is approvable (46).
l.

Full reports of investigations which have
been made to show whether or not such drug
is safe for use and whether such drug is
effective in use.

2~

A full list of the articles used as·components of such drug.

3. ·. A full statement of the composition of
such drug.

4.

A full description of the methods used in,
and the facilities and controls used for
the manufacture, processing, and packing
of such drug.

5.

Such salilples. of such drug and of the arti-·
cles used as components ther.sof as the .
Secreta~; may require; and

· 6~

Specimens of the labeling proposed to be
used for such drug.

The firm submits the final printed labeling for review,
and an inspection of the facilities that 1t1ill be producing
the drug product is made by the field personnel to determine
the firm's ability to manufacture the drug, and their.compliance with the Current Good Manufacturing Practice regulations.

lffien the final printed labeling has been reviewed

m1d

approved and a satisfactory inspection report has been received,
the drug product iS allowed to be marketed.
The Reviewers
'l'he review and evaluation. of IND 1 s and UDA 1 s at the FDA
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:i.s probably one of the most scrutinized, r•er5rganized, debated,
and criticized functions of the agency.

Congressional hear-

ings hav-.e brought many attacks on the process.

On one hand,

the agency is accused of taking an inordinate amount of time
in the approv:Lng new drugs thus creating a "drug lag" between
their marketing in the United States. and the Europeru1 countries

(54).

On the other hand, the opposite viewpoint was

presentedin the August 16, 1974 hearings before the Senate
Health Subcommittee by some agency employees who felt the
agency '\'Ja.s allowing unsafe drugs on the market (55).
What is the purpose of the review process and

it been so heavily criticized?

'I'Jhy

has

The history of reviewing

dates back to the safety question ra;Lsed by the Sulfru:1ilamide
Eli:x::lr Tragedy oi· 1937, and the more recent Thalidomide
Tragedy of 1962.

The passage· of the Federal J!'ood, Drug,

and Cosmetic Act in 1938 and the Drug Amendmeuts of 1962,
gave the FDA the responsibilityto assure that new drugs
are safe a.11d effective.

To control effec.tively these new

drugs coming onto the market, certain parameters abou·t; their ·
safety and e.fficacy must be knovm, and the information
included in the IND's and NDA's must be complete, accurate,
scientifically competent, and substantial.

~1he

trained·

scientists must make these decisions.
The reviewer 1 s job has a variety of descriptions.

~'o

begin, reviewing is a difficult job, an intricate operation
'~ith

many different facets.

It is a "general" job.

Although
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the revie•11ers are assigned drugs in some specific drug
category, they must be capable of handling a variety of
different kinds of inform.o,tion on new techniques for animal
testing, drug

m~~ufacturing,

or clinical procedures from

experts in those fields in industry.

.The reviewer must,

therefore, be flexible and have the ability to educate
himself in new areas.

As the FDA's kno\vledge of problem

areas increases, then the agency tightens up. its requirements and demands more of the industry, thus increasing
the amount of general "specific" knowledge required by
the revie'\ver.

This "tightening" has been very evident

since 1962, with the quality and quantity of the submissions increasing every year.
It is a denia.'1ding a.-'"ld pressu..--:-j_ng ;job.
sibili ties of· the revie'l'rer are gre:at.

l'he respo.n-

Although the dead-

lines for revievl work a.ppear to be adequate to be met
easily (e.g. 180 days for the.

~IDA),

one must remember that

the reviewer does not handle just one

nm

or NDA, but many.

Thus his time must: be organized adequately to allow for
thorough coverage.

Some clinical data fill over 400 volumes

or jackets and. t:tms the medical officer vwuld be required
to review IJ. j aclmts of over 1200 pages per day!

The work-

load never decreases, it either remains relative;Ly constant
or increases.

The number of applications received (56)

depends upon the timing of the firms, and for the past
years has been:
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127.2.

122!±

.12.22.

IND's

913

842

818

NDA's (original and
resubmissions)

332

333

338

2447

2461

2705

Supplements
(original and
resubmissions)
It is a lonely job.

Although the reviewer can utilize

advisory panels, consultants, and colleagues, he alone is
faced with making a decision or evaluation about the adequacy
of the data to assure safety and efficacy, and must be prepared to defend his-decision.

It must be remembered, too,

that drugs are toxic substances and are intended for "the
diagnosis, cure, mitigation, treatment, or prevention
of.
,,
disease" or "intended to affect the structlu'e or fu.'1.ction.
of the body" (57).

'l'lhen one begins to alter the body's

physiological 1Jalances, or the imbalances which occur in
certain disease states, it i.s both dangerous and difficult
to preQ_ict all of the possible reactior1s.
Wno are the reviewers?

As mentioned previously, the

review work is done utilizing the team approach with the
pha.rmacologist, chemist, and medical or dental officer 1tlorking together to review the data that have been submitted•
Additionally, to aid the primary team of reviev1ers, the
consuraer safety officer, microbiologist, statistician, and
biopharmaceutics specialist are utilized.

Each member takes

a different look at the application in his area of expertise.
The Pharmacologist.

'l.'he primary concerns for the

pharmacologist as a member of the review team are the safety
of the drugs and their pharmacological activity.

In the IND

and NDA regulations, the information on safety of the drug
as cl.etermined in animal studies includes (48) & (52):
IND:

Statement covering all information
available to the sponsor derived from
preclinical investigations and any
clinical studies and experience with
the ~~gs as follows:
adequate.information about.p:re.clinical investiga.tions, including
studies on laboratory animals on
the basis of which the sponsor has
concluded that it is reasonably safe
.to initiate clinical investigations
with the drug: identity of person
· conducting the study; identity and
qualifications of the individuals
who evaluated the results and concluded it is reasonably safe to
initiate clinical investig,?otions.

NDA:

Fu11 reports of preclinical investigations
that have been made to shcM whether or not:
the drug ie safe for USE' end e:ff'ectiYe in
use\10

The

pharmacologis·~

the regulations.
review.

thus concentrates on these· sections of
The first big review is the 30 day safet-y

'!!he pharmacologist hasthe crucial responsibility

of determining, whether the submitted data a:r:e adequate ·and
justify the use of the drug in humans.

The studies that

will generally be accep·table for the Phase I trials are outlined in an artic,le appearing in the FDA publication, I•'DA
;t>a·£>~:1:.§.

entitled "Current Views on Safety Evaluation of Drugs",

by Edwin Goldenthal (58).

The types of animal studies

required for the phases of drug investigation are outlined
in this article, and vary with the route of administration,
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the duration of human administration, the phase of study,
and the type of patient in which it '<lill be used for each
individual drug (Table I).
After the 30 day safety evaluation has been made, and
the initial dose has been determined to be relatively safe
to begin the Phase I studies, the pharmacologist must then
begin the task of monitoring the additional, chronic animal
studies that are submitted to support the extended use o·f
the drug in humans.· This \vork continues throughout the IND
phases, as many of the chronic toxicity or carcinogenicity
studies can take several years to complete.

The.se tests

can also be both difficult and costly a.s many animals must
be used for the. long-term .studies to assure an adequate num···
her at the end of the trial for significant .data.
In the lWA, the pharmacologist's work has been mostly
completed, because -if the animal studies >vere inadequate in
any phase of the IND, the NDA would probably not be submitted.
The work that does remain involves the review of some of the
most extensive chronic toxicity and the carcinogenicity
studies.

In addition, the pharmacologist makes comments on

the labeling for the product in the areas of his review work.
This could include eomments onthe description, actions,
indications,

~mrnings,

animal phm·macology, ·and adverse

reactions sections that reference animal data as justification for inclusion.
The Chemist.

The chemist is responsible for the review of

all those documents (IND's, NDA's, amendments) which contain

Category

·Oral
Or

Duration Ot
Human Admlr:!s!rz\lcn

Phaset'l

Subacute Or
Ci1ronlc Toxicity tzl

ObServations

Speclel Studies

Se-.'erai Days

I, II, Iii,

2 soecies:'2 weeks

Body Weights,
Food Consumplio",
Behavio•,
Hemogram,
Ccagulation Tests,
liver and Kidney Function Tests,
Fasting Blood Sugar,
Ophl~atmo!ogic Examination,
Metabolic Studies,
Gross and Microscopic EKaminatiOn,
Others as App:opriate.

For parente•ally
administered dru~$:
irritation s~uc:es,
compatibilitY w;th
blood whert~ a;lplicab:e:

!~DA

2

Parenteral
IJ~

to 2 V!ee!<.!t

tQ

1-j

2 spe;::!es; up

llt,NDA

2 sp"lci<:s; up to 3- months

s-

1-'·

s

m
m

G Months
to Unlimited

1-'·

'"' ~~

l:l

()

1-j

1-'·

~

<"!"

~

s::p..

1nhala:lo;,

:?.

sp<!ci~s;

--------------~

--------~

11~,

NDA

4 species; 5

d;;~ys

{3 hoursjday)

(General Anesthetics)

(1)
(1)

Dermal

1 spec13s; single 24-hour exposure

Single Applicstlon

fotiowed by 2-week
obserVation

H

1 spoci~s; 20-day repeated exposure

Single or S~orHerm
Application

II

1-'·

Short-term Applicallc-n

Ill

As above

(1)

Unlim\!!!d Application

NOA

,... 'lbOV.;!, but intact .;kin study
extended up to 6 months

§l
p..

1-'· 1-'
(1)
1-'·

m l:l
(1)
m

~

Ophthalmic

{intact and abraded sk\nj

1,11,111

1 specie:;: 3 weeks daily application&,
as in cl~r:ic<:~l use

NOA

1 .!;pecies: du..-ailvn commensurate wtt.,
'
p.3riod of drug administration

------------------------~------~-
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information pertaining to the chemistry and manufacturing
and controls of the drug.
review topics include:

In the review, the individual

components, composition, facilities,

personnel, synthesis, raw material controls, other firms,
manufacturing and processing, container, packaging and
labeling, laboratory controls--finished dosage form, control
numbers, stability, samples and

results~-methods

validation,

labeling, establishment inspection--CGI1P 1 s, registration, and
environmental impact statement.
The time frames for the review of the documents are the
same for all of the disciplines:

IND·-;...30 dey safety and 60

day for initial deficiencies, and NDA-··180 days.

The chemist

concentrates upon his portion of the documents <<ith some
checking into. the clinical section to make certain that the
formu.lation. that was or j_s tO be used i_n clinical -'cx·ials is·

the same as the one submitted in the composition section, and
that there are no additional drugs being used about which the
..firm has submitted no manufacturing m1d controls data.
To further define the types of manufacturing and control
informa.tion the IND or NDA should contain, the Pharmaceutical
Manuf·a.cturers Association (PMA) and the FDA met to develop
criteria.

The product,

Qu}~.=kn.~?D'lli!.l~g.i\f£.il:flL@lSUJ.2~§.

!.2Vl.ill..:.IL2ll(LliPn. prqvides the specif'ic information to be
submitted that will adequately meet the requirements in the
regulations.

These guidelines were very helpful for the

chemistry reviews done by the author.
In the 30 dey safety review,· as stated earlier, the
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chemist is responsible for the assurance tha.t the firm has
properly cha'T.'acterized the new

d.:cu~,

the formulations listed

in the manufacturing and control section agree with those
listed in the protocols, adequate quality control procedures
are utilized to assure the proper strength, pw:•ity, and
identity of the drug,

a~d

the labeling has the required

information.
In checking the proper characterizations of the new compound (in addition to structural determination from the
synthesis), there are several steps (59):
1.

gross examination:
odor.

2.

determination of purity and physical
characteristics:
a.

b.

pbysica.l state, color,

purity: although used, the mel;:;.ing point, boiling point, refrs.etive index are generally not the
bes>c tests for purity; but l'B.ther
gas,· liquid, or thin layer chroruotography should be used.
physical characteristics: melting
point, boiling point, density,
refractive index, empirieal formula
(from elemental analysis), molecula:r
. \veight;, solubility, opt:i..cal rotation,
spectral properties.
·

3.

classification by function g.roup:
soluoili ty, .element?-1 analysis. ·

4.

final identification: absorption spectroscopy,
nuclear nagnetic resonance, inf'rlli~ed and ultra-·
violet spectrometry.

acid, .base,

The quality control procedures generally use a reference
standard which has been completely characterized for comparison of the results of certain tests, for example, gas
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chromotography, with the sample batch.
sample batch is also included.

An assay of the

]'or a clinical hold to be

placed on the Phase I studies due to deficiencies in the
chemistry, the:re must be evidence of inadequate controls
over the ne\•1 drug, i.e. the sponsor does not kno\•1 what is
being given to the patient, whether due to stability problems, impuri.ties, or lack of proper characterization of the
compound.
The 60 day review·of' the IND involves more thorough
scrutinization of the information, \"lith the minor deficiencies in the application being noted to the sponsor in a
letter.

The

nm

does not need to contain as much informa-

tion as the 1--TDA, and the sponsor can have some flexibility
in the pr·ocedures while l:te is deciding ho'rl and i£ they \oJill
market their new drug.

As the drug approaches the Phase III

clinical trials; however, the sponsor should ha.ve a. defi11ite
formule.tion that he will propose for marketing, complete vd th
on-going stability st-udies in the container to be .used, the
purity of the reference compound should be at a high level,
and the sponsor should l1e developing more detailed manufacturing and control data.•
The chemist'B review of the NDA is lengthy and involved,
and generally the application is not approvable on. the first
submission, due to the fact that many fail to J:espond adequately to the requirements directly stated in the Form 356H.
In the past few years, the chemists (as with the other disciplines) have become much more stringent in their reviews,

?0
requiring much more information about,. for example,
packaging and stability, as more knowledge is gained
about the problems that ca:n occu:r·.

The area of mett,:red

aerosols is one in which the requirements for information
to be submitted has increased considerably.

Over the past

few years, interest has developed in the difference between
the types of valves; good, indicative function tests for
the metered aerosols; and the possible effects of the change
in a mouthpiece on particle size.

Stability data on these

dosage forms includes not only the potency of the active
ingredients as with most dosage forms, but the. \'Thole unit,
i.e. the stability of the mouthpiece, valve, actuator, bottle,
and the contents (mostly freons) within.

Addit:ionaJ.ly,

packaging materials are being checked more thoroughly today
for poten".;ially hazardous leaehables, for exa;ople 2··
mercaptoimidazoli.ne in gaskets and vinyl chloride from
polyvinyl chloride con_tainers.

As kl1o\vledge about the

hazards of leachables and the ability to detect small amounts
(parts per billion) of the chemicals is gained, more work in
tracking these down in the NDA will be made for the chemist.
The chemist reviews several sections of the package
insert, and has the responsibility over the package labeL
In the insert, the chem:i.st reviews the description, .structural
formula, and ho'\'1 supplied sections for accuracy.

In addition,

the chemist generally skims the remainder of the labeling 'to
see if the firm is in compliance with the regulations as far
as the number of times the trade name can be mentioned on a
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page and the height and prominence of the lettering.

On

the package label, the chemist niu.st review the entire document fo~ the required information, 1.e. the statement of
the ingredients, the declaration of the quantity of contents, and the form for making and the adequacy of the
required statements.

Most

ot these

·labeling regulations are

included in 21 CJ!'R sections 1.100-1.115.
The chemist generally must revie\<r the drug master file ·
(Dl"'F) as many IND 's and NDA' s refer to one.

The drug master

file is. a document submitted by a firm to either avoid duplicating information that'is submitted to the firm's several
IND' s or NDA' s or from a supplier that \vi shes to maintain
tr·ade secrets and not divulge the information··on components,
manufacturing and controls, etc. that is r·equ:Lred_ by FDA for
an nm or NDA to its customer.

The Di'IF can contain most ru1y·

aspect of the manufacturing and controls

information~

facili··-·

ties, personnel, composition, ra'tl material description,
specification and controls, synthesis, general manufactur·ing
and procession or packaging

~md

labeling. ·

Hedical Officer o,., Dental Officer.

---~----'"""""

-

u-

The l-'ledical Officer or

the Dental Officer is the team leader in the Review Process.
After all disciplines have made their respective reviews, it
is the- team lee:der that pieces them together to make a final
decision.

As a member of the team, it is his responsibility

to determine the efficacy and safety of a new drug from the
clinical trial results, 8lld to weigh the benefit-to-risk ratio
in making that judgment.

He is generally faced with a
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voluminous amount of data. to sort through .and evaluate, as
most NDA submissions contain several hundred jackets, most
of which contain clinical data.
In the 30 day review, the Medical or Dental Officer,
together with the Pharmacologist, determine whether the
animal data are adequate to support the proposed use and
the initial dose for the Phase I trials.

Along l'lith the

initial dose to be used, the protocol that accompanies the
IND must also be approved.

It must include adequate pre-

cautions to be taken that '\'Jill detect any toxic effect
readily so as to minimize the risk involved to the volun-·
teers.

In addition, Phase I dose ranging studies will be

perforrn0d to determine the best dose to use in the Phase II
studies, and generally contain tests which '.vill be indicative
of the tolerance and toxicity of the drug as it is used ir1
man from a very low dose to higher doses E.;;em'lrally oYer 'I'Ieekly
time periods.

The tests may include blood pressure, pulse,

.ECG, and laboratory (urinalysis, total protein, albumin,
globulin, uric acid, glucose, BUN, SOOT, alkaline phosphatase,
total bilirubin, and CBC), •ri th side effects monitored carefully.

If the Pharmac.ologist and the

~1edical

or Dental Officer

agree that the initial dose is sufficiently low to begin the
trials, an.d that the protocol is adequate, the 30 day safety
release slip is signed and the firm will be .allowed to begin
the studies.

(In actuality, if the firm has not heard from

the FDA within the 30 day
begin the studies.)

\~aiting

period, they are

allo~md

to
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The Medical or Dental Office:r· rwu o.ssumes the
responsibility for reviewingall information that comes
in on the IND concE:rning additional protocols, data from
the studies, adverse reactions, and additional investigators.

The first two phases must be watched carefully to

see that the patients are not subjected.to unnecessary risk.
In Phase III, the drug has been fairly well characterized,
and the protocols are reviewed.

The results are generally

not submitted to the IND from this phase, but are rather
included as part of the NDA.
In revie\ving the NDA data, the t1edical or Dental Officer
is faced 'Vl:i.th a great volume of !naterial.

Fii·st, the total

docUJne;:J.t is ZCJ.rveyed to determine the types of... studieE: that
have" been submitted to prove the drug is safe a11d. effective.
Any cor:r·espondence either from the firm or the FDA is revievled
so as to obtain a total picture.

The submitted labeling

J.s

scrutinized for the claims of efficacy made by the firm
a).ong with the adverse reactions and contraindications found.
After this overall picture of the NDA is obtained, the review
of the individual studies begins 1t1ith notes made on the study
design, the rating system (subjective vs. objective), the
adherence to the protocol by the investigators, and the
adverso rea·;)tions.

To characterize the drug, clinical,

labora.tory, and observation data of the effect of the drug
in n::an are submitted.

The clinical data include information

on the patients physical examination, vital signs, and
possibly a chest x-ray.

Laboratory data on the urinalysis,
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clinical chemistry, and hematolog-<J aid in the determination
of the

~~ug's

effect on the

va~ious

body systems.

Addi-

tionally, the investigator must make clinical observations,
noting any adverse or toxic effects the drug may have on the
patient.

This monitoring of the drug must be consistent in

each of the studies to yield meaningful results and thus
requires strict adherence to the protocol.

A variety of

studies all have their place in the evaluation of the drug.
These studies include dose ranging, metabolism, pharma- .
cokinetics, detoxification, enzyme induction, bioavailability,
and efficacy with each requiring different measurements.

The.

results of the evaluation of each of these studies are pteced
together to obtain an overall picture of the safety and
.efficacy of the drug.
i',JJ:1en all 'the reviews hav-e been.. completed, the team Jea.der
then coordinates them into a final evalu.ation of the drug.
All aspects of ·the labeling. are scrutinized for adequate
substantiation by the submitted data.

The recommendation

for either approval or disapproval of the NDA is made based
upon the v1eighing of the benfi t-to-risk ratio.
'l'o aid the principle

revie\~ers,

the consumer safety

officer, microbiologist, statistic:ta.'1, and biopharmaceutics
specialist are utilized.

Each of these members has a specific

area of the review process in \vhich he can add his expertise
in order to add thoroughness and depth to the revie\v.

Consumer Safety Officer.

The administrative member for the
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team of revie;o;ers is the consum0r safety officer (CSO) •
.As a trained scientist (requirement for employment is a.
Bachelor of Science), many of '-'lhom are pharmacists, the
consumer safety officer is responsible for the classifying
of doc.uments and insuring their smooth :flmv th1.•ough the
division.

Additionally, the CSO coordinates the work of

.the reviewing disciplines and handles the division's responsibilities on the regulatory actions taken on IND' s and HDA' s.
Further, he must answer the inquiries that come into the
division on its drug products.

Many of the CS0 1 s come from

the field offices of the agency and thus have a good background in drug regulatory procedures and can answer questions
in the division about the regu.lations.
After a document has been pl'Op.erly logged into the.
division's doc.uments room, the CSO 2'eviews it for complotenegs.

At times, an HID or HDA may be

r!>~jected

prior to revievl

if there are omissions of parts of the regulations.

has th:i.s :t·espons:ibility.

The

cso:

This procedure saves reviewer time

by eliminating an unnecessary review, as the document is
deemed nonspprovable on its face.

Other administrative

functions for the IND ar1d NDA process ru.'e ;numerous. · 'These
functions are basically regulatory and include the drafting
of letters to firms stating the. agency's decision on the
application,

~Ihether

deficiency, comment, or request.

Due to the number of reviewers:

pharmacologist, chemist,

microbiologist, statistician, medical officer, bioavailability
analyst, advisory committees, and consultants, involved in the
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review of an IND or NDA, there is a definite need to
coordinate their activities.

The CSO is responsible for

this coordination, keeping in mind the various time limitations to assure .that the decisions \vill be made within the
statutory limit.

After all reviews are gathered together,

the CSO extracts the conclusions, recommendations, and
requests made by the reviewers and includes them in a letter
to the sponsor of the

In addition, the CSO keeps

document~

track of any document going to another division for a consultative review.
Mi~.~-oJ..qgj..&!i_.

Although most microbiologists are located·

in the Division of Antiinfective Drug Products to revie\1
IND's ana, NDA.ts for antibiotics and sterile pi'•oducts (i.e.
optha1mic5), the Surgical-Dental Division has one reviewing
microbiolngist-.

The microbiologist in the division handles

those. sections of the documentE which include microbiological
informat':i.on on its drug products:

sterilization, pasteuri-

zation, tmd microbial studies done on antimicrobial products.
ThEo introduction of the polyvinyl chloride, flexible
b2gs usecl :for blood and la.rge volume pa.renterals, has created
a considerable amount of work for the division, ·and in par··
ticularly, the mic:robiologist.
products

~:;liffers

The sterilization of these

from· the moist heat steriliza-tion described

in the U.H.P., thus each submission needs a separate review.
The development of the good manufac-turing practice reg\1lations
for large volume parenterals will set more definite standards
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for sterilization and will alleviate some of the review work
that must be done on these products, although all deviations
will have to be approved on an individual basis •.
The types of data to be reviewed in this area include
the method of sterilization, the physical and microbial
methods used to develop and quantify the cycle's efficacy
and to validate the sterilization of the entire product, and
checking the controls of the firm over the microbiological
environment of the process.

The pasteurization of these

products is also important to prevent mold contamination of
sterile blood bags that have an overwrap or cover.
Some drug products in the division not only have the
requirement to. be. sterile,. but. are designed to prevent infection as vrith the sm'gical, 'tlound,
P.nimal studies designed to

test~

~mel.

burn d::.•essings.

The

the ef:!'icacy of' si.1ch products

are reviewed by the.microbiologist from the protocol and
methods, through the submitted data..

These studies generally

include both qualitative andquantitative assays of the microbial populations that are present in the wound site.
Those products which contain chemical

~timicrobial

agents must also be reviewed by the microbiologist for
efficacy.

The review criteria for both the

.ULYJ-..t!:£

~d

·clinical studies of these products must· be set up by t:he
division.

The evaluation concentrates upon certain criteria:

reduction in microbial counts, development of resistant strains,
~d

the identification of the

the populations.

microorg~isms

to note shifts in
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Statistician.

Due to the volume of data submitted by the

manufacturers in their ,justification of the . safety and
efficacy, the primary
statistical analyses.

revie~l

team frequently request

The sta.tisticians are not part of

New Drug Evaluation, but rather in Biometrics and
Epidemiology.

The requests for statistical analyses are

sent from the revimrle!' through the division director to
the Division of Biometrics.

A statistician is then assigned

to do the review.
l"leetings are held bet•reen the statistician and the
reviewer in which the types of analyses are discussed.
·Depending upon the types of information to ·be.· extr·acted
i'rom the studies, different reviews are done.,... These reviews
can cover the design of the study; the ir>..fluence of va.r·iailces,
for example

~Ieight,

height, age, sex,

~eve:C'i ty

of disease and

the condition of the patient; the significance of the improvem.ent; and the comparability of the drug with the placebo.

The

information. from these revie\vs aids the reviewer in his determination of the safety and efficacy of the drug •
.!li~.!>l£.ceutics

Snec:i.ali.§.i.

With the increased interest in

the bioavailabiJ.i·i:;y of drug products, many of the revievm:rs
are requiring this kind of information to be. included in the
NDA.

The agency's expertise in this area of bioavailability

is in Drug l'lonographs.

Documents are routed from the reviewer

(generally tlrrough. the Medical Officer), through the division
director to the biopharmaceutics specialist in the Division of
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Biopharmaceutics.

Here, the clinical studies on· the

absorption.,. distribution, metabolism, and e:Kcretion of
the new drug are reviewed.

Determinations of the amount

of drug which the patient is actually receivingaids in
dose determination.
revie~/S

Recommendations based upon these

are returned to the New Drug Evaluation reviewer

for use by the Medical Officer in determining the safety
and efficacy· of the drug product.
Assignment<! in the Division
As part of the work-study program, the author was
expected to participate in the execution of the Division of
Surgical-Dental Drug Products' responsibilities, ru1d was
assigned various projects that met a specific"·need in the
division.

The bulk of the work was the review of the

chemistry portion of many IND's and NDA's.

Additionally,

the analysis and evaluation of data submitted pursuant to a
l!'ederal RegifJter notice on vinyl chloride and polyvinyl
chloride,

2.11

investigation of problems which had occurred

with the metered aerosol dosage form, and the organization
of clinical data in preparation for a medical officer's review
provided \'Vork for the student.

These projects not only met a

need .for the Division; but simultaneously provided the student
\'Ti th a working knowledge of

Ne~v

Drug Evaluation, the agency,

and the contents and flow of docUlllents.
Polyvinyl chloride, a resin used as a major component
for a

\~ide

variety of plastic products, received its sanction
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by FDA in 1956, in that it was listed in Lehman 1 s "Food
Packaging".

Its acceptance was based upon its lack of

mig.-ration into foods when tested in the early 1950's (60).
However, in January 1973, the FDA received reports from
the Department of Treasury's Bureau of Alcohol, Tobacco,
and Jl'irearms that stability problems \'lere experienced in
those distilled spirits packaged in polyvinyl chloride (PVC).
As vinyl chloride is considered to be a poisonous substance,
the Bureau of Alcohol, Tobacco, and Firearms banned the use
of PVC containers for distilled spirits, and the FDA became
concerned about its use in food packaging.
A new development, a year later, caused the concern to
become more intense.

On January 22, 197L1., the Or:.cupatidnal

Safety and Health Administration received word that E. F.
Goodrich Chemical Company had. reported .several deaths of its
1.1orkers from a rare form .of liver cancer, angiosarcoma, and
. that these deaths may have been related to their '<Jork wi.th
vinyl chloride.

In addition, Professor Cesare !1altoni of

Bologna, Italy \vas conducting studies of the effect· of vinyl
chloride inhalation on rats, mice, and hamsters and found
tumors at 250 pa:r·ts per million (ppm) which were histiologi··
cally similar to those or the Goodrich workers.
As the FDA was concerned about what drugs might c.ontain
vinyl chlor·ide or were packaged in PVC with the potential oJ
the leaching or extracting of vinyl chloride from the PVC, a
Federal Register Notice was published on April 22, 1974,
detailing information the agency required to understand the
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extent of the use of vinyl chloride and polyvinyl chloride
in drugs and drug packaging.

The request was authorized

ttnder Sections 201, 510, and 70l(a) of the FDC Act, and
required each manufacturer registered under Section 510 to
submit (60):
1 •. reporting firm name, address and
registration number.
2.

list of drugs containing vinyl chloride
and a list of drug products for which
polyvinyl chloride is used as a container
or container liner.

In addition, the following information was requested, but
not required:

3.

National Drug Code number, if one' had ,
been assigned.

4.

statement if drug is OTC or prescription.

5. route of administration.
6.

amount of vinyl chloride in average daily
dose.

7•

quantity of drug distributed in the past
twelve months.

B.

copy of label and labeling.

9. vinyl chloride content of the polyvinyl

chloride used for manufacture of container
·or .liner.

10.

rate and level of extraction of the vinyl
chloride from the polyvinyl cnloride.

11.

rate and level of absorption of vinyl chloride
.as an ingredient or of vinyl chloride extracted
from polyvinyl chloride liner or container by
the drug as an average daily dose.

12.

name and address of the manufacturer of the
polyvinyl chloride resin.

These data were sent to Drug Listing for coding, then to a
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member of the Bureau's vinyl chloride committee.

The

responsibility of the analysis and evaluation of the 146
polyvinyl chloride reports, ranging from a single page to
over 100, was delegated to the author.

The points felt

to be pertinent for initial use were investigated:

drugs

containing vinyl chloride as an ingredient, amount of vinyl
chloride in an average daily dose, vinyl chloride content of
the polyvinyl chloride used for manufacture of container or
liner, rate and level of extraction of vinyl chloride from
polyvinyl chloride, and the rate and level of absorption of
vinyl chloride.· Upon completion of the initial analysis, a
report "'as written to the Bureau of Drugs representative on
the vinyl chloride committee, indicating the ;results of the
pertinent pOints.:
1.

2.

Nanufacture Compl:i3l1Ce
a.

list of the firms that responded.

b.

completeness of the reports.

Results
a.

drugs containing vinyl chloride as
an ingredient.

b.

vinyl chloride content of polyvinyl
chloride used to manufacture containers ru1d liners.

c.

rate and level of extraction of
vinyl chloride from polyvinyl
chloride.

d.

rate and level of absorption of vinyl
chloride.

3. Potential Problem Areas
A second analysis required some quantification of the
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data from the reports, to determine the impact certain
regulatory actions would have.

The first fifty polyvinyl

.chloride reports were examined for information on the

num~

ber of cap liners, containers, and blister material used
in drugs with approved NDA's vs. drugs which did not require
NDA's.

The second analysis included all 146 reports to

determine t;he number of cap liners, containers, and blister
material of all drugs vs. solids made of polyvinyl chloride. ·
These results 111ere submitted to the Office of Regulatory
Affairs to aid in the drafting of

~deral

Register proposed

rules on drugs packaged in polyvinyl chloride.
sem•ches o.f ·the data '<'ere made upon request.

Additional
The names of

some Bolid d·osage forms in blister packages \'lere sent to the
Bureau o£ Drugs l'harmaceutical Research and 'I'esting Labs so
they could be ro:1alyzed for PVC content and those tirms which
included b:i•c1.ogic.al products in their reports were sent to
the Bureau of Biologics.
Interb:u:reau ro.eetings on \vhat action the l!'DA should take
on PVC used in all of the products were held and the student
v1as HllovFed to attend these discussions.

They provided

insight into the interrelationship of the various Bureaus of
the agency, and the procedures involved in the development
of FederaJ:...B.'?:E}S.!fl:_ rules and ref!,'Ulations.
In thee pulmonary drug products, a fed.rly unique dosage
form has, in the recent years been under close scrutin;r by
the FDA.

The metered aerosol has a valve that delivers a

measu:c-ed dose to the patient.

The proper metering of the

valve is especially important as some of the more potent
pulmonary drugs are administered via this route.
Two recalls of metered aerosols

ea~·ly

in 1974, due

to leaking propellents from the valve which led to a c.oncentration of the active ingredients and subsequent overdose of the drug through the valve, caused concern with the
supervisory chemist as to the adequacy of the function of
all other metered aerosol drug products.

The author was

requested to compile information from IND's and NDA's about
the metered aerosols which included:

IND/1TDA number, trade

name, sponsor, valve type, container, manufacturer, gasket,
seal, diaphragm, material supplier, composition, dosage form,
expiration date, if any, and ioihether the drug".was OTC or
:prescrigtion.

To obtain the information, over 60 HTD' s and ·

NDA' s were surveyed.
tion.

The first

i'laS

T\vo memos were i1ri tten •·ri. th the in.forma-.
for the. information of the revievrer on

the type of problem that had occurred warranting the recall.
T'ne second covered the results of the search:

discontinued

or vii thdravm IND 1 s or NDA' s, the background of' the valve
problem, the types of valves used by the firms with metered
aprosols, and the problems \1hich occ'\.UTed in obtaining this
information.
The assignment familiarized the author with

DTD/NDA

contents, the Indexing and Abstracting service, documents
control, m1d the importance of valve and mouthpiece in
obtaining proper dose.

Additionally, processes involved

in the manufacture of aerosols which included stability of

I
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the entire unit, quality control testing done on metered
valv-es, cold fill (one stage) vs.

~~o

stage fill, suspension

vs. solution, control of parts or components, spray tests,
particle size distribution, was presented.
In addition to problems with the valves of metered
aerosols, the gaskets in some of them contained small
amounts of the potential carcinogen, 2-mercaptoimidazoline.
A Federal Register notice of May2, 19?4, stated that the
possibility of 2-mercaptoimidazoline rearranging to form
ethylenethiourea, a known carcinogen, existed.

The notice

proposed that the use of the chemical as a stabilizer in the
neoprene rubber parts would be prohibited.

The task was to

locate those firms >1Tith metered aerosols that"·use gaskets
;;i tb. the compound.

The search '11Tas incorporated into the

seeking of inf·ormation on metered aerosols.

Once this

irlformation vla.s obtained, two memos were written.

The fh'st

was to the master files of those firms which had 2mercaptoimidazoline in their gasket formulation to po:i.nt
this out to reviewers.

The second memo was·sent to the

supervisory chemist ar1d listed which metered aerosols had
the stabilizer in their gasket formulations.
Following the work on the special projects assigned,
the author began
IND's and NDA's.

revie~ling

the chemist 1 s portion of many

The types of IND's included one new chemical

entity, two new dosage forms, seven individually sponsored
(noncommercial~·marketed),

and one IND amendment.· One

original NDA was reviewedin its entirity.

Several
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supplements and an amendment which included information on
stability, particle size distribution, labeling, overfill,
manufacturing changes, container changes, additional quality
control procedures, and annual reports 'ITere also reviewed.
Additionally, the student worked with a medical officer on
the organization of one of the agency's most lengthy NDA's.
The chemist's review of the NDA required careful
examination of techniques, calculations, drug master files,
and data to evaluate its adequacy. ·The review process is
very individualized and each reviewer develops his own procedure from experience with the documents and consultations
with fellow revie'llers.

The student developed her O"!ll pro-

cedure, as follows:
1.

Scan. Brief survey of the document to
beCOme familiar with its contents. Note
deletions of any sections of the regulations.

2.

Background. Check documents room for current correspondence, amendments, related
documents, and other action taken relating
to the drug.
Guidelines.

Review the requirements in
Study Guidelines:
Manufacturing and Controls for IND'"'S"a:nd
NDA 1 s written by ~~A and Pf~.

~orms

1571 or 356H.

4.

Gross Review. Reread the submission again
tak~ng note of \vhat is or is not included.

5.

Resears~·

6.

Revie\•1. Close scrutiny of the document.
Take one requirement at a time using the
PMA-FDA Guidelines and other sources.

Utilize reference texts, articles,
and other sotu-ces to gain familiarity with
any areas that are unknown.
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Consultation. Possible conferences with
colleagues, team members,
advisory committees, the Associate Director.
for New Drug Eval.uatL:m, and the Director
of the Bureau of Drugs.

surei~or,

B.

Write Review. Include summary under each
heading of' i'he information submitted 1Hith
explanations as to its adequacy.

9.

Decisions and Recommendations. From the
notes and review, determine the comments to
be included in the chemist's portion of the
letter to the sponsor.

10.

Draft letter. The chemist's portion of the
letter to the sponsor of an IWD includes the
listing of the deficiencies and asks for
additional information. \'lith the NDA, the
application is either approvable or nonapprovable. The decisions must be supported
by citing sections of the Act, and making
statements that explain the types of def'icien·cies and V<hy. In supplements to NDA' s, · the
chemist writes the letter to th~. firm stat:i.:ng
the decision and the reasons·

The contents of a drug master file were also presented
to the author in that several of the mahuf'acturing and colltrols sections reviewed referred to a drug masterfile.

The·

drug master file is a document which is submitted by a
supplier or manufacturer separate from the IND or NDA, and
contains manufacturing and controls illformation which is
pertinent to the document review.

'I'here are basically two

reasons for the submission of a drug master file.

The firm

may either refer to their ovm drug master file 1.<1hich contains
information c:ommon to several of their IND's or NDA's and
thus decrease the amount of paper that must be submitted with
each application; or they may refer to one of their suppliers'
drug master files which possibly contains trade secret
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information the supplier does not went to disclose to·the
new drug sponsor.
Compliance
To obtain an indepth knowledge of the way in which
Compliance acts to assu:re ·that drugs are safe, effective,
of acceptable quality, and properly labeled, three weeks
~;ere

spent in the various divisions.

Compliance has the

responsibility of the establishment and enforcement of drug
standards based upon the sections of the U.S. Food, Drug,
and Cosmetic (F .D.&C.) Act pertaining to drugs.
nent sections include:

The perti-

50l(a)(2)(B) Good Manufacturing·

Practices, 501(b,c,d) Adulteration, 502

Hisbr~ding,

20l(p)

and 505 Ne<r Drugs, and 506 and 507 Certification of Insulin
and Antibiotics.

'l'he establishment of standards j_nvolves

the development of regulations through the interpretation
of these sections of the F.D.&C. Act.

Although this process

is considered interpretive, the regulations can and do become
substantive through due process in the courts.

Thus, the FDA

goes into court with strong cases, for if the agency loses a
case, the effect of regulation can be lessened.
~'he

enforcement of the st.andards set in the F .D.&C. Act

and in the regule.tions can be either volunte.ry or involuntary.
Voluntary means are reg;ulatory letters and recalls, and are
not directly defined in the F.D.&C. Act, but are rather

administrative methods utilized to curb violations before
court proceedings are warranted •.. However, the F.D.&C. Act

89
does provide for three legal mechanisms for its enforc.eme!lt,
to include seizures, injunctions, and prosecutions.

The

regulatory letters and recalls have provided more efficient
and sometimes more effective methods of insuring conformance
to the F.D.&C. Act and its

The regulatory

reB~lations.

letters have just recently been incorporated as the procedure
used to deal with most first time offenses, and have reduced
the number of seizure, injunction, and prosecution actions
taken by the

BQ~eau.

This procedure carries with it a change

in philosophy, that is, solutions to problems are sought in
I

an

administrative.

\~ay

which saves time through the encourage-

ment of voluntary corrective action.

This is not to imply,

however, that Compliance is being "less tough" on the
.

offenders.

e•

The letters cr.n•ry a good deal of weight in that ·

. the violations

of'

the F .D.&C. Act are cited, and the firm is

requested to respond llithin 10 days or less

conce1~ning

the

corrective action to be taken, or regulatory action (i.e.
seizure, injunction, or prosecution) will follow.
The fastest, most efficient method of removing products
which are a potential hazard to health from the market is the·
secondvoluntary compliance action, the recall.

The recall

involves the volrmtary action by a firm to remove its product
from

th(~

mar1cet

t:hrough the notification of distribution

centers, retailers, practitioners, and consumers about the
hazards involved, and urging them to return all stocks.
There are several types of recalls, depending upon FDA's
involvement:
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l.

FDA Initiated. 'l'he l!'DA requests tha:t the
firm recall its product from the market.
Although compliance is not mandatory, the
firms generally .::omply, so as to avoid bad
publicity. Only the Commissioner of FDA
and the Associate Commissioner for.Compliance
may request such action.

2.

Vol1mtary: FDA Advised. The firm voluntarily recalls their product and notifies
the FDA either before or after the recall.

3 •. Voluntary:

FDA Not Advised. The firm voluntarily recalls their product, and doesnot
notify the FDA. There is no.requirement for
the firms to notify the FDA about their recalls.

The recommendation for an FDA initiated recall generally comes
from a field report.

If the firm does not agree, and a

health hazard exists, then FDA can seize the product and/or
"advert5.se" the problem, leading to bad publicity
.. . fer the
firm.

So, although volunta:I?y, it is in the firm's best

interest to :Lni tiate the recall vihen VJarranted.
In addition to the types of

~·ecalls,

there are classes

of recalls which categorize the medical significance of the
health hazard involved with the

p~·oblem

product.

The class

of recall is determined by a medical officer in the Office
of the Associate Director for Compliance.
I.

II.

These include:

Emergency situation with imminent danger:
the. cor1sequences are immedia.te or long rRnge
and life threatening, and 100% effectiveness
checks are done to individual pharmacies,
ma.rkets, hospi -Gals, and possibly consumer·s.
Examples include botulism, label mix-up on
potent drugs, defective heart valves, excess
radiation exposure, sub or super potent lifesaving drug.
Priority situation: may be immediate or long
range, not quite as life threatening as Class I,
publicity given. Examples include sub or super
potent drug (not life saving) or DESI violations.
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III.

Routine: remote possibility of a threat
to life. Examples include label error,
mislabeling, subpotency, and leaking
capsules.

The depth of the recall is determined by the severity
of the problem and the distribution system of the product.
It can go to the distributor (wholesaler), the pharmacy
(retail), or to the consumer.

The effectiveness and depth

are monitored by the various district offices, mainly
through telephone contact with the distributor and pharmacy
(90%) with some visits (10%).

The levels for the effective-

ness checks include:
Level I:

Level II:

100% effectiveness. Check all
distribution, retail and possible
consumers; e.g. Class I"recall.
"intensive" eztensi v·e coverage (not
"normal" 1096 of the direct
(distribution) accounts per district
with two customers per direct account.

100%).

Level III:

2% direct accounts and one customer
per direct account.

F'or the Class III recalls, the effectiveness checks are the
exception rather than the rule, howev·er, in a case of a
Class I recall for botulism, the whole district office contributes t:i.me to the effectiveness checks to make certain
that all of the adulterated product is removed from the
m=ket.
Under the authority of Chapter III of the :B'.D,&C. Act,
several legal actions can be taken fo:v violations.

'l'hese

actions include seizures, injunctions, and prosecutions.
Generally the initiation of one of these actions is made by
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the district offices.

The cases are prepared by the district

compliance branches and sent to Compliance, Bureau of Drugs
for evaluation, development, and coordination through to the
General Cotmsel of Health, Education, and Welfare, the group
that will generally try the case.

(The U.S. District

attorneys will at times handle the cases.)
A seizure is a civil action taken against the "goods"
(i.e. violative product).

An example of such acti.onis FDA

vs. Amygdalin Injectable. and Yellow tablets which is a new
drug on the market without an approved NDA, and was seized
to prevent its sale or distribution.

The process for a

seizure action is described as follows.
as being misbranded or adulterated.

The drug is suspected

The investigator (FDA

field personnel) collects an official samplE>.

'rhe sample

is submitted to a district lab for analysis.

The lab work-

sheets, coupled \;lith the inspection report are sent to the
district's Compliance branch where a summary and recommendations for seizure is developed according to guidelines which
define those violations which warrant seizure.

If the vio-

lation is not d.e.fined in the guidelines, the district confers
with Compliance, Bureau of Drugs, for approval of the seizure
action.

~~he

seizure notice is then sent to the

Attorney who, in turn, contacts the

u.s.

u.s.

District

Marshal.. The

u.s.

Harshal puts a \vri t of Attachnrent on the goods for a set period
of time, while a claim and answer to the violations are filed
with the court by the offender.

A bond, which is greater than

the product worth, is put up while the product is being reworked.
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If, after reworking, the product does not comply, the
offender can be held in contempt of court, and the product
is destroyed.

This action may lead to prosecution of the

responsible individuals.
Injunction involves court action against a firm and/or
responsible individuals to restrain violations of the provisions of the F.D.&C. Act.

The injunction prohibits the

firm from producing its product(s) when inspectional reports
indicate that the firm has a history of violations of the
F.D.&C. Act and continues to do so, although responsible
individuals have been notified about them, and warned to
correct them.

The injunction is filed thirty days after

the last inspection with the following information:

.firm

officie.ls involved, investigation findings with citations of
the sections o.f the F.D.&C. Act violated, recommendations
based on the findings, and possible affidavits on CGMP's
to document deviations.

A requesi; for a temporary restrain•

ing order (THO) may be obtained to prevent distribution of
the products manufactured under poor conditions.

The court

then sets a brief hearing on the TRO and gives the defendent
firm time to present its case.

Several days later, a full-

fledged hearing on the injunction will be held, after which
the court rules on the order.

When appropriate, the injunc-

tion proceedings may also provide for a recall of all products
manufactured during the violative period as noted in the
injunction recommendations.
The third legal mechanism is the prosecution.

The

prosecution taken against the firm and r·esponsible individuals
based upon a history of problems and past regulatory actions.
The action is based upon inspectional evidence that sho•tls
the firm has not observed essential control elements and a
record of faulty past performance, which might include
several recalls, seizu:r.•es, an injunction, or a combination.
As the prosecution is a lengthy procedure, these other actions
are considered in advance.

The defendents in a prosecution

can include the firm's responsible individuals (e.g. president, vice president, directors of qua.lity control and manufacturing), a corporation, or an association.

Prior to

prosecution, citations (provided for in Section 305 of the
F.D.&C. Act) are given to the defendents which. state the
cause for the contemplated criminal action.

The legality

for citing the firm's responsible individuals, e·v-en though
they may have no knov1ledge of the wrongdoing, was tested in
the famed

u.s.

vs. Dotterweich case in 1.943.

The case

involved the president and general manager of the Buffalo
Pharmacal Company, Dotterweich, who was tried for violation
on three counts of Section 30l(a) of the F.D.&C. Act which
prohibits the introduction of misbranded or adulterated drugs
into interstate commerce.
counts in the lower courts.

He was four;d guilty on all three
The Circuit Court of Appeals

reversed the conviction, hov:ever, on grounds that only the
corporation was the "person" subjeet to prosecution.

The FDA

took the case further, and in a landmark decision, the conviction was upheld in the Supreme Court due to a unique
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interpretation of the F.D.&C. Act, which dispensed with the
conventional requirement for criminal wrongdoing:

"the aware-

ness of .some wrongdoing" (61).
This, then, makes the top officials of a firm (i.e.
those who can control what happens in the firm, for example
extra moneys for quality control on the products) responsible
for all of its activities.

Prosecution is a lengthy court

procedure, and :i.t generally takes many months to prepare.
~'he

charge may be either a misdemean.or or a felony depending

upon the incidence of bodily harm from the violative act.
This decision is not made within FDA, b1,1t rather by the
prosecuting attorney.

The penalties, as defined in the

F.D.&C. Act, for the first. conviction can include imprison-·
ment fer orie year or less and/or $1000 fine; a:nd for any
additional convictions, imprisonment for three years or less
and/or $10,000 fine (62) ~
To carry out its responsibility of the establishment
and enforcement of the drug

lm~

is divided into four divisions:

of the F.D.&C. Act, Compliance
Drug Nanufacturing, Drug

Product Quality, Drug TJabeling Compliance, and IvJethadone
Nonitoring.

The divisions become involved in most phases

of compliance from the establishment of standards and the
development o.f programs designed to insure conformance to
these standards to the final handling of cases recommended
by the districts for violations.

The concerns of the divisions

frequently overlap with respect to the regulation of drugs as
misbranding, adulteration, and poor manufacturing practices
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are violations are difficult to separate.
Drug Manufacturing
The Division of Drug Manufacturing, under the provisions
of Section 50l(a)(2)(B) of the F.D.&C. Act, establishes and
enforces current good manufacturing practices (CGMP's) through
its two branches:
Assurance.

lVJanufacturing Standards and Standards

Thus the division.concentrates on the adherence

of the firms to CGMP's through the development and direction•
of compliance programs designed to police the drug industry
through field inspections of the manufacturing in-·process,
and the recommendation and coordination of the cases involving
compliance actions taken regarding violationr; of CGl'lP 's.
These functions overlap with those of the Divisions of Drug·
Labeling Compliance and Drug Quality Assurance, as in most
cases, viola.tions of CGJ.V'"JP' s lead to misbranding and adul teration.
As of late, the division 1 s functions have te.ken on
increased importance.

The Department of Defense's cha.c'1ge

in the method of drug selection for purchasing, the

ma.'l:imum

allowable cost regulations (MAC) for the reimbursement by
the Depar·tment of Health, Eciucation, and Welfare for drugs
purchased under the Nedicaid and Medice.re programs, and the
approach of some form of National Health Insurance have at
least one view in common:

all assume that the FDA assures

the quality of all drugs.

In order to assure the quality of

drugs, the way in which they are manufactured must be adequately controlled.

The realization that one cannot "test"
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quality into drugs, but must rather "build" it into them has
taken on increased significance, especially in this division.
The responsibility for the development of the CGMP
regulations resides in the Manufacturing Standards Branch
of the division.

The regulations are included in 21 CFR

Part 133, and discuss, in general terms (using such \'lOrds
as "adequate" and "sufficient") what s:nould be done in the
~anufacture

and control of good quality pharmaceuticals.

Until this year, these general "tunbrella" CGMP •s \'lere all
the agency had to enforce 50l(a)(2)(B); '1hich made court
proceedings rather lengthy as these

CG~W•s

would have to

be defined by lmown experts for such individual case.

The

··conc.epts have changed, and with the reorganization of the
Bureau of Drugs in October 1974- \'lhich led to the development
of this branch, more specific regulations will be

pu.bli~Jhed.

The new approach to CG1·W' s is th:!:-ough its manufe.ctu.":ing
process.

The first of these specific CGMP's to be published

will be those for the manufacture of large volume parenterals.
Problems that have oc.curred, most evidently and dramatically
since 1956, identified this area of' need for stanclards in
menufacturing practice.
free large volume

The production of sterile, pyrogen-

pa~enterals

is a good case where it is

essential (potentially life saving) that qua1ity ·be built
into the products.

The. United States Pharmacopeia XIX in

its definition of Sterility Tests reenforces this thought
by stating that "·t;he significance to be attached to a demonstration by test that a drug or device has been rendered
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sterile is determined largely by the extent of the control
exerted during the manufacturing an.d sterilization processes" (63).

The proposed regulations for large volume

parenteral good manufacturing practices were a compilation
of expertise from industry and li'IJA. . They provide detailed
information about those areas considered to be critical in
assuring a good, sterile large volume parenteral.
areas include:

These

water and air quality, sterilization equip-

ment, sanitation, sterility and pyrogen testing, and stability.
The CG!1l?'s, with the pooled knowledge from the manufacturer
and

re~~latory

agency, will improve processing techniques

ro~d

will·hopefully avoid recurrence of the problems that have been
plaguing the large volume parenteral industry;·
Another example of some proposed. work would be specific
CC'rl1l?' s on tableting.

The tableting process could be broken

down into t'••o categories:

the types of tablets to be made

(coated, time release, uncoated) and the amount of active
ingredient included (low dose-high potency vs. high dose-low
potency).

These CGMP's would describe the various types of

granulations or slugging, drying cor-trol (with its effect on
stabilit-y), lubrication, grinding (size of. granules), mixing
time, tableting (to maintain proper pressure), and coating
(which can create a variety of problems if not done properly).
The project of developing the specific CGf.'IP' s is sizeable,
and will take many years to achieve.

It will be a big step

for\...-ard towards assuring that drugs on the market are of the
highest quality.

•ro assure that the drug industry is aware
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of the development of CGMP's, so as to be able to conform

to the standards, the

br&~ch

serves as an education coordi-

nator and liaison to the industry.
r-~

~~e

Standards Assurru1ce Branch has the responsibility

of enforcing the CGMP's developed by the Manufacturing

Standards Branch.

Through the investigations, lab findings,

and recommendations of the Compliance Branch of the FDA
district offices, the Branch provides for uniform i.nterpretation of the firm's compliance with CGMP's.

The field

.reports are evaluated by the Branch where determinations are
made as to whether regulatory actions based upon CGHP violations are v1arranted through checks for misapplication of
policy or lack of evidence in the reCO!l';llJepdations.

If the

decision is made by the Branch to proceed t'fith complirulCe
action, the case is developed further, and sent to the General.
Counsel (DITElrJ) ¥There the proceedings e.re handled.
Another responsibilityof the Branch is to provide
information to New Drug Evaluation (NDE) concerning a company's adherence to CGMP's in connection -with the approval
proce<;s of new drug applications,· abbrevj_ated new drug
applications, supplements, and antibiotic or insulin certification.

In the approval process associated with these

documents, a statement is required about the Gl'lP 's of the
firm.

The divisions of NDE notify Standards Assurance that

such a statement is required at any given time, the branch
will send out a request for an inspection to the field, and
will relay the results back to the appropriate NDE division.
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prug l':rodu.ct Qual).t;z:
The Division of Drug Product (iua::Lity's name is
descriptive of its function:
drug products.

to assure the quality of

This goal involves a variety of compliance

programs vlhich are administered by. the division:

drug

quality assurance, antibiotic a.>J.d insulin certification,
and drug product defect reporting.

These progran1s are

handled by the three branches of the division:

Drug Product

Quality, Antibiotic Certification, and Product Surveillance.
The Drug Product Quality Branch directs the compliance
prog:r.•an1s issued in the area of product quality .assurance by
enforcing the adulteration sections of the Ji'.D.&C. Act.· The
Branch differs :i.n jurisdiction from Standards ".Ass·t)_rance in
the Division of Drug Nan1.l.f.s.ctur:i.ng in that its action stems
from. laborato1~y findings of drugs already on the mark:et rather

than from the in-process proceduras involved in the manufacture
o:t the product.

Again, the functions of the t1110 branches do

overlap, but this is the definition given to separate them.
The programs in the a-rea of drug quality assurance are
the lm·gest in terms of the utilization of the field manpower
for drugs.

The programs involve

on the market.

th~

surveilla.nce of drugs

This survey provides good data bs.se for the

monitori!lg o:f the quality of drugs through the ce>llectionof
random samples and subsequent laboratory analysis.

In that

there m·e many more drugs on the market that could possibly
be tested, certain drugs are selected for inclusion in the
compliance program.

The selection is based loosely upon one
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of the following criteria:
1.

impact of' the drug: low dose-high
potency medications.

2.

wide use: several chosen from the
Gosselin "Top 200" drugs prescribed
list.

;s. therapeutic significance.
4.

documented production problem.

Detailed information is sent to the district offices to
implement the program.

This includes the sampling plan,

the types of' lab tests to be done, and the drug products to
be tested.

The

progra~

not only aids to identify possible

industry-wide problems in production, but the use of several
l!'DA laboratories in the analysis of the

SB.'llples

provides

better coU.aberation of assay methods which lead to their
improvement and. possible inclusion in the USP/r:.'F.

If

any

drug product on the market is found to be in violation·of
the F.D.&C. Act primarily through adulteration, the Branch
will also develop and coordinate the cases utilizing the
same tools (:regulatory letter, recall, seizure, inju..."lction,
or prosecution) as the other divisions, depending upon the
extent ct.'ld severity of the problem.
The chief responsibility of the Product Surveillance
Branch is to coordinate, evaluate, ·and monitor the .reports
received from pharmaCists in the ·drug product defect reporting system (DPDRS).

The system has been highly successful

in providing a central location to

\~hich

the pharmacist can

report defects in the products dispensed, thus adding an
extra quality control check for FDA.

DPDRS was initiated
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through the combined. efforts of the United StatesPharmacopeia
(USP) and the FDA to:
·1.

serve as a central location that would
compile data on drug product defects.

2.

identify drug product defect areas and
inform the drug manufacturers.

~.

follow-up on tho correction of the drug
product defect.

After two years in a pilot program status, the DPDRS has
developed into a permanent, viable information source for
drug product defects.

It is cosponsored by the American

Society of Hospital Pharmacists and many state and local
pharmacy associations, and endorsed by the American
Pharmaceutical Association and the National Association of
Retail Druggists.

The .USP and the FDA share the responsi-

bility for the .smooth flow of the 125 reports received weekly
from pharmaci.sts nationwide.

:!'he USP sends, receives, checks,

and computerizes the DPDRS reports.

The l<'DA Bureau of Drugs'

Product Surveillance Branch reviews, evaluates, identifies,
and follows.:..up on problems, in conjunction •"lith Compliance
to aid in the maintenance of quality pharmaceutical products
(Table II).
The DPDRS is set in motion at USP, where periodic mail-·
outs which include a cover letter, tvm DPDll.S forms (Appendix :!!'),
and a

po~1tage

prepaid return envelope are sent to every ·pb.ar-

macy in the nation.

In the letter, the program is ex1Jlained,

and pharmacists encouraged to send in the reports to USP
identifying problems with containers, closures, labeling,
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PHAR!Ji.ACIST:

1.

Identifies drug
product defects.

2.

3.
4.

InitiHtes drug product
defect reports.
ReceiVE:lS aclmo\vledgement
from USP.
May receive other "feedback".
Provides valuable service
tovmrd better quality ·
drugs.

1.

Report assigned
special number.

2.

:;.

4.

5.
1.

Priority assigned.

2.

;.
4.

5··

MANUFACTUP.ER:

A.lerted to the
problem.

1.
2.

:;.

Assigns special number to
each report.
Immediate review :for
health hazard.
Computerized drug defect
report data.
Provides liaison with
pharmacists, sponsoring
organizations, l!'DA, and
ma.nu:facturers.
Uses data base for setting
drug stan.d;oJ.rds.
Screens report. immediately
for priority of action.
Stores computerized data
and makes '.;rend analysis.
Pert·orms invest;igations,
lab analyses, and surveillance.
Advises USP of .investigational findings.
Uses data as bar•is for
special programs or
regulations.
E"valuates report.
May ccmmuni<~ate \vith
pharmacist, :l"DA, or USP.
Corrects as necessary.

T.Al3LE II

Drug Product Defect Reporting System Flow of Documents

104
packaging, contents, or the drug itself, which could include:
underfills or overfills,· foreign material in the prod.uct,
broken tablets, mislabeling, or lealcing capsules.

Upon

receipt at USP, the DPDRS reports are dated, and checked
twice by professionals for priori ties, i.e. imminen·!;ly
hazardous situations, which are identified and relayed to
the FDA by phone.
to the FDA.

Any samples submitted are bagged an.d sent

The reports are then assigned an accession num-

ber (to be referred to in all communications), the daily
log is typed, then checked by the pharmacist.

A letter of

acknowledgement is sent to the reporting phro.•macist along
with two ne1-.r forms and a return ·envelope.

Eight copies o.f

the reports are xeroxed and distributed:

six-·copics to tM

:B'DA ' one COP"'
to the product man'ltfactm•er, a.nd one copy i:o
~· ~I
USP's files.

The forms are cod.Eld and

l~;e;ypunched.

for the

comput.;:,r, both by the clerical and the pharmacy sta.ff, doublechecked along 1r1ith a check for the pharmacist on an off-·line
printout.

The keypunched data is then transmitted to magnetic

tape and put into the Bureau of Drugs computer.
On the same day as USP receives the·reports, the six
xerox copies are

sent~

to the Product Surveillance Sta.ff for

evaluation, circulation, and :follow-up.

Each report is

evaluated individually ,md on a daily basis by the sta.f:f.
From the review of both the reports and the USP phone calls,
decisions are made concerning the potential problem, and
those that could involve an imminent hazard to the patent
are handled expediently.

This immediate action could involve
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phone calls to the pharmacist who sent the report, the
pharmaceutical manufacturer who makes the product, or the
FDA district office where the manufacturer is located.
This is designed todetermine the exact cause of the
problem, how widespread. it may be, and what measures need
to be taken to correct it, i.e. inspection;

sam~ling;

and

investigations leading to possible recalls, injunctions,
or seizures.

In the three years of existence, the DPDRS

has been directly responsible for over 60 recalls.
All reports are entered into the computer, and used
in periodic trend analy·ses.
are

ciJ~culated

The other copies of the reports

to various I''DA offices to include the Bureau

of :Biologics, Bureau of Diagnostics and Medical Devices,
Ne'\OJ Drug :F;valuation and EDEO, depending u.pon their content.
The follm·r-up on the DPDRS reports involves an inspection of the firm to determine 1t1hy the problem occurred So."'ld
if any act on had been taken to alleYiate the situation.
Thef'ollow-up inspection reports are receiYed by the staff,
coded, and entered into the computer system against the DPDRS
report accession number, to ascertain whether each report has
been handled.

This completes the cycle of the report from

pharmacist to follow":'up.
lin important aspect of the system is the.snalysis and

interpretation of the computer printouts.

These printouts

are capable of listing defects by manufacturer, drug name,
dosage form, defect type, accession number, and text from
the pharmacist.

1Tend analyses ·Of these printouts can reveal
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certain classes of defects:
.I.

Defects in one product from one company.
Indicates ei'!;her a breakdown of controls
on the one product, or difficulty within
the company to manufacture that product •

. II.

Defects in. several products in one company. Indicates a breakdown in the Good
Manufacturing Practices of that company.

III.

Defects in similar products on an industrywide basis. Indicates that the manufactt~
ing technology has not been perfected on
that kind of product.

In the future, these printouts will provide an early detection mechanism, so as to catch a defect problem before it
reaches recall proportions.
Utilizing an untapped resource, the professional
intimately involved >v:Lth the assurance that t};i,.;. patient'
receives quality pharmaceutical products, the drug product
defect reporting system fills a defil'li te need for the phe.rma·cist and the consumer.

In the past year, the program has

become highly successful and truly l!Jidespread, with a fifteen
percent return on all mailouts, and with.one out o:f every
three reports considered to be significant.

It has increased

the phac>macists 1 awareness of the services of' both the USP
and the FDA, and has provided him with a mechanism through
'1-lhich corrective measures can be ·taken.

T'.ae

early surveillance

allows the agency to foresee and correct problems before they
reach significantly detrimental proportions, thus increasing
the agency's effectiveness as a consumer protection agency.
Under the provisions of Sections 506 ond 507 of the
F.D.&C. Act, the l!'DA has the responsibility to certify all

' 107

batches of antibiotics and insulin.

The responsibility for

the issuing the antibiotic and insulin. cer'cificates is in
the Antibiotic Certification Branch of the Division of Drug
Product Quality.

The branch combines the information received

from the Division of Antiinfective Drug Products of New Drug
Evaluation where the IND's, Form 5's and Form 6's (NDA end
ANDA for antibiotics) are reviewed and approved, with the

laboratory results :from the National Center :for Antibiotic
Analysis.

A determination is made as to whether the batch

can be certii'ied, and if so, issues the certificate.
To better tmderstand the Branch's functions, a description of the· series oi' activities involved in antibiotic
certification is needed.

If a firm desires to market an
"'

antibiot:ic, the first procedures are similar to those used
for any other new drug.

An IND is filed with the Vi vision

of Antiinfective Drug Products.

M'ter the appropriate

Phase I, II, and III testing is done, a

l~'orm

5 is submitted.

The Form 5 includes the same safety, ef:ficacy, manufacturing
and controls data that are in a NDA •. The Divisiou reviews
the application and

mal~es

a decision as to whether the

application is approvable.· \Vhen it appears that the appHcation is likely to be approved; the analytical methodology-·
included in the I•'orm 5 is sent to the National Center for
Antibj.otic Analysis of Pharmaceutical Research and Testing,
where the tests are run for validation.

If the Form 5 is to

be approved, methods to actually be used in the certification
process are developed, validated, and published as regulations

108

in the ;F:,ederal Regis.E£.

These published regulations are

in.cluded in the 21 CFR Part 400,. and contain detailed
.information about the types of tests (sterility, biological,
chemical, and microbiological) to be run on the antibiotic
and the procedures by

to perform them.

~lhich

'I'he bulk of

the approved antibiotic is sent in as the first step in
pertification.

All bulk antibiotics must be certified prior

to the certification of the final <:lesage form.
from the analysis, coupled

~lith

The results

those of the firm, are sent

to.the Antibiotic Certification Branch of Compliance, for
issuance of the certificate.

After the final.dosage form

has been prepared, an analysis is done and the results are
sent to the B:ea.nch.

Results from the 1ab, firm and the

previously analyzed bulk are evaluated, compared, and checked
for conformance t;o the regulations.

If all is in order, the

certificate is issued and the product may be marketed.

About

1% of the samples.submitted for certification per year are
found to be below standards.

The process for the certifica-

tion of insul:in is similar.
The antibiotic and insulin certiHcation program is a
unique regulatory tool for the agency, and. gives 1!"DA much
tighter control over the quality of marketed B.J':ltibi.otics a.r:td
insulins than any other of its reguJ.a1;ed commodities. . '.l'he.
B~~anch,

in addition to its power to prevent the marketing of

drugs through noncertification, can also "decertify" a batch
of antibiotic or insulin based upon post-certification data,
and the drug then becomes misbranded under Section 502(1) of
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the l!'.D.&C. Act.

Dr-ug I;abeling

Com.I!]i~

The Division of. Drug Labeling Compliance is concerned
with a variety of regulatory activities which derive their
authorit-y :from the sections of the l!'.D.&C. Act prohibiting
the misbranding .of drugs.

TI-ro branches:

Prescription Drugs

·and Over-the-C'..ounter Drugs handle the notification of the
firms whose products are involved in the Drug Efficacy Study
Implementation (DESI) program and the Over-the-Counter (OTC)
drug ingredients reviews, about the

~.cJ.epal Rez~

state-

ments on those products, and implement the subsequent regulations.

These branches are responsible i'or the complim1ce

actions (regulatory letters, seizures,
tions) involving drugs

>~hich

in;jm:~ctions,

prosecu-

require new drug appli(>ations

(NDA) but are on the market without on<~.

'Ine third branch,

JJrug Listing, has the responsibility for the direction of
1.'he J!'DA Drug Product Listing and Establishment Registration
Program.
The Prescription Dr1.1g Branch handles DEBI, which is
D(>aring completiot1.

In addition, the Branc.h

handl~s

com~·

pliance actions iz.wo.lving misbranding of prescription drugs,
or violations of the new drug sections of the ]'.D.&C .. Act.
The DESI program is one of' the more important projects

~;hich

l!'DA has had to improve the quality of prescription drugs.

The Kefauver-·Harris Drug Amendments of 1962 were responsible for the existence of the DESI program in that the
requirement that drugs be efficacious was added to the ne1rr
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drug section.

This implied that all dxugs that had NDA's

from 1938-1962, which were reviewed for safety only, would
have to be

revie\~ed

for efficacy.

The task was an enormous

one, as the FDA had to tackle over 8,000 drugs with its
limited resources.

To overcome the problem, a contract

proposal was written.

The National Acadenry of Sciences/

National Research Council (NAS/NRC)
. the revie"'·

\~as

designated to do

This body is composed of top scientists who

have proven themselves in their respective fields prior to
membership in the Academy, and seemed well suited for the
job.

The reviewers were divided into various panels, each

covering a certa:in drug category with the drugs being revie'Ned
individually by marketed product.
be from

\~<ell-controlled

T'.o.e data required

\~a.s

to

clinical studies on the effectiveness

of each o:f the· drugs, along \-Jith other in:formation on the
drugs to in<:lude the claims made for the product and a full
l:l.st of its ingredients.

The panels then revievmd the data,

and came u,p with one of.the following conclusions (64):
Effective: the evidence was adequate to support
the claims.
E.ffeetive with :reservations: the claim might be
.effective, but some change. had to be made
such as in labeling or in ingredients.
P:ro'bably eff'ective.: more evidence was needed to
support the claim, but likelihood was that
the evidence 1·1ould be gathered.
Possibly e.ffective: the claim needed more study,
but the chances that evidence could be
.ga;thered to prove its effectiveness were
· oit.ly moderate.
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Lacking substantial evidence of effectiveness:
there was no scielitii'ic evidence to support the claim.
Ineffective as a fixed combination: although
each of several ingredients might be
ef:fecti ve, combining them. did not mak.e ·
the drug any more useful than if one or
more of the ingredients were used separately.
The reports from the NAS/NRC review on the effectiveness
of the over 7,000 drugs (with many more claims, each claim
being examined individually), vrere released from

1967-1'~69.

It was then the FDA's responsibility to interpret them accordIn 1968, a task

ing to agency policy, and implement them.
force vms formed \'lhich led to DESI.

Timetables were estab-

lished fo:e manufacturers to meet requirements cf proving

In addition, although the NAS/NRC panels reviev;ed each drug
product separately, these

M~!...B§~~iP~

not;ices contained

statements that applied not only to that particular drug
product, but to all identical, related or similar products.
Thus, :i.n essence, all drugs ("me-too's", i.e. generics,
included) that had not submitted evidence to the panels would
be subject to the agency's rulings under DESI.

This "class

action" s.s it is termed, \<las no"!; without opposition, and was
contested in the courts.

The :B'DA,

ho~mver,

and the "class action'' 1r1as implemented.

won its case,

'l'he timetables to

allo\<l the firms to respond to a "less tha<'l effective" status
as def'ined by the NAS/NRC have all been published in the
Federal

Registe~

using the guidelines of:

one year with

reasonable extensions for probably effective; six months for
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possibly effective; and sixty days for i.neffecti-ve.
Allowances were made for the firms to have s.ut:ficient
time during which to set up adequate clinical studies, and
in Some cases, reformulations of a drug product warrmited
reclassification into another "less than effective" class,
thus extending time.

The related, similar, or identical

products were identified by the districts.
~ras

This information

sent to compliance so that all manufacturers could be

notified of FDA's position on the NAS/NRC review of their
product and of the timetables that had been se·i; up for
supplying information as to the effectiveness of their
product.

The reformulations or changes in labeling of tb.e

drug products required additional

status in light of the revisions.
panels ha.d finished

th(~ir

to d.etermi.n.;·, their

As most of the NAS./NRC

,.;ork a.nd been disbanded, the

assignment fell to the six
Evaluatj.on.

revie~;

revie~r

divisions of :Ne\'1 Drug

The incoming data (clinical, pharmacological,

manui'ac-turing and controls) 'I'Jas reviewed fol' safety and
efficacy by the various disciplj_nes depending upon the
nature o:f·the changes.
published in the

The new status of the drug is then

~·al_R~tElr.•

and if it is

less~tha.'l

effective, the drug will be removed from the market.
If the time runs out and no information has been
received, or it is inadequate to substantiate effectiveness,
letters are sent to manufacturers allowing 10-15 days to get
the drug off the market.

Most firms anticipate this type of

action and deplete their stock so as not to necessitate a
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recall.

The district offices, then, in the DESI compliance

programs, follow-up on the drugs to det;er:nine if the drug
is indeed off the market.

If the firms. have not complied,

regulatory action "'ill be taken.
To notify healtb.·practitioners about products which
have been classified·as ine.ffective and are to be removed
or have been removed from the market, a listing has been
compiled by the Branch.

This is to be directed to

pro~·

fessional organizations, state officials, and others, on
request.

This will aid the pharmacist in clearing the

inventory o.f those products which are ineffect:i_ve and in
explaining to the consumer the reason
purchase those particula.r

\~hy

he can no longer

items~

In addition to its DESI responsibiliti.es, the
Prescription Drug Branch must make certa:i.l:. the "new :irJ,gs"
are uot on the market vii thou-t; an approved nevi' drug appli-

cation, and. that prescription drug manufacturers are in
compliance with the labeling of their products.

'rhese mis-

branding violations are generally received in reports from
the field, and the cases are evaluated and·coordinated
tbx·ougb. the Branch much the same as the other Compliance
bra."lche s operate.
The OveJ?-i;he-Counter Drug Branch 1 s responsibilities in

the en.forcement of the OTC panel monographs are just beginning as the Prescription Drug Branch i.s finishing DESI.

The

OTC panels have been meeting only since 1972 and have released
the first 3 of 19 reports.

They are conducting their review
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in a manner that is a bit different from that of the NAS/NRC.
There are over 26 drug ingredient

categori<~S

identified which

.have been assigned to 17 panels.

The drugs, instead of

undergoing product by product evaluation, are being studied
for safety and efficacy by ingredient.

The operations of

the OTC panels are much more open than those of the NAS/NRC.
The FDA had received criticism for the secrecy in which
decisions on drug products leading to DESI were made, and
thus a.ttempts have been made to keep them as open as possible.
The reports published vlill be incorporated into
~f}:t;~~L

EQ.~.J'~.

monographs, and will contain the information about

what ingredien·l;s products can contain and hovl these products
may be labeled.

The Division of OTC Drug Evaluat:ion in DI11g

Monographs has the responsibi.li ty for ooo:t'd.:i.nating the panels
and. the Branch has the responsibilit-y "to enforce the monographs from their reports and monitorj_ng their implementation.·

For :fm•the.r discussion, see Drug Monographs., Division of OTC
))rugs.
Legislation which gave authority to the l!'DA in an area
essential to the regulation of drugs was finally passed by
Congress in 19'72.

The Drug Listing Act authorized the FDA

to obtain a cm·rent listing of every dru.g manufactured or
processed. under the F.D.&C. Act.

Thus, this much mleded

in:forruation will soon be a reality.

The Drug Listing Branch

of the Division of Drug Labeling is responsible for assembling,
evaluation, and coding this tremendous amounts of data on some
167,000 human drug products, 5,000 veterinary products, 9,000
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biological, blood and blood derivatives, and 13,000 i!L...Y.:[:ttQ. ·
diagnostics (65).

The data to be accumulated will include:

name of the drug, manufacturer, quantitative listing of the
ingredients, classification according to any special
authority of the F.D.&C. Act under which the drug is
marketed (NDA, antibiotic, insulin, or animal drug), labeling
and package insert, and for the non-NDA prescription drugs,
copies of advertising.

The information is being computer

programmed and should be readily retreivable by 19?6.
the advent of this new information, the regulation

o~

\'lith
drugs

\'!ill become facilitated as FDA 1-1ill have a better knov;ledge
oi"

the products on the market.

Metha.done l"ioni
to:rirw:
.......

....,,_~...,...,.-~

-~---

The primary responsibility of the Division of Methadone
Non:ttoring is th>e control of the distl'ibution of methadone
to ·nro:cotic addiction treatment centers a11d to hospital
pharmacies for use as an analgesic.

The Division works

closely with the Drug Enforcement Agency (DEA) and helps
coordinai;e the activities of other federal, state, and local
methadone monitoring programs.
Nethadone ha:s beenput under strict control only in the
past decade.

In the early 1960's, the

d~'ug

was on 'the market

.for its ani;itussive and a.nalges.ic activity and was under
invest:igation (IND) for use in narcotic addiction treatment.
It was then limited to use as an analgesic in narcotic addiction treatment by the Comprehensive Drug Abuse Prevention and
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Control Act of 19'?0.

A special IN.D form and DEA licensure

were required for maintenance therapy.

]'rom 1970-1972, the

P.rug was distributed through any pharmacy.

Pro bleras with

the control of methadone became evident to both FDA and DEA
as physicians were. prescribing the drug wi thou1; regard for
the special requireJJlf:'.nts.

Jl

decision was made to either

limit the distribution or stop it altogether.

In 1972,

regulations were written which required a closed system of
distribution of methadone.
out opposition.

These regulations were not with-

Methadone may now be dispensed only in

narcotic addiction treatment centers which meet the FDA and
DEA requirements and in a limited number of approved hospital
pha:r.•macies j:'or use as an analgesic.
The Narcotic Addict

~'rea·l;ment

Act of 1974 defined the

requirements :for the use of methadone 'in tne centers.

These

re qui.rement;s al:?e :

1.

registration with DEA of any treatmen·t program
using any narcotic drug for treating addiction.

2.

adherence to the DEA security and recordkeeping regulations.

3.

..
· 4.
~'he

adherence to the medical st&"l.dards of. narcotic
. addiction treatment (rehabilitation) as set by
the Secretary. ( 1'o dai;e, methHdone is the
only drug with such standards, therefore
ruling out the use of other narcotics.)
file special IND form.

Federal Interagency Methadone Review Board shares the

responsibilities for monitoring methadone and is made up o.f
representatives from FDA, DEA, National Institute for Drug
Abuse (NIDA), and the Special Action Office for Drug Abuse
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Prevention. ·The. FDA has the responsibility of revie;dng
the IND's and inspectj.ng the treatment centers using
methadone (done by the field investigators).
the programs.

DEA licenses

NIDA is concerned with the psychological

rehabHi tation. of the addicts, . in that methadone is only
used for maintenance, not for treatment of addiction, this
aspect is very important.
The use of methadone for analgesia in hospitals also
carries a number oi' special requirements.

Hospital pharma-

cies must be approved before they ean dispense the drug.
In addition, the approval commits the pharmacist to maintain
the s'>cm.•i ty of the drug and obtain a statement from the
physician statiz.lg that:

"Methadone is to be used for

analgesia in patients with severe pain"; thus the physician
cannot set up his own e.ddiction treatment program
the_ proper :forms.

~~i·thout

If not used properly according to the

signed statement, the physician can be held liable for not
adhering to it.

(The drug is generally used :for analgesia

in (\flllCer patie11ts, because il; has properties similar to
morphine, but is longer acting.)
Methadone is the first drug to have a limited NDA, that
is, the ch'ug has speciaJ. controis ovel.' the conditions :for
distribution and use.

The authority for this action is

stated. to stem from the safe and effective requirement in
Section 505 of the F.D.&C. Act.

If the FDA does not con-

sider the widespread distribution and use of a drug to be
safe and efficacious, then it can impose a limit as
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exemplified by the. methadone program.

However, this

approach has been contested in the courts in the case of
·"~'he

American Pharmaceutical Association (.APhA), three

individual pharmacists,

an~

a physician vs. the Secretary

of HEW, Commissioner of FDA, Attorney General and the
Acting Administrator of the DEA.

The .APhA, et a.J.• ,

challenged the limited distribution of methadone in a suit
brought against Casper Weinberger,

~h.

in the

District Court :for the District oi' Columbia in

u.s.

~1ay,

1974·.

The .lil"hA charged that the restrictions imposed on the dist:ri bution of methadone exceeded the Ji'DA' s limits of authority,
\vore discriminatory, and in violatim1 of due process !J!'Ovided
for ill the Fifth Amendment.

The chargefl 'de:ce c01mtered by

ci'l;ing that the :l!'DA 1 s authority under the F .D.&C. Act allowed
. the agency to control access to market of all ne\v cLcugs (21
USC 371).
.Act o.f

In addition, the Drug Abuse Prevention and Control

1970 authorized the development of "appropriate methods

of professional practice in the medical treatment of •••
narcotic addicts."
(lowe~'
. -·

The judge ruled in favor of the APhA

court
decjsion) and this decision is now in the process
.

~'he

outcome of the appeal will have an impact on the

future of J!DA' s control over lim:i:l:;ing the distribution e.nd
use o.f certain drugs.

~1ethadone

is, at present, "in-behleen"

the investigational and approved ne\v drug stages.

If the

limited. use concept is sanctioned by the courts,.then tho
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the approval of. drugs v;hich are considered to be
inapproprj.ate for general use but rather for certain
specialties, may come into existence.
Biometrics and Epidemiology
Biometrics and Epidemiology provides several valuable
services to the other areas of the Bureau of Drugs.

The

DiYision of Biometrics works with Ne\'1 Drug Evaluation on
the review of IND 1 s and ND.A 1 s;

~~i th

Pharmaceutical Research

and Testing on the development of analytical methods; and
\'lith Drug I1onographs on the analysis of bioavailabili ty data.
The collection, evaluation, and dissemination of ii1formation.
on the toxic ei":fects of drugs is provided by '!;he Division of
Poison Control and the same functions in relation to adverse
drug reactions are furnished by the Division of Drug;

Biometrics

.,_,_,.__..,..,.....~

Supporting the Bureau in its programs requiring statistical or biomathematical services, the Division of Biometrics
is relied uponheavily.

The Division conducts research and

development in methodology in statistical ·a.."'1d biomathemai.:ical
services, and evaluates ne\1 statistical methodologies.

Com-

puter programming for the statistical andbiomatb.ematical
computations is also performed by the Division (1>3).
New Drug Evaluation, with its responsibility to review
IND's and NDA 1 s frequently requests a statistical review of
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data submitted.· 'l'he responsibility of the statistician
reviewer is described in the section of this report on
New Drug

~'valuation.

In addition, the statistician may

be requested to revie'tl the bioequi valence data in an. llNDA
£or Drug Monographs.

He may become involved in the review

o£ both the design and the evaluation of data in these
studies.

It is important that the design of the study be

reviewed prior to its conduction because variables can be
minimized, and statistically sound comparisons can be made.
Once the studies have been completed, the statistician then
analyzes the data for significant dif.ferences

bet\~een

the

_ bioavailability of 'c;he generic drug product and the standard.
In the Bureau of Drugs 1aboratories, the;·s·t;atj_sticia'l'ls·
provide .input which will minim..i.ze variables' in the laboratory
analysis and thus give more accurate results.
duc-ibib~ty

'fhe repro-

of e:ny assay procedu.re is its n:ost important

feature, for values that change due to the variances inherent
in the assay invalidate it.

An example of a

projec·~

1-1orked

on cooperatively by this Division and PRT j,s the comparison

of rad:i,oili1illtul0 vs. biological assay.

'fhe study is to ascer-

tain whether the radioimmune assay vJhich is much easier to
do can be int,.;rchanged

~;i th

the biological assa.y.

Input

fx•om the statistj_cian in both the design of the study and

the analysis of' the results e:x:pediates the development of a
useful procedure.
A process through

~<hich

the agency can solve a problem

with limited manpower, is contracting.

By contracting experts
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in some field of study to work for a liroi tP.d time, resero:·ch
is done on a particular problem.
.events in contracting, the

'l"nroughout the chain of

sta.tifr~ician 1 s

input aids in the

achievement of data .,.,hich are statistically valid.
chain of events can be described as follows.

This

The agency

recognized a problem for which additional data or a solution
is sought • . The problem is thoroughly researched to determine
its exact nature.

Based upon the research, a memorandum of

need is written which defines the problem a'ld the need for
data to clarify or solve it.

A projeGt officer and e.dvisor·y

group are appointed to study the problem and to write a work
statement.

'l'he problem mt1st be ;,rell understood at th:Ls po:Lnt,

fmd the vrork statement should be. specific so· as not to obtain·
superfluous information.

Statistical input at this point is

helpful in achieving specificity.

:!!'rom the

~;ork

st;a.tement,

the cc>ntract officer dra\'lS up the contract which, after review,
is announced in Commerce Busines£._])ailz.

Proposals a't'e sub:'"

sequently subnLi..tted, and _are reviewed by the. project advisory
group and the contract officer,

~eading

to the selection of

a . qualifj.od contractor if one is available.

.Du.:t"ing the co1:trse

of thr; study, the contractor's 1t1ork is monitored closely by
the project officer and contract officer "rlith the option of
termination of the contract if the \'lark is unsatisfactory.
If all proceeds well, the contract is completed and a report
that aids in the solution of the problem is submitted.
Poison Control
The Poison Control Division works to support the
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activities of the state and local governments in their
poison contl'ol centers, by furnishing them. with information
on the to:x:ic, hazardous, a.'ld caustic substances that may be
:i.njested.

The information includ.es clinical and statistical

data on the toxic effects of drugs, chemicals, and household
substances.

Additionally, suggested educational programs

.and. printed. material is supplied.

The Division evaluates

reports received on injuries and fatalities from the above
mentioned substances, and through these evaluations, the
determination of which substances require child-resistant
packaging or special labeling is made with recommendation
sent to the FDA and the Consumer Product Safety Commission.
Furthermore 1 research on the treatment for persons \vho ·have
injested toxic substances and on product modifications '.1hich
are necessary to cut-doirm inj·uries is done

(l~3).

J!l'UiLl'~~-eE.,ee

Although clinical trials are conducted prior to marketing of a drug to determine its. safety, adverse drug reac·tions
with a
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incidence fail to be presented in these tests.

The

·function of the Division of Drug J<Jq>erience is to monitor drug
experience reports on marketed drugs to serve as a warning for .
any unforeseen adverse drug reactions.

In this respect, the

system works as a Phase IV follo\1-up program aiming to identify
the adverse d:t'Ug reactions when a drug is used. on the general
population.
The adverse drug reaction data is obtained from physicians,
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hospitals, and

~-ug

manufacturers, and are reported on the

Form FD-1639 (Appendix G).

Copies of this form are sent to

FDA and are numbered, card punched, and computerized using
the Costart language for the reactions.

The computerized

printouts from the Form FD-1639 list drugs both by trade
name and generic.

The impossibility of delineating .the

incidence of the adverse drug reaction in the absence of
the number of exposures, leads the division to dependence
upon two other surveys of adverse drug reactions, one in
Boston and one in Florida for comparison.

In Boston, 20-30

hospitals participate in an intensive surveillance program
and the incidenceo(reaction/exposure) of.the adverse drug
reactions is obtained.

The University of Florida conducts

a surveillance of two hospitals to determine the number of
adverse drug reactions.

'l'he comparison ·of the Drug Experience

information tli th that. of the Boston and Florida studies is
tabulated.

If there are frequent occurrences of adverse drug

reactions that are not listed in the drug labeling, .the discrepancy is examined and evaluated with a possible labeling
change being made.
Pharmaceu:t;ical Research and Testing
Pharmaceutical Research and Testing is the laboratory
arm of the Bureau of Drugs.

Located in downtown Washington

D.C. (separate from the Bureau's main offices in Rockville),
the laboratories develop methods of analysis for drug products
and confirm these methods through collaberative studies in
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conjunction \dth the EDRO district labs.

They work with the

US:P/N.fi' Committee of Revision in the development of their drug
monographs.

All ani7ibiotics and insulin are test;ed in the

labe as part of the certification process.
received from the field are analyzed.

Unb1own samples

'l'o accomplish these

.functions, Pharmaceutical Research and Testing is divided
into four areas:

Division of Drug Biology, Division of Drug

Chemistry, National Center for Antibiotic
National Center for Drug l!nalysis.

P~alysis,

and the

The National Center for

Drug .Analysis is not pbysically located in Washington D.C.,

but is in St. Louis, Missouri, so that t;he author was unable

to visit it.
these

In addition to serving the Bureau of

l~tboratories

~r-ugs,

support the efforts of the· district

laboratories and aid other federal agencies ;vith drug analysis
upon request.

1kl.l6.J?io1slliY.,
~~e

Division of Drug Biology is predominantly

rese~rrch

oriented, studying the pharmacological and toxicological
effects of drugs on biological and microbiological systems.
The group aJ.,so develops bioassay a.'ld animal system utilization techniques in the study of drugs.

The four branches

of the division include Drug Bioanalysis, Drug :Pharmacology,
/'

Drug JVii.crobiolog,y, and Drug 'l'oxicology.
The JJrug Bioanalysis branch bioassays such fu'Ugs as
digitalis, insulin, d-tubocurare, and some other endocrine
drugs and develops new bioassay methods.
in the various organs is determined.

~·he

amount of drug

Their bioanalytical
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findings are correlated \1j_th the physiochemical methods of
the division.

Support and advice

cu'e

labs! USP/NF, and others on bioassays.

given to the field
The Branch is cur-

rently developing new radioiromune assays for various drugs.
Drug Pharmacology is lnvolved with the development of
animal models and the parameters to be measured for drug
effects.

The Branch supervises some extramural contracts,

and does some studies which are on request from the New Drug
Evaluation or Biometrics and Epidemiology sta.ffs

~;hich

have

detected problems not being researched by industry, academia
or ·other government agencies.

Some exmnples o.f the types of

projects include the factors that influence the absorption
of drugs into the brain and their seque1ae; i;he effects of
nutritional deficiencies or

enviro~~ental

pollutants on drug

absorpt:Lo::1; BJ."l.d behavioral teratology, drug interactions,
and ei'.fects on the heart and respiration.
Drug Htcrobiology has four areas of study:
enzymology, taxonomy, and immunology.

sterility,

'The· group· does pyrogen

testing to deYelop better methods than the rabbit t0st; vlhich
is time consuming ro1d expensive.

These other methods include

the lymulus lysaJGe and antisera, but false positives and false
negatives have been a problem.

Research into assays designed

to determine microbial contaminants in drugs is on-going and
the group warks with the official

com~endia

and other FDA

units in their development.
Drug Toxicology is similar in function to Drug Pharmacology,
however, the studies deal with parameters used in testing

•'
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toxicological effects of drugs and the manifestations of
these toxic effects.

The applicability to man of these

toxic effects, i.e. animal models, is studied, along with
the specific changes that o_ccur and their significance.
!)rug

Chemi~
~~e

Division of Drug Chemistry includes four brro1ches:

General Methods Research Bra.."J.ch, Instrumental Analysis
Research Brarwh, Drug Standards Research Branch, and the
Natural Products Research Branch. . The General Methods
Research Brro1ch updates and reviews the monographs in the
official compendia and develops .methods for analysis.

'I'he

Instrumental Analysis Resee.rch Brtmch handles the instrumentatim::, sn.pporting tb.e lli ;rision and intere.cts
ether bran.ches.
include:

~ii th

all -!.;he

The types of instrumentati.on available

thi11 layer chromotography, infrared spectTornetry,

gas ch-:•omotog.r·aphy-mass spectrometry, electron synthetic
reactor, nucleal:' magnetic resonance, and liquid.,.. liquid
ohromotog:r.aplzy.

~'he

brffilch, as an example, runs

samples for drug stan.dards..
Br~.nc.h

kno~m

The Drug .Standards Research

handles the IND/NDA methods validation requests 'tlhich

come- i:n from Ne\·1 Drug E'valuation revie\<Jing chemists.

The

efforts of the districi; laboratory 'in thoir vJOrk on the
valj_dation aTe coordinated.

The bJ.'anch also does unknovm

identification, with the help of the instrumental analysis
brro1ch, receiving most of the samples from the field.
tionally, the group works with reference standards.

AddiThe

Natural Products Reseaxch Branch is responsible for methods
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development and analysis of the hormones, and other natural
products.
National Center for Antibiotic Anallsis
The National Center for Antibiotic Analysis is broken

into five branches:

Biology, Chemistry, Sterility Testing,

Nicrobiologic.al Assay, and Antibiotic Residue.

These

branches share the Division's prime.ry responsibili.ty of' the
analysis for certification of all batches of antibiotics. .
The number of batches ranges from 20,000 to 21,000 per year.
They reviev.•, validate, and develop the antibiotic cer•tification tests to be published in the J!'ed§_ral Re_gi,ste:t;: and become
part of the antibiotic.' s monograph.

Problems dealj_ng with

antibiotics a:t.oe investigated upon request .from other parts
of the Bureau of other federal age.ncies.

Consumer complaints,

residues, and inspector samples that .need analysis fo:::> nn:t;ibiotics i.!J.'e a.lso handled.
The Biology Branch performs all animal testing i'or the
antibiotics.

This includes:

pyrogen testing in rabbits,

histamine testing .in cats, and toxicity and safet--y testing
in mice.

The Chemistry Branch certifies. and maintains the·

official antibiotic standards.

In addition, they perform all

the chemical tests listed in the CFR which include:

pH,

moisture, identit--y, potency, and ash/heavy metal content.
Sterility testing branch does its testing on all those samples
required to be sterile.
the most common.

Tests using membra..11e filtration are

'rhe Microbiological Assay branch determines

the potency of the antibiotic through microbiological means
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either by cylinder plate or turbidome·t;ric assays.

In

addition, some work on official standards is done.

The

Antibiotic Residue group is divided beh1een regulatory work
and research.

The work consists of' testing official samples

of foods for drugs (residues); certifying all antitumor
agents (requires special precautions as they are potent
drugs); and methods validation.

This work involves inter-

action with the Bureau of l!'oods,

u.s.

Department of

AgTiculture, Bureau of Veterinary l"Jedicine, Bureau of
t·1edical Devices and Diagnostic Products, National Institute
for Occupational Safety and Health and the Environmental
Protection Agency.
D.r-c'.g Monographs
In the past fe\·J years, the FDA has pJ.accd increased
err.phasis in c.<:l'taj_n problem areas of drug quality that either
1rrere not recognized as such; or Ttlel?e identified, but manpower
restric·!;ions prevented active pursuit for solutions.

Que.s-

tions about the safety and ef'ficacy of over-the-counter (O'J:G)
dr•;;g products, an ar·ea criticized, led to the development of
the OTC drug ingredient review program.

~~e

concern over the

l):i.oequivalence of generic drug products he.s occurred in the
last decade.

The development of the digoxin bioequivalence

problem emphasized the importance of the determination of
the bioavailability of some drug products prior to the substitution of one for another.

The coni'lict in the regulation

of some drug products under the strict new drug applications
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vs. the regulation of their generic equi.va.lent under the
abbreviated new drug applications, and the lack of licensing
procedures for others, has led to the discussion of a possible
program to change the designation of some of the "new" drugs
to "old" drugs, and to develop a monograph system to regulate the "old" drugs.

The area of Drug Honographs is

responsible for the implementation of these most recent
agency policies through its three divisions:

Over-the-

Counter Drug Evaluation, Biopharmaceutics, and Generic Drug
Monographs.
Ove:z.::::."!'he-,9ill]11ter

Dr.)Jg

EvaluFJ.tion

The purpose of the Division of Over-the-Counter Drug
Evalue:ti.o:n is the implementation of the p:r:·cgrruu desigllfJd to·
eveluate for safety and ef'ficacy all ingredients included in
over-the-counter (OTC) drug products.

The division identifies,

categori:<:ns, and gathers data on the ingredients in the O'rC
drug products in preparation for their re·iTie\t for safety an<i
eJ'ficacy by panels of experts.

After panels are chosen, the

division personnel serve to support and coordinate panel
activities through research on the ingredients, re.c:ording of
the minutes of the meetings, and the drafting of memos and
reports.

The informai;ion submitted by the drug product manu-

fact-urers on the drug ingredients is reviewed and coordinated
by the division for use by the panel.

~'he

division then

recommends Bureau action based upon the panel reports &'1d
assists in the preparation of the final drug monograph (43).
The procedure involved in the review of the over-the-counter
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cL."'"'Ug products differs from that USfld in the; N.AS/NRC review
of all drugs with approved NDA's prior to 1962 that has been

going on in this past d.ecade and is nea..r.ing completion.

In

lieu of reviewing each drug product individually as the NAS/

NRC project did, the OTC drug evaluation reviews each ingredient in a given therapeutic class.

No action is taken

individually on any given drug product, but rather the use
and labeling for the active ingredient are specified in a
drug monograph to which the drug product must comply i f it
is not to be deemed adulterated or misbranded.
The process began with the identification of all of the
active ing.c·edie11ts (over 700) contaj.ned j_n the estimated
100,000 to 500,000 .OTC drw5 prod.uci;s.

These h1@,'2'ed.ients

were placed i.n. cne or more of the 26 therapeutic categm::·ies
esi;abJ.isb!i'ld.,

~.'hese

therapeutic categories were grouped into

. 1? pano:i. topics for review.
1.

Antacids

2.

Antimicrobial I (antimicrobial soaps, scrubs,
pre-op preparations, skin antiseptics, skin
~mund cleansers and protectants, antimicrobials
f.or continuous topical application)

?).

Ini;ernal AnaJ.gestcs (internal analgesics and
internal antirheumatics)

l~.

Cough-Cold-Allergy-Bronkodilator-Antiasthmatic

5.

Sedatives-Sleep Aids-1'ranquilizer

6.

Topical Analgesic-Burn Treatment-Sunburn·
Treatment and Preventative~·Antirheumatic
(topical)-Otic

?•

Dental-Dentifrice (fluoride toothpastes)

8.

Antimicrobial II (antiseborrhea, ru1tiacne,
topical antibiotics)
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9.

J,a.xatives-Antidie.rrheals-Emetics-.Antiemetics

10.

Ophthalmic (eye washes, contact lense
preparations)

11.

Contraceptive and other Vaginal drug products

12.

Hemorrhoidal

13.

Oral Cavity (mouthwashes, oral antiseptics)

11-1..

Vi tamin-t1ineral-Hematinic

15.

.Antiperspirants

16.

Internal Miscellaneous (alcoholism cures,
antiflatulents, digestive aids,
hair gro11ers, impotency cures, OTC
cancer cures, smoking deterrents,
.
weight control products, worm remedies)

17. Ex·t;ernal Missc(i)llaneous (baby cream, bleaching

preparations, boil ointment, bust
developers, corn pads, depilatories,
medicated bath prepare,t:!.ons, OTC cancer·
cu.res, tattoo removers, wrinkle removers)

Once the panel topics w-ere determined; the advisory review
pro1el selection was initiated.

The panel is composed of seven

voting members (Chairman seleeted from ·this group), an Industry
Liaison, a Consumer Liaison, an Executive Secretary, a Panel
Administrator, and a Drug Information Analyst.

The. seven voting

members and two·non-voting liaisons are chosen :froll1 nominations
made from a number of professional, trade, and consumer organizs.tions..

The vo'Ging members are experts in the area of the

panel review, a.11.d include physician· specialists, pharmacists,
and Ph.D. toxicologists a:nd pharmacologists.

~)be

consumer

liaison is chosen by one of the eonsumer organizations.

1~1e

industry liaison is chosen a.11.d supported by the Proprietary
Association.

He serves to answer questions the panel has w-ith
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respect to industry and to keep the industry informed on
any special needs the panel may have for information on the
drug ingredients.

These liaison members furnish the needed

interaction between ·l;he panel, the consumer, and the industry
so as to allow for the smooth development of the monographs.
The Executive Secretary, Panel Administrator, ru1d the

Drug Information Analyst are all employees of the agency.
The Executive Secretary is familiar through his work at the
agency with the drug categories that the panel is reviewing.
He \'lrites the summary minutes, answers questions about agency

policy, and compiles a complete file of information for the

pa.nel.

The Panel Administrator and the

Drul?:~

Information

A."l.alyst work in the OTC Drug Evaluation :Division.

2-'he Penel

Administrator asmll:'es the smooth operation of the pa-c.el b;r
ha11dling all administrative functions to iltclud.e meeting dates,

circuJ.at:i.on of minutes,

an~l

distJ:·ibution of the

:Lncom~cng

de.ta,.

The Drug Information .Analyst ser-ves as a resource person by
a:i.ding the panel in the accumulation of needed information.
Initially, the division sends out a request for data on
the drug ingredients in the panel revie•T categories to be set
up next.

The data on the ingredients generally are provided

by the firms \vhich have drug products containing ingredients
to be revieoJed. and include animal and human .safety and efficacy
data, labeling, and the quantity of the ingredient in the

d~cug

products, and can be submitted throughout the entire review
process.

The firms also have the opportunity to present their

data to the pa.'lel at one of their meetings.

In addition, the
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research done by the staff of the OTC l'lrug JS"valuat:i.on Division
supplements this information.
The panels are charged. v1ith the responsibility to review
the OTC Drug labeling and to establish monographs stating the
~'he

safe and e:f.'fective conditions for use of the drug.

panel

makes its decisions based upon the. expertise of its members
and the data presented.
ness

fu~d

allo~;ed

The standards for safety, effective-

labeling are defined in the 37 CFR 9464.

They are

to meet as often and as long as appropriate.

lli.'})eri-

ence to date has shO\"I!l this to be biomonthly meetings for
about; 2-3 years.

The decisions made on each ingredient to

define its proper category:
1.

GR~S (generally recognized as safe) and
GRAJ<:; (generaliy recognized as eff'9ctive)
and not misbranded

2.

Not GRAS an.d/or not GRJIJ!: and/or urisbranc1.ed

:.;.

Suf'f:icient data not available at time of
judgment to decide status of a11 ingreclien·t

Once the panel has made their decisions on all ingredients, the panel report is v1ritten.

The decisions included

a:t.'e translated into the language of the

~§.eral Jl~ist.~JL

by

the OTC D:r-ug EvaJ.uat:i.on. Division as the drug monographs, and
sent to the Commissioner for his approval.· The labeling is
defi:Lled explicitly

t~i th

all indications not determined to be

safe and efficacious excluded from the monograph.

1'he condi-

tions for marketing., conditions for exclusion, and the full
report of the panel are published as the Proposed Nonograph.
Sixty days are allowed for comments to be sent to the Hearing
Clerk.

The 'fentative Final monograph is published and an oral

hearing is allo•,led, after w·hich the Final Monograph is
printecl.

The monograph regulations are enforced by the

Division of Drug Labeling, OTC Branch of Compliance.

.Arty

changes desired are handled by appeal through the courts
and could lead to amendment procedures.
The OTC panels have been meeting since 1972, and to date
have published 3 of the estimated 19 reports (some pro1els
l'Iill be publishing more than one report):
Laxatives

(~~oposed),

Antacids (l!'inal),

and Antimicrobial I (Proposed).

~ioph~~r~~

In the past decade, the bioequivalence of drugs has
been a major issue especially with reference to the repeal
of the antisubst:l.tution la1r;s which have prevented the pharmacist from substituting a less
brand name counterpart.

The

e)~ensive

t1~""imum

generic drug for its

Allowable Cost (r1IAC)

regulations for reimbursement for drugs promulgated by the
Ilepartmeni; of Health, Education, and Welfare for their health
programs such as Nedicare ,and Medicaid, have increased the
emphasis of FDA on assuring that substitutable drugs are
b:i.cequivalent.

The bioequivalence, bioavailability, and

pharme.cokinetics questions in the FDA a:r·e handled by the
Division of Biopharmaceutics.
three brane):les:

The Division is divided into

Biopharmaceutics Labora'bory, Biopharmaceutics

Review, and Pharmacokinetics Reviei"J.

The branches i11terrelcd;e

to perform these functions.
The Division.has several major responsibilities.

The

data submitted to IND's, NDA's, ANDA's, Form 5's, ro1d Form 6 1 s
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that contains information on the 'bi()availabili ty,
bioequivalence, and pharmacokinetics is reviewed.

The

pharmacokinetics work most frequently involves Eltudies
inPhase I of the investigation (IND).

These studies

include absorption, distribution, metabolism, blood level,
~llld

excretion information which are performed early in the

investigative stage to characterize the drug, generally
utilizing radioactively tagged material..

Bioequivalence

studies are frequently included in the ANDA to demonstrate
the equivalence of one formulation of a drug to a stru1dard
(usually the formulation with the approved NDA).

For a

change in formulation in a drug v1ith an approved ND.II., bioequivalence studie.s may be required.

Addi.tion,ally, drug

disposition data, dosing regimen, and specialized drug
delivery systE-ms are reviewed to assn.re bioavailabi1:\.t;y.
~:'he

divisions in New Drug Evaluation and· the Division

of Generic Drug Honographs are responsible for the revieN of
the above mentioned documents, and send requests \dth the
appropriate jackets to the Division.

The data are reviewed

and recommendations for approval, disapproval, or additional
information are retl.lrned to the appropriate division fm·
incorporation into a letter to the firm.
'l'he drugs that are already marlceted, such as those to
be included in the MAC proposal, require surveillance by the
Division for bioequivalence.

On June 20, 1975, the proposed

bioequivalencc/bioavailability regulations \vere published
in the Federal Register.

As the back-up to the MAC these
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regulations define terms relating to bioequivalence and
bioavailability, and list 193 problem drugs and dosage
forms.that require special testjng for bioequivalence/
bioavailability determination.

The 193 problem drugs are

separated into 4 groups (66):
1.

2.

47 drugs requiring }.,n vivo bioayailability
testing to establish b~oequivalence.

70 drugs requiring in vitro l1ioavailabili ty
to determine dissolution rates.

test~ng

3.

4.

62 products requiring special regulatory

handling because of special dosage forms:
aerosols, enteric coated tabs, controlled
release, radiopharmaceuticals, supporsitories•

14 products requiring special regulatory
handling because of menu£acturing problems:
7 biological preparations and 7 intrathecal
or intraventriculm' injection.

The Division nm,1 has the added responsibility of revie\·ting

all data that come :in in response to the
thus

inc~reasing

ne~;

regulations,

its vlorkloe.d.

Gen~<;<..Jl.£lli!>...J;:Ionog,ra;g.h.a

Generic drug monographs (or old drug monographs) is a
concept being developed end v1ill be implemented by this
division.

T'ne inequitable method of regulating the drug

proclucts wi·i:;h approved

NDA' s by

t:he strict

NDA

requirements

\'lhile their generic equivalents are ma-cketed under the more
lenient ANDA requirements has been criticized both inside
and outside the agency.

l!'u.rther, those drugs under the

grandfather clause are regulated solely through the misbranding and adulteration sections of the F.D.&C. Act, thus
adding to the inequitable approach to drug regulation..

The
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new approach involved the classification of drugs into three
categories: ·new, old, and banned.

The

ne~r

drugs are those

which will be regulat&d under the current NDA procedUre.
Old drugs are those drugs which are generally recognized as
safe and effective either under the grandfather clause, or
through reclassification of neVI drugs VTith approved NDA's
\'thich have been on the. market for an adequate length of time
to prove they are safe and effective, the latter group having
undergone the NAS/NRC revieVT.

These old drugsVTill then be

written up in a. mo:o.ograph which specifies labeling requirementa for indications, side effects, contraindications, etc.;
in-Pl'ocess specifications for the development of the dosage
'
f· orm ~;o

assure .th
, e proper s t rengt:'h ,

identity; and bioavailabili.ty data.

. ...

PU-L'l.·~y,

qus.1'l. ty , and

The Old Drug l·lon.ogra:pb.s ·

>-Jill eliminate the existing MIDA procedvre 1 with the enfo:cce-·
ment being throush e2:isting means of CGHP inspectiol!s,

ao.ulteration, and misbranding •.
The process by \'Ihich the Old Drug r1onographs will be
developed by first publishing proposed . rt<lemakings in tho
;E'~£If'yal

fuJJQ-§1£:£.•

Hearings will be held

011

the rulemakings,

after wh:i.ch the information from the hearings,. where applicable,

will be incorporated into the drug monograph which is published

right to petition for changes.

For additions to the ind:i.ca-

tions for the drug, the sponsor will be required to file an
NDA.
In addition to the responsibility for the old drug
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monographs, the division reviews the Abbreviated New Drug
Applications (ANDA's), Abbreviated Antibiotic Applications
(Form 6 1 s), and their supplements, for approval, disapproval,
or withdrmval.

These applications contain similar information

to that contained in the New Drug Applications (NDA) with the
exception of the clinical data on the safety and efficacy
of the drug.

Instead, data on the bioequivalence of the

generic with the original drug under the NDA must be proven.
This data is sent to the Division of Biopharmaceutics for
revie>'l.

The remainder of the application, the labeling,

inanutacturing, and cont-rols data, is reviewed by the chemista
and·medicaJ. officers in the divicion.

~'he

Executive Director for Regional Operations (EDRO)

has by :fa-r.• the largest unit in the Food and Drug Administration
as it includea all of the agency's personnel in the field, or
about 47% of the total FDA work force.
<Jre divided among the Bureaus:

These manpowe:r· reso.urces

Foods, Drugs, Veterinary

Jvledic:i.ne,. Radiological Health, and Biologics, and the National
Oentel' i'or Toxicological Research according to their needs end

to the priorities set by the leadersh:i.p of the agency.

These

needs and priorities are communicated to EDRO mainly in the
form of Program Management System (Pli'JS) Oompli~.nce Programs,
that have been developed within the individual bureaus.

The

basic Compliance programs for the Bureau of Drugs include:
Drug Application

Evaluation~

Drug Production Quality, Drug

139
Efficacy Study Implementation, Drug Pharmaceutics and
Methodology, Clinical Investigation Evaluation, end Drug
Abuse and Methadone Honitoring.
In addition to its function·of implementing compliance
programs .from the other areas in the agency, EDRO coordinates
the work of the other .federal, state, and local regulatory
agencies vlhich have jurisdiction over the same consumer
products as the FDA.

Through the cooperation of these agencies,

greater assurance is provided that all areas·o.r regulatory
activity are adequately enforced and there is no unnecessary
duplication of effort.
To coordinate the activities of the field personnel \'iith
those of the bureaus, the main office of FJ)RO ;is divided into
tt.1.l:'ee divisions:

Planning and Analysis, Federo.l-State Relations,

and :F'ield Operations.

·l'hese divisions ·not onl;r coordinate

activities, but also se.rve as support to the ten regional
offices. ·These regions are comprised ·Of nineteen district
offices and are located in major cities.tbroughout the United
States and Puerto Rico (Figure III).

·The functions of these

divi!lions e.s they relate to the mission of the Bureau of Drugs
wi11 be

der~<;ribed.

Planning and Analysis
The Division of Planning and Analysis has a name descrip-'
tive of its function:

to create the EDRO workplan and to

monitor manpN;er utilization and the progress of the compliance
programs in the various districts.

The EDRO workplan is

created through the interfacing

~•i th

the Bureau of Drugs'

project officers and the .Associate Commissioner for
Compliance, and the monitoring is done by a program oriented
data system (PODS).

The system aids in planning by giving

out cost efficiency data on the compliance programs, tracking all compliance programs, giving monthly reports of what
has been accomplished to that month, and comparing the results
with the year's

workplan~

The districts' operations are

. quantified in categories such as the utilization of manpo\ver,
quality indicators, plan the number of_hours, and staffing
patterns.

In addition, the Official Establishment Invento:ey

is maintained.· This _provides information on the elli',psed time
between firm inspections, giving 18 and 23 month alerts to the
districts where the drug firms have not been inspected 'tlithin
those time periods so that action can be taken.
firms must

bfJ

By lcM, drug

inspected every tvro yem•s •

..Another useful data source m.aintained by the agency is
the mapping by computer of the number and types of firms
located in each count-y of. the

u.s.

This tool allo\'JS the

agency to better distribute and utilize its specialized manpo~ter.

A "sldlls bank" has also been developed and includes

deta:l.led information :!.'.s to the skills of

't:he

various in7esti-

gators so that they can be utilized in emergency si tv.at:i.ons.
The benefit of lab automation vs. increase in personnel,
technical training, and the value of special labs are also
analyzed by the division's personnel.
The three branches of the Division of Planning and Analysis:

ll~l

Program Planning and Review, Systems Analysis, an9. Special
Studies share the Division's respons:Lbilitiea.

The branches'

as well as the Division's functions relate directly to the
Program J1ana.gernent System (PMS).

As mentioned previously,

the Pl"IS describes the objectives of the.agency in terms of
proje•::ts for the year rather than through functional descriptions of organizational units.

This has allowed a more direct

relationship from budget categoryto program to project to
compliance program, and thus is easier to plan.
Federal-State Relations
The Division of Federal-Ste.te Hela·i;ions serves as the
liaison between the FDA and the state and, ldcs,l cl.gencie.s

co~l

cm:ned with food and drug regulation in operations, training,
and progra.'ll deveh>pment.

T"nree e.rea.s:

Program IJeveJ.opmeni;, and the Cincir...l'lati

State Services,
T~'aining

Fac:l.li:ty

. assume these responsibilities •.
State SerYi.ces covers three main areas:

information

dissemination, eommissioni.ng of state a11d local officials,
fllld gathering state resource data.

The information dissemina-

tion involves communication on the latest: happenings in foods
and drugs, for example recalls or new regulations.

Three

method.s of dissemination are used depending upon the urgency
of the message.

The faste ert is the TWX, which is used for

urgent messages and are only one-way from the FDA to the
states.

HOI'lever, a new system is in the stages of deYelop-

ment;, NRSTEN (National Regulatory State Telecommunication

142
System),

\~bich

will provide

"tt~o-way

rapid communication.

The second method is through the office tapes which handle.
less

R~gent

information and are handstuffed in the mail.

The third is by far the slowest, taking 20 days for receipt,
as it goes through the department mailing keys and covers a
broad segment of the state officials.
The commissioning of state and local officials to conduct
investigations for the enforcement of the F.D.&C. Act is
authorized in Section 702.
their co!IJlllissioning.
the agency.

The Branch is responsible for

The states provide various services for

For example, medicated feed inspections and food

sanitation of the .final pr·oduct in restaurents are handled by
the stat·e o.fficials as the FDA does not have the resom'(;es to
carry out this responsibility,
'l'he state· resource data are being compiled by the Branch
bao,ed upon a ra:ndom survey of 'rlhat the states are doing in

the regulation of foods and drugs.

In the futtli'e, this survey

\'lill exten.d to all states, thus providing a complete data base
which vlill aid the FDA in planning \1here it should concentrate
its resources.

The Branch does aid the states in the

execu~

tion of a better food and drug program 1 responds to inquiries,
and maintains mru1.uals \~hich include a summary of the !~li~"~
~JQJz.:tfiJr

requirements and the weekly recall, seiztiTe, and

prosecution list.
The Pr·ogram Development Branch handles the state contracts, the work sharing agreements, and the information gh,.en
concerning pending state food and drug legislation.

The state
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contracts (over 70 of them) are both developed and monitored
in the Branch.

Examples of the common contracts include

food service .sanitation (inspections of facilities and

an~ysis of samples), ru1d the methadone monitoring programs.

Work sharing agreements are made with the.states so that
resom•ces can be conserved.

In the legislative area, the

Branch informs states about federal plans, and encourages
uniform food ru1d drug legislation.
Field Operations
The Division of Field Operations coordinates the
day activi·ties in the field and serv.es their needs...

day·~to··

Its

bran.ches mirror those of the district of.ficern"· Investigations,
Sciene"'' Compliance, and Consumer Coordina·t;or.

These brru1c:hes

provide a host of support services by ru1swer:ing technical
questions, supplying experts to aid in solving problems, and
developing inspectional techniques.

\vi th the Bureaus, the

Division prepares the investigational operations manual,
coordinates multiregional activities, and represents the field
personnel in dealing with the Bureaus.
The ]'i.e J.d.
sections:

Investiga~ions

Branch is divided into four

Operations, Epidemiological Investigations, Foreign

Inspections, and Quality Assurance.

'I'hese four parts relate

to the district offices mainly through the Chief Investigator.
Operations provides procedures and techniques (the investigator's manual), coordinates manpower needs, and handles
inspectional problems, with its "specialists" staff which

' 1'+4.

includes experts in the areas of microbiology, complex
manufacturing, antibiotics, an.d canning.
The Epidemiological Investigations group has the task
of monitoring all reports of food and drug related disease,
illness or injury.

The group then coordinates the efforts

of the Bureaus, :E.'DRO, the press, the Associate Commissioner
for Compliance, Center for Disease Control and others through
the stages of the report investigations.
I.

TheBe stages include:

Alert. The initial receipt ofthe report;
information without support data.

II. ·Presumptive. Have some lab analysis, possibly
clinicaldiagn()sis.
III.

Confirmed. Lab analysis, clinical diagnosis,
and tracings to product.

Action may be taken at either II or III depending upon the
:natm.'e of i;he problem.

If action is \·larranted on any px·oblerJ,

ephlem:Lological investigations follovm up and makes certain
the;t; all interested parties are in.formed.
·The inspection of over 150 fore:i.gn drug firms primal'ily
for antibioocics and New Drug Applications is coordinated
through Foreign Inspections utilizing the best seasoned
investigators from the field.

.Antibiotic firms are inspected

yearly, 1trhereas the firms

l'illA' s are inspected on request

from the Bureau of Drugs.

~lith

Additional drug firms a:::·e visited

<Ihen time and maupo>"er permit •
Engineers are the chief componen°G of Quality AssuraJ1ce, ·
and they are available on request from the district to provide
ad_vice in solving technical problems.

The group has inj_t:i.ated

an inspector's technical guide which includes suggestions for
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handling problems that might occur in such areas as:

steam

pressure control for retorts and autoclaves, ultrasound in
the :food, drug and device industry, and the calculations of
initial gas concentration in ethylene oxide sterilization,
and keeping them informed on the latest de·velopments.

The

group promotes qualit7 in activities of the district offices
and industry.
'I:he activities of the nineteen district laboratories are
coordi.nated. through the Field Sciences Branch.

The activities

incl1.1de not only the routine analyses, but also the collaberative studies run to develop methodology, research projects to
avoid duplication, and the training programs that are designed
to combat· obscelens<:ence of the labs.

Quality.. assurance

checks on. the lab are c.onducted by the Brarwh to determine·
ar.y lab-lab va:dation.

The training prograuw include not only

cou.:r,ses in lab techniques but

t~m

others which connect the

distric-t; lab with a nearby university:

-the Science .Advisors

and the Science Advisor Research Associate Program. ·Universities within corn..'Tlu.ting distances of the district offices are
contacted, and ge:nerally, a professor in analytical chemistry
is contracted to come to the labs and aid the scientists to
keep currcmt.
Science

Al.·so, research proposals may be h1ade to the

~klviE.:ors

school to do some .method development for

the agencye
1~e

Field Compliance Branch provides for direction and

counsel for

thei~

counterparts in the field, develops the

Regulatory Procedures and Import Manuals, and coordinates
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emergency and recall operations.

These services are divided

j.nto four ar·eas a:1d assigned to either Regulatory Operations,
Emergency and Recall Operations, Compliance Programs, or
Import Operations.· Regulatory Operations tracks and monitors
the information sent between the Bureaus and thG Field,
evaluates what EDRO sends, and trains compliance officers
in law and interpretation.

Emergency and Recall Operations'

name is descriptive of its function, to coordinate flood,
hurricane, and recall effectiveness che.ck activities.

Policy

guidelines for the Field-Compliance sections a:re developed in
Compliance programs in addition to its duties of monitoring
and coordinating them.

Chapter VIII of the F.D.&C. Act

con·~

tai:ns the autho:i:'i ty of the dutie.s of Import Op?,ra-l:;io11s.

T'nis

section on Imports a<"ld Exports covers v<hat the FDA should do
wi.th respect to the imports aild exports, and is ver:·y similar
to the sections dealing with adulteration and misbranding.
The Consumer A:i:fairs

Coordinate~'

hand.les the program

pla.uning, budgeting, coordinating and adyising of the 52
Consumer Affairs Officers thxoughout the country in their
dutie.s of responding to consumer inquiries and keeping the
press i:r>..f'ormed of FDA actions (e.g. recalls).
Field Offices .
There are ten regional offices of li'DA (Figure III)
according to the divisions of the Department of Health,
Education, and Welfare.

.These are brolcen into nineteen

district offices which in turn have various resident posts.
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The resident posts are located in cities without a district
or regional office and involve from a single person to close

to district size staffs.

They have been set up to give the

field offices a broader base from which to work.
offices are divided into four branches:

The district

Administrative,

Investigations, IJaboratory, and Compliance.

The branches

have chiefs which report to the Deputy Regional Tiirector
(District Director) and he reports to the Regional Director.
In the regional structure, there are the Consumer Affairs

Office, the Federal-State Relations, and Recall and Emergencies
~lhich

coordinate the information from EDB.O with that of the

district offices.
The Investigations Branch handles the plant inspections,
sample collections, and the other components oi' the compliance
programs.

The routine complj.ance inspect:i.c:t:ts (e.g. GJ.'Iii''s.,

QualH:;y- Assurru1ce1 :,)rograms) are set up by the district offices
with some guidance and monitoring from EDRO.

Special requests

that come in from the Bureau of Drugs, from other districts,
or from EDRO require modification of the time schedules and
plan.n:i.ng.

Recalls, too, can rearrec:nge the calendar.

The Investigations Branch contains a Chief InveE:tigator
and several supervisors over the investi.gators.

The chiei'

and supervisors meet daily to discuss the prevj.ous day 1 s
activities (e.g., recalls, regulatory actions, inspectional
findings) and to make the daily special request assignments
to the investigators.

Suggestions about how various problems

should be handled are made.
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The investigator for FDA is a person with a science
background, for example, biology, zoology, microbiology, or
pharmacy.

The investigators attend an accelerated training

course to learn the basics of inspectional procedures.

In

the .first .few years at t-he agency, the investigator is
generally assigned to inspect food plants, drug manufacturers,
blood banks, and all other areas under jurisdiction o.f the
agency.

This provides him

tional procedures.
specialize.
e~~c.,

\~ith

a broad background in inspec-

Then, many o.f the investigators begin to

This "specialization" whether in foods, drugs,

generally is accompanied \"lith another training course

to teach additional inspectional procedures.

There a:ce various ·types of inspections conducted by the
agency, and i;h6y are loosely separated into
general and

srJe-::o~i.fic.

t~ro

categories:

They can inclUde such a:ceas as:

good

manufacturing -practices f"or Nll.A approval, E'tatutory, or
limited; adverse drug reactions or drug product d.efect report
for follo\v-upi and quali t·y assurance for collecti.on of' sa;·nples
for analysis.
~1e

inspection procedure requires an increasing amount

o.f paper;·mrk.

This paper\wrk can and .for the most part, does

·include:
1.

Notice of Inspection: c:i.tes the authority
o.f Section 70Lf. of the F.D.C • .Act that allo>is
the FD.A to make inspections.

2.

Samples
a.

official: require that the integrity
o.f the sample is maintained and that
the interstate movement of either the
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finished product or raw material is
documented with an a.ffidavi t. The
sample is assigned a specific number,
placed in a container, and signed
with the investigator's signatm·e .-

b.

documentary (eg. large device such
as a respirator, T.V.): need to get
picture, shipping records, sales
literature, diagrams, and any other
information that describes the product
to put into collection report.

3. Receipt for samples:

need information on the
types, lot numbers, and charge as the FDA p~ys
for all of its samples.

4.

Affidavit: -need to cite the responsible per. son, product sampJ,.ed (type, lot numbers,
description of sample, document interstate ·
movement vrith shipping records, freight bill)
and must be signed by responsible person and
investigator.

5.

Collection report: report stat;h1g that the
sample ~ms collectE:d.

6.

Form 2275: oboervations, that have b<:>en ma.de
<;luring the investigations in '~b.:i.ch mw violB.ticnls e.re cited. A copy is given. to the
responsible indi'Vidual after completion o:f
the inspection.

An example of' the procedures involved vrith one of the

general inspections is_ the one required prior ·!;o the approval
of a ne1.1 drug application.

The purpose of the inspection is

to c.heck .for thE: adherence of the f'irm to the specifications
in the NDA, and their ability to manufacture this and other
products according '!;o current good manufacturing practices.
Rx:;3.mples of the types of things "looked for in the· NDA inspec- ·
tion incb;.de the qualifications of the people who 111ill be
performing these tests, sampling plans, testing o:f raw
materials, processing equipment adequacy, the traceability
of the batch records, and the :final product assay procedures.
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i

At the end of the inspection, the deviations are accessed
by the investigator, as to whether they are significant.

They are vmighed and then a recommendation is made to the
investigator's supervisor -vrhere the .findings are scrutinil!'.ed

and discussed.

The results of these discussions are sent

to the chief investigator for his signature and then to the
district director .from whom the report is sent to the Bureau
of Drugs, Compliance.

The report is relayed to the appropriate

New Drug Evaluation division and incorporated into the chemist's
revie>v .for the NJJA.

On routine CGMP inspections, many of the things covered.
in the NlJA inspection are also looked l'or, however, s.ll types

of products are evaluated.
produci~s

sel.eci::c-~d'-1!

\'lith. the larger firms Vl.b.ere 1nany

a.re ma:m.i.fa.ctu:t'ed; certs.in signific.;m.t categaries a.re
]'or exarnple, those drugs ''Jhich m.--e of great· thera .....

peutic :i.m:portance, those Jc..nown to be problem products to manufacture, or those drugs vlhich are .administered in low doses
thus creating

nar~·ow

ranges for error would. be considered as

significant categories. · Drugs 11hich are not manufactured often
in a firm >vould be scrutinized more closely· to ascertain wheth$r
the production personnel are capaple of mak:i.ng the product •
. Conversely, drug products 1:ihich are manufactm;ed

Ve1~Y

fre-

quently iqould also undergo special supervision to note certain
production personnel are not becoming careless in the routine
of maldng it.
Many of the types of analyses the district; laboratories

run on the various food and drug items are fascinating:

from
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looking for insect fragments in flour to testing·and smelling
tuna, or soaking teacups in acetic acid to check the lead
content of the paint.

The chemists and microbiologists must

be "generalists" in the Field Laboratories as there is such
a wide variety of products under regulation by FDA that need
examination.

Samples are received from consumers, lnvesti-·

gators, and from other FDA offices.
be validated by lab analysis.

Consumer complaints must

The "official" samples collected

by the investigators generally are part of a compliance pro·gram l?hich includes the lab vlOrk to be done, e.g. method vali-dation for a NDA, or quality assurance.

The officiality of

the sample must be maintained, and the analyst must sign the
seal

~1hen

it is broken.

Other FDA offices may call upon the

la1)s tc participate in collaberative studies on method() logy.
About one third of the analyst's time is spent in this and
othe:t' mission oriented. research.
A firm 1 s adherence to the :B'.D.&C. Act and the recommendations of action whether regulatory letter, injunction,
seizure, or prosecution to be taken for failure to comply
· are decisions made by the Compliance Branch after the review
of the <lata from the labs and the inspection reports.

The

recommendations for action are written up by the Consumer
Sai'ety Officers in the branch, and then se11t to the Bureau of
Drugs :for checks on the •Ltechnical completeness" and application of the agency's policy.

The FDA is one of the few, if

not only, federal agencies which prepares its own legal documents utilizing people who are not lawyers.

After the documents
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have been processed through, they re·turn to the
Attorney, and proceedings a.re begtm immediately.

u.s.

District

Members of

the district may be called to testify at these proceedings,
and in prosecution cases.

CHAPTER IV
DISCUSSION

Discussion of t):l.e Pilot

Progra~

The residency experience flll'nished an excellent
opportunity to gain information about the inner workings
of the FDA unattainable from any other source.

The dis"-

cussions with FDA personnel supplied·first--hand accounts
of the responsibilities and activities of the agency in its
regulation of drugs.

As a pharmacist, participation in this

program emphasized the importance of the existence of s. dJ:·ug
regulatory agency, coupled ;d th the

knoJ~lec'tge

that its :reg-u.··

latory ac.tiv:i.ty ca.nnot assure the absolute quality of drue;r;
due to the large number of drug manufacturers and the small
FDA field force.

This clearer unde:?.'standing of the complexi-

ties involved in assuring that drugs are safe, effective, of
good qu.ality, and not misbranded will lead to a greater will-·
:i.ngness to cooperate vii th the agency in

PlLt'Sui t

o:f

its goals

through the utilization of good quality control procedures,
and will enhance collllllunication with patients and feJ.lo;; health
p1•ofessionals in the explanation of" the. actic•ns of" the ageney.
Additionally, the progra>n is valuable to the academic community
in that it provides resource personnel to teach pharmacy
students about FDA drug regulatory procedures, thus broadening
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the scope of cooperation between pharmacy ro1d

th~

FDA.

The work-study technique utilized in the pilot program
proved to be very appropriate for the attainment of a comprehensive knowledge of the agency's responsibilities and
functions.

The principle assignment to New Drug Evaluation's

Division of Surgical-Dental Drug Products presented several
positive features.

The length of time spent in the Division

was greater than the suggested time in the Draf't Syllabus.
This extension supplies enough time to acquire an adequate
understanding of the Division responsibilities so as to participate adively in their execution.

The Division served as

a home base \"here an orientation to the FDA, specifically the
Bureau of Drugs was obtained, and from which the rotations to
other areas.of the agency were planned and·implem.ented..

In

addition, the length of. time allowed for' the acquisition of
an indepth lmowledge of the comple:x::i.ties of' the procedures
for premarket clear(?.nce for· safety and efficacy of ne>v dr-t1.gs ·
which were of special interest to the resident.
For the academic portion of the program, the student
'I<Ias requested to record activities and e:;.cperience during the
residency within the agency.

A daily log was maintained..

The

initial impressions noted in the log provided a. baseline to
determine >vb.at wras learned in the residency at the agency.
These were expanded into periodic Progress Reports which were
sent to the

facult~

advisor, so that the performance of the

student and the development of the program could be measu,":'ed.
The Progress Reports, as far as applicable, addressed the
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assigr~ent

sections listed in the Draft Syllabus, and covered

the areas of the FDA, Bureau of Drugs, Office of Scientific
Coordination, and the Drug Product Reporting·System.

The

Reports contained a smnmary of functions and responsibilities
· of the rotational areas, and formed the basis for the thesis
"1hich included an indepth coverage of what was learned in the
residency.

Periodic telephone conversations

bet\~een

the

student and her advisor provided an added line of communication.

Ho•rever, to be a viable academic program, graduate

studies at FDA must be given adequate faculty supervision at
the agency during the time of residency.

In this initial

program, the faculty advisor made three visits to the Agency
to provide needed direction for the development of the thesis,
a task difficrul t to achieve through telephone con11ersations.
In addition, the presence oi' the faculty advisor strengthened
the cooperation between the Agency and the U:uivers:i.ty in t:he
implementation of the pharmacy graduate studies program.
Meetings \d th the key officials within the Bureau of Drugs
·served to acquaint them with the progress of the program and
to receive their comr.u.endation.

Input from these officials

served to lay the gro1mdwork for the continuation of the pro··
gram in other areas of research.
The residency experience identified and provided indepth
lmO\;rledge of several areas of cooperation between the FDA and
the pharmacist.

These include:

recalls, drug product defect

reporting system, current good manufacturing practices, d:rug
efficacy study implementation, over-the-counter drug evaluetion,
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antibiotic and insulin certification, methadone monitoring,
drug product packaging and stability, maximum allowable cost
and bioeqaivalence regUlations, and the IND/NDA new drug
procedure.
The effects of packaging material on the integrity of
the drug product has become evident due to the work done
under the supervisory chemist in the division.

The materials

can be leeched or extracted into the product, possibly leading to toxicity or stability problems.

Firms, with drug

products regulated under the new drug application, can be
required to submit information about the possibility of the
interaction bet11reen the paclcage and the drug, but most drugs
do not have a new drug application on .fHe with the FDA.
Ac'cd:Lt:i.ona.l::i.y, questions have arisen about what happens -J:;o the
drug product \vhen it :i.s repackaged by the phe_'t"macist.
problems can occm:-.

~Jith

If

the drug product ir; its original

container, what effect on the stability and integrity of the
drug product does the packaging used by the pharmacist have?
The new Fre.edom of Information (FOI) regulations were
published dm:·ing the student 1 s residency at the agency.

These

regulHtions specifically delineate what information the agency
can release upon request, thus the pharmacist has a ne\• resource
. for more detailed information on the dr,.<gs be dispense.
Another set of regulations promulgated by the Department of
Health, Education, and Welfare \vill decisedly affect both the
FDA and the pharmacist.

The Maximum Allowable Cost (HAC)

regulations describe the amount pharmacists will be reimbursed
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for drugs dispensed under one of the government sponsored
health plans, e.g. Medicare or Medicaid.

This amount is

determined by the minimum price for a given drug product
that is widely available plus some dispensing fee.

~.'he

FDA must, therefore, assure that the generic drug products
are of good quality and bioequivalent to the trade name
products so there will be no problem with substitution.
The recent proposed biopharmaceutics regulations promul·q
gated by the Agency delineate the drug products which have
the potential for bioequivalence problems and need additional
in vi i{J:Q. or in vivo testing for consideration under the JV"J.AO
program.
Although the student bad a vague knowledge of the procedure by

ne>• drugs are marketed, the residency pr(;vided

~;.hich

i:udept:h u:nd.erstanding of. t!w complexities involved.

'I'he

decisions that must be made are not based upon clearcut
data, but rather the risks must be weighed against the benefits.

These decisions are further complicated by the

voluminous amount ·of data submitted to support the safety
and efficacy.

The assimilation of the data

~!here

has a high degree o:.f effectiveness is dif'f'icult.

a placebo
In addition,

the proper interpreta.tion of the sometimes vague regulations
to determine what information is adequate and sufficient is a
.formidable task.
Overall, the pilot program enjoyed successful implementation.

The. goal.s of the program as described in the Draft

Syllabus were accomplished in that it provided the background
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research material for a graduate degree thesis and trained
the author in FDA drug regulatory procedures.

Additionally,

from experiences gained in the program, a revised syllabus
for subsequent residencies was developed.
~commendations

for

the_R~idency

Based upon the experience gained in this preliminary
program, some modification of the Draft Syllabus should be
inade.

It is recommended that the length of time should be

extended from 4-6 months to 6-8 months to allow for the
rotations to the suggested areas.

However, it will take

the experience from several residencies to arrive at the
mont suitable period for both the student and "the· agency.
The length

ruay

va:ry from individual to individual alrd w:i.ll

depend. upon the nature of their research :i.r; the agency.
Due to the reorganization of the Bureau of' Drugs in
late·se:ptember, 19?4, most rotational headings of the Draft
Syllabus are. obsolete.

'l'll,e Residency Syllabus in Chapter V

is consistent \vith the changes.
FDA and the Bureau of Erugs

ru~e

The introductory tmits to
to be included as part

o~

the

i.n.formation to be presented in the pr:i.nciple rotation for the
first t;reek' s orientation.

In addition, the Executive Director

for Hegional Operations (EDRO) has been included as part of
the rotational experiences.

As the area of the agency enforc-

ing the F.D.C. Act and regulations :i.n the field, it is imperative that the student have the opportunity to visit EDRO so
as to allow him to integrate the enforcement procedures of
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the field force with those. of t.he Bureau of' Drugs.
There are two methods for understanding of FDA drug
regulations, through didactic work and through the residency
program.

Whereas didactic work on FDA drug regulation meets

the needs ·of the commun.ity or hospitaLpnarmacist in this
area, those wishing to specialize in FDA drug regulation
should supplement the. cover work by spending time in a
dency program at the agency.

resi~

At the present time, the

residency program is most applicable to a graduate.pharmacy
student.

As part of a graduate studies program, the residency

at the FDA may provide the research material for a thesis.
The emphasis in New Drug E\7'aluation listed in the Dr;Ji'',:;
Syllabus has been made flexible as noted in the Residency
SyllEbus.

Joint discussions among the student, t;he advisor,

.and representatives of the agency would determine the principle :r·otation ;.Jhich ivill provide the area of research.
During the pilot program, consultations with officials indicated the availability of a wide v·ariety of reseal:'ch topics.
These could easily be incorporated into the program and

;~ould

be both beneficial to the agencw and educational for the
student.

Examples of' such research topics could include:
The effects of radiosterilization on drug
products.
The legal implications, if any, of drug·
product labeling.
Development of agency policy on particulate
matter, additives, and sterilization of
large volume parenterals.
·
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Development of review guidelines to be
utilized in review of timed··release dosage
forms,-large volume parenterals, aerosols.
Utilization of adverse drug reaction information by the agency.
Study of the implementation of bioequivalence/
bioavailabili ty regulations by the agency.
Development of assay methodology.
The implementation of the over-the-counter drug
monographs; i.e. for use by health professionals.
Further discussions between officials of the agency and
representatives of the university would expru1d upon suggested
topics and lead to the development of the research area.
~'he

goals, methodology, and assignment sections were

re~~ritten

to correspond with the

net~

rotational headings and

the <axperier.ce gained in the pilot program..

f·1any

of the

agen.cy 1e impoxtant .drug regulatory programs 1N'e::::·e not included
in these sections of the Draft Syllabus.

The goals a-re

directed towards the 1.mderstanding of the prog,-rams designed
to assu:ce that drugs are safe and effective, and the FDA's
enforcemen·!; o.f the F .D.&C. Act and its

regulations~

~'he

methodology xecomraended ps.rallels that used in the imple-·
mentation o:f the pilot program.

Discussions were held with

key official.s within the Bureau of Drugs and the Executive
Directo:C" for Regional Operations in which the i'm1ctions of
their areas in relation to the regulation of drugs was
explained.

Severa1. divisions 1dthin the agency supplemented

these discussions by allowing the student to review their
work.

The assignments in the Draft Syllabus served as guide-

lines for the kind of information to be included in the per-iodic
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Progress Reports.

The Study Assignment;s in the Residency

Syllabus are proposed to serve that same purpose.

They

are directed towards developing the student's understanding
of the relation of the functions and responsibilities of
each of the rotational areas to the enforcement of the
F.D.&C. Act and the regulations.

These periodic Progress

Reports should be a brief summary of the ro.tational experiences.

In addition, the progress of the research the student

is doing in the agency should be included.

They should be

submitted to the faculty advisor within a month after the
rotation, as a measurement of the performance of the student
and the development of the research.
In

acldi't~ion

t:o the information on FDA drug :regulation

acquired duri.ng the residfmey period 1 the r;:tudcnt should
attend a food and drug law course offered d.u:;:i.ng the time
spent in :H'DA.

This will serve to enrich the e:xpHrienco and

enhance knowledge of the F.D.&C. Ac'!; and its enforcement.
The potential of the off-campus educational programs
within the FIJA has just begun to be recognized.

The resources··

available within the agency and the interest of the staff
participation

i11

educati.onal prog:r·ams indicate. a capacity

for increased :i.nteraci;ion between the FDA ar1cl phaL'macy education.

Programs such as these serve both the FDA and the

profession of pharmacy through the improvement of communications .•

The heightened awareness of the regulation by the FDA of

16:?

the drugs pharmacists dispense, acquired through the
residency

eJ~erience,

has underscored the need for all

pharmacists to have a reasonable understanding of FDA drug
regula-tion and its impact on the practice of pharmacy and
the products forming the basis of the profession.

A pharma-

cist should know why a given drug product is safe, effective,
not misbranded, and. of good quality.

This encompasses the

knowledge of how the F.D.&C. Act is enforced both through the
promulgation of regulations by the FDA and. the development
of its drug regulatory programs.

The regulato:t'y tools

utilized by the agency that need to be rmderstood incl.ude
general prohibitions against adulteration. and misbr.anding,
premarket clearance for new drugs, and the certification of
antiM.ot;ics and insu.lin.
The pha:r'macist should understand the basis for the
determination by the FDA that a nmv drug is reasonably sai'e
a11d effective.

The k:no~Iled.ge oi: the limitations of clinical

trials will allo·w him to ur1derstand better the possibilities
of, for example, unexper;ted adverse reactions for a drug
a.:fter it has been marketed..

Additionally, the knowledge of

the importance of good record.,keeping

\~hen

handling investi-,

gational new ctrugs 11ill be useful in praci;ice.
The Drug Efficacy Study Implementation (DESI) and the
Over-the-Courlter Drug Ingredient Revie11 are two programs
having a significant effect on the products pharmacists dispense.

The results of the programs have been that mruzy

products have been removed from the market and others have

1M

been reformulated.

The pharmacist should be aware of the

reasons behind the removal of the products so as to be able
to answer questions received from the physician and the
pa·l;ient.
The pharmacist should. understand his role in supporting
the actions of the agency to protect the consumer from substanda"t?d or hazardous remedies.

Through the Drug Product

Defect Reporting System, pharmacists mld the FDA work together.
Acknowledging the fact that the agency works to control the
quality, but cro1not assure the absolute quality of drugs,
the pharmacist must share this responsibility through cooperation >1ith the FDA.

The practicing pharmacist must understand

when and· why a drug product is not considered ,to be He.fe and
effective·.

A basic knowledge o:f both the reasons beh.ind and

the implementation of a drug product reca.ll w:i.ll aid. in this
determination.

The importance of quality control in the manu-

facture of drugs is re:flected in the Current Good I1anu.facturing
Practice (CGMP) regulations promulgated by the agency.
concept is applicable to the pharmacy.

This

As the final check

before the patient receives the drug product, the pharmacist
should be alert to the problems in labeling and packaging of
the drug product, coating and size of tablets, contamination,
etc.
The outcome of the controversy concerning the legality
of the FDA-approved pacl;;age insert
on both physicians and pharmacists.

~till

have a marked effect

Although the FDA claims

that the package insert is merely an authoritative guide, it
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has been used in malpractice cases as a definitive statement
of the approved use of a drug.

:B"'urther developments in this

area will serve to better define the insert's use.

Addi-

tionally, in the area of labeling, FDA is in the process
of developing· patient paclcage inserts.

The agency will be

soliciting comments from health professionals and consumers
about what types of information and £'or what drugs these
should be included.

This should give pharmacists an excellent

opportunity for interaction

~~i th

the agency.

In response to increased consumer knowledge of drugs,
the pharma.cist must be prepat-ed to ans\'ler patient questions
about the actions of tl:J.e agency, as he is
public and the FDA.

in-bet~leen

Although it is the FDA's

the

~responsibility

to assure that drugs are sa:fe, effective, and not misbranded,
the agency's decisions are frequently misinterpreted.

Often··

times, the cry of th(;l public has been that l"DA deprives them
of dr·ugs capriciously, although the drugs have not been proven
·to be safe and effective.

Examples of these.outcries will

become more evident as the OTC drug ingredient revimv panels
publish more of their reports, · >vhich in turn will lead to
regulations removing many mwafe or ineffective, but widely
used, drug products form the market.

1'his furor has already

been exemplified over FDA's proposed regulations classifying
lac-ge doses of vitamins as drugs.

The public needs the

protection of the agency, but as opinions are frequently
diametrically opposed on any given question, the agency acts
in opposition to someone all the time.

Only with a
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compx·ehensive understanding of the procedures involved in
FDA's regulatory activities can the pharmacist deal effectively

~Jith

his patients on these matters.

The need for a comprehensive understanding of the drug
regulatory procedures of the FDA can be met by providing a
course as a component of the curriculum in pharmacy school.
In such a course, the F.D.&C. Act and the regulations which
give the agency its power to regulate drugs, and the programs
developed and utilized

by

them should be emphasized.

the Bureau of Drugs to implement
The outline for such a course on

FDA drug regulatory procedures is included in Chapter

v.

.l.s expected that the descriptive material included in
Chapte:!' III might serve as part of the basic text for such
a cdu:r:·se«

It

CHAPTER V
RECQII1ME~IDATIONS

From the preceding discussion, a prototype of a course
of study in FDA Drug Regulatory Procedures has been developed.

In the following pages are included the objectives (Figuro lJ.),
the catalog description and related information (Figure 5),

and the outline for the didactic
study.

portion of the course of

The Residency Syllabus for the practical ex-perience

component which may form an optional component of the course
of study

follo~JS.
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-Lr.D__E_P_,A.~-TM F. NT/DIVISION

CODI::

1-C-0_\J_R_S_E_·_N_O_._ _ _ _ _ _ _ _ _

.

COURSE TITLE

--

FDA DRUG REGUJ~\TORY PROCEDURES~--------~.-----~--~~~~~~
N.O. LECTURES/WEE!<

UNIT VALUE

I.ABORATORY HOURS/WEEK

I

. 2 lectures/week
student Shall demonstrate a_ knowledge
of the regulatory control of drugs >vith respect to their safety,
effieacy, and quality as governed by the J?DA; how regulations m'e
promulgated and enforced to insure that only drugs which are·safe,
efficacious, of good quality, and not misbranded are marketed.
Perhaps most importantly, he should understand the responsibilities of the phar-macist in supporting· those actions by >vhich the
consumer is protected from substandm'd or hazardous remedies.

2 units

-----------~~~
COURSE OBJECTIVE AND GOAL: The

·~---------------·----~--

.

--~----~

1.

The student shall be able to:
Trace the history of the FDA, identifying the legislation
that gives t;he agency its povter to xegulate drugs.

2.

Outline the organization and define the filllCtions of the J:<'Il.A,
'l'lith emphasis on the Bureau of Drugs.

3.

Describe the procedures involved in the premarket clearance
of ne~1 d.c'ugs, to include the material :r:eg_u:i.red in IND ond ND.A
submissions.

6.

Explain the role of the FDA and the pharmacist in drug product
xecalJ.s and. the procedures involved.

?.

Specify the penalties defined in the Federal Food, Drug and
Cosmetic Act for means of its enf.orcement.

8.

Describe the various concepts of the re€,·ulation of d.rugs
utilized b;7 the Bureau of Drugs in their programs vii th empha··
sis o:u Drug Efficacy Study Implementation, Over-the-Counter
.Drug Evaluation, Biopharmaceutica, Drug Application E-valuation!
Generic Drug l-lonograph.s, A."'ltibiohc .a:o.d Insulin Certification,
a:o.d r1ethadone i'loni toring.

9.

Characterize the Drug Product Defect Reporting System, to
j_m:lude the roles of the phar-macist, the USP, and the FDA.

ELEMENTS/SUB OBJECTIVES:

Figure 4-.

Objectives for the course in li'DA Drug Regulatory
Procedures.

I
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C011ffiE DESCRIPTION

FDA DRUG REGTJLATORY PROCEDURES (2)

An introduction to the regulation of drugs by the Food and
·Drug Administration "I-Ii th emphasis on the responsibilities of
the pharmacist in supporting these regulatory activities.
REQUIRED TEXTS:

Federal_]?ood"- Drug an,d Cosmetic Act as amended January
~U:B. Governmen·t; Printing Office, No. 1712-0126.
Qlaimed Exemption for an Inve~tigqti~nal-New P-~~. Form
17/T;J'Jei)artment of Health, Education, and \-Jelfare,
Public Health Service, Food and Drug Administration.
;N~\LJ1i:>ue;,..AJJplicati..2]1.,

Form 356H, Department of Health;
Education, and \·/eli'are, Public Health Service, Food and
Drug Administration.

A Bti.?f' Legislative. Histo:I;';'L_Qf t_h~.P.ryg,_f)..lld Cosmetic
Corumi ttee Print Ho. 1L~, Committee on Interstate and
l!'oreign Commerce, Ja'1UaJ.'Y J. 974.

jfr.f,

RECONHENDED. ANCII,I.AllY TEXTS MID REFEiillNCES:

· .Q.§..9£.§_..£-Yl~l ... r1§~.'ial£,._~~Foo~"92fLJ2~r.l~Ji~l'L'- .Cristop_her,
Thomas ruKi. Goodrich, \'iilliam, Con!lllerce Clearing House,
Chicago, 1973.

Co,mpilll."ti.91l...S2.:f.~<l.te~,li,S. He11J...tl} Law.§., Joint Committee
:Print for House Gommittee on Interstate and Foreign Commerce
and the Senate Committee on Labor and Public \'lelfare, March
1973, u.s. Governmen·i; Printing Office.

P;!.J,}:£!_, Pr:ofi ts_,_,};Oj. .:~ ti.£.~, l'Iilton Silverman and Philip
t'ee, Universi·~-y of California Press, Berkeley, California,

1974.

STUDENT RATING SYSTEM:

The grades \~ill be based upon the performance of the
student on three hourly exams which will be of equivalent
value.
Figure

5.

Catalog description and related information for
the course in FDA Drug Regulatory Procedures.
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FDA DRUG REGULATORY PROCEDURES
I.

II$

INTRODUCTION (2 hours)

A.

History o.;f drug regulation and the FDA
1. Pure Foods and Drugs Act
2. Shirley Amendment
3- Sulfanilamide Elixir Tragedy
4. Federal Food, Drug and Cosmetic Act
5· Insulin and Antibiotic Certification
Amendments
Humphrey-Durham
Amendment
6.
Thalidamide
'fragedy
?.
B. Kefauver-Harris Drug Amendments
9. Drug Listing Act

B.

Organization of the FDA and Description of
the Ji'unctions of each of the areas
1. Bt~eau of Foods
2. Bureau of Drugs
3. Bureau of Veterinary Medicine ·
4. Bureau of Radiological Health
5. Bureau of Biologics
6. Bureau of l<ledical Dev-;i.ces and
Diagnostic Products
7. National Center for Toxicological
Research
B. Executive Directo:r of Regi.onal
Operations

REGULATORY RESPONSIBILITIES OF TRE FDA (2 hours)

A.

Introduction to the Federal Food, Drug and
Cosmetic Act
1. Definitions
2. Prohibited Acts and Penalties
3. Food
4. Drugs and Devices
5· Cosmetics
6. General Administrative Provisions
7. Imports and Exports
B. Niscellaneous

B.

Title 21 Code of Federal Regulations
1. Federal Register: Notices, Proposed
Rules, Rules and Regulations
2. Parts l-9, 133, 138, 141-151, 310,
312, 314, 328-330, 369·! IJ-29·-460,
600-end

C.

Regulatory Philosophy
1. Methods for regulation
2. Premarketing vs. Postmarlceting
3. Cost Effectiveness
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(2)

D.

III.

Responsibilities of the Pharmacist
1. USP/N1!' Dispensing requirements
2. Dating
;. Repackaging
4. IND Drugs
5 •. Adulteration and Misbranding

BUREAU OF DRUGS (2 hours)

A.

Specific sections of the FDC Act enforced1. 201 (g) and 20l(p)
2. 301-307
;. 501-510
4. 701, 703, 704, 705, 706, 707

5.

IV.

801

B.

Organization
1. Biometrics and Epidemiology
2. Compliance
;. ·Drug l\1onographs
I~.
Information Systems
5. New Drug Eve-1uation
6. Pharmaceutical Research ru.1d Testing

D.

Programs
1. Drug Application Evaluation
2. Drug Quality Asm1:rance
3. Over-the-Counter Drug b""'valuation
4. Olin:i.cal Invef;ti.gat:ion :Svaluation
5. Biopharmaceutics
6. Drug Efficacy Study Implementation
7. Drug Experience aJ1d 'L'rends Analysis
8. Methadone· i'loni tor·ing
9. Drug Listing
10. Poison Control
11. Prescription Drug Advertising

PREMARKET CLEARANCE OF

NE~I

DRUGS (4 hours)

A.

Claimed Ex:emption for an Investigational New
Drug (IND) ·
1. Requirements
2. \>/ell-controlled studies
3. Phases I, II. and III
4. Pharmacist's Involvement

B.

New Drug Application (NTIA)
1. Requirements
2. "Substantial Evidence"
3. Revie\~ Process

(~)

c.

Labeling
1.
2.

3.

4.
V,

VI.
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Requirements
Importance: J_,egali ty
Class I,abeling ·
Patient Package Inserts

"CLOSING THE GAP" (2 hours)

A.

NAS/NRC Review and DESI
1. Procedures
2. Enforcement

B.

Over-the-Counter Drug Evaluation
1. Procedures
2. Mon.ographs

c.

Generic Drug Monographs
1. Purpose
2. F2•ocedure for development
·
3. Contents

DRUG PRODUCT QUALITY ASSURANCE (5 hours)

A.

Current Good Nanufactro:'ing Practices
1. Description
2. Pm:pose
3. Use by the Pharmacist

B.

Inspections
1. Types
2. Requirements ·
· · 3. Sampling

c.

Drug Product Analysis
1. Antibiotic and Insulin Certification
2. National Drug Surveys

D.

Drug Product Defect Reporting System
1. Purpose
2. Ilesults
3. Procedm•e

E.

Biopharmaceutics
1. Projects
2. MAC Regulations

F.

Corrective Actions
1. Recalls
2. Regulatory Letter
3. Seizure
4. Injunction
5. Prosecution

(4)

VII.

VIII.
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PROGRAMS SUPPORTIVE OF THE TOTAL EFFORT (2 hours)
A.

Methadone Honi'l;oring
1. ProcedurGS
2. Effect on the Pharmacist

B.

Poison Control
1. Procedures
2. Involvement of the Pharmacist

C.

Prescription Drug Advertising
1. Advertising vs. Labeling
2. Pharmacist 1 s Involvement

D.

Drug Listing
1. Types of information required
2. Importance

E.

Drug Experience and Trends A.'la.1ysis
1. In:formation for Form 1639
2. Pharmacist's involvement

F.

Drug Abuse
1. Description of Program
2. FDA and DEA

llliSCELLA.lffiOUS (2 hours)
A •. I'reedom of Information Regulations

1.
2.

T;y-pes o.f information available
Procedures for requests

B.

Bureau of Biologics
1. Contrast the FDC Act and regulation
of' drugs with the PHS Act and. ragu··
lation of biologics
2. Descript;ion of Programs

C.

Bureau of r-1edical Devices and Diag,Llostic
Products
1. Authority
2. Prod.UctB regulated
:;. Description of P:r:ogra.ms

D.

USP/NF
1.
2.

Role as "official" compendia
Involvement with the FDA
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RESIDENCY SYLLABUS

This syllabus represents guidelines for the continuing
residency program at the Food and Drug Administration designed
to train graduate pharmacists for specialization in governmental drug regulatory procedures.

The program utilizes the.

work-study technique, as it applies to the development of a
graduate study in preparation of a thesis for the Master of
Science

Degree~

Specifically, the goals of the program are:
1.

to provide background research material as part
of a graduate degree program.
·

2.

to create' a resour·::e pool of professionals trained
in governmental drug ret,"Ulatory procedures.

It;

is anticipated that the program shall be of approxi-

materly 6··8 months duration, during •rhich time the. participat-·
ing students will hold an appointment with the Food and Drug
Administration.

While they shall be salaried by that agency,

it is the responsibility of the student to furnish transpor-,.
tation and living arrangements.
The program is to consist of th:C'ee areas:. rotational
experiences, work assignments and graduate research.

The

rotational experiences are described in the

pages

follo~ling

and constitute approximately 8 weeks of .the 6-8 month period
of residency.

The remainder of the time is to be spent in

the area of emphasis agreed upon for the resident's time at
the agency.

This area is determined through discussions among
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agency officials, the student, and the faculty advisory,
and could include one of the divisions of Pharmaceu·t;ical
Research and Testing, Biometrics and Epidemiology, Compliance,
New Drug Evaluation, or Drug Monographs.

The extended time

period spent in the area of emphasis will allow the student
to take an active role in the execution of the area's regulatory responsibilities, and. contribute to the agency's enforcement mission.· The work assignments for the resident should
be made by his supervisor in the area of emphasis.
of emphasis

~;ill

The area

also provide the general background and

possibly the specific title of the resident's FDA-related

St,.ldents assigned to this program shall be screened by
the

Progre>~11

Director of' the. School of Pharmacy, University

of the Pacific·, .and shall be subject to review by the Bureau
of Drugs.

The assigned students are expeci;ed to comply with

the rules and regulations of the Bureau and will respect the
confidentiality of matters being handled by that agency.
Because this program >-rill be implemented most effectively
through the work-study technique, working assignments should
be made by ar·ea supervisors to supply study examples \1hich
furnish models of genuine situations and problems.

The

Study Assignments outlined in this syllabus are designed to
direct the student's course of study.

However, flexibility

should be maintained to accommodate changing needs and
emphasis.

lrny changes which are made should be cleared

through the Program Coordinator and Liaison Officer of the
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Bl.ll'eau, as well as the Program Director.

Assignments vlill

be evaluated by appropriate representatives of the Bureau
and the University, but the responsibility for academic
compliance will be assigned by the Program Director.
The position of Program Coordinator should be assumed
by one of the key officers within the Bureau of Drugs.

He

shall assist in making admin:i.strative provisions for the
induction of the student and his assignment to·the various
offices of the Bureau.

A Liaison Officer who should be

located in the resident's area of emphasis is appointed to
provide scheduling of rotations throughout the Bureau and
to assist in directing the student to specific activities
within his term of residence.

Further, the Program Coordinator

or Liaison Officer may wish to designate staff members to
serve as preceptors during the-periods which the student is
studying within the various subdivisions.

Designation of

individuals to fill these two principal positions

~;i thin

the

progra.:n shall emanate from within the Bureau of Drugs.
The student is expected to submit periodic reports of
his study at the completion of the work in each of the units
delineated within this syllabus.

The Study Assignments s)lould

serve as guidelines for these reports, and are directed towards
developing tlte student's understanding of the relation of the
functions and responsibilities of eac)l of the rotational areas
to the enforcement by FDA of the Food, Drug, and Cosmetic .Act
and its regulations.

The progress reports should be a brief

summary of the rotational experiences.

Additionally, the

1'77
progress of the research the student is doing within the
agency should be included.

These should be submitted to

the faculty advisor within a month after the rotation, as
a measurement of the performance of the student and the
development of the research.
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ORGANIZATION AND
A.

F~roTIONS

OF TEE FDA AND THE BUREAU OF DRUGS

Ob;je.«Jti.~

1.

Outline the organization of the total Food and
Drug Administration.

2.

Identify the functions of the organization and
its subdivisions with special emphasis on the
Bureau of Drugs.

3. Trace the history behind the development of the

Federal Food, Drug and Cosmetic Act and di.scuss
.
the sections pertinent to the regulation of drugs.

4.

B.

Explain the methods of implementation of drug
regulation as it relates to the safeguarding of
public health.

~~o±_og;y

1.

Study the Federal Food, Drug, and Cosmetic Act.
Re-view the 'ri tle 21 Code of Federal Regulations
· sect:io:r;s that pertain to the r(;ogulation of drugs.
ReYiew the structural chart of the organfzation.

4.

Survey the FDA Justifications of Appropriations
Estimates for the Committee on Appropriations
(budget) in which the FDA regula·t;ox·y programs
are defined.

1.

What is the charge given to the
legislation which created it?

2.

Describe the history behind this legislation.

~~A

by the

3. Describe the functions of each of·the components
which contribute to.the accomplishment of the
mission of the Agency.

L~.

Delineate· the sections of the Federal ]'ood, Drug,
and Cosmetic Act which perte.:i.n to the regulation
of drugs.

5. Depict the structure of the agency and identify
the key personnel reponsible for the operation
of each of the subdivisions.
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PHARMACEUTICAL RESEARCH AND
A.

~ISTING

(minimum 1 week)

flb,;jectives
1.

Outline the organization, functions, and
responsibilities of the subdivisions of
Pharmaceutical Research and Testing.

2.

Describe the procedures followed for the
certification of antibiotics, insulin, and
digitalis derivatives.

3. Discuss the interaction of Pharmaceutical

Research and Testing with New Drug.Evaluation,
Compliance, and. the Executive Director for
Regional Operations.

c.

b.-.

Characterize with the types of resea:rch done
by the laboratories.

1.

Visit the divisions of Pharmaceutical ReseaL'ch
and Testing.

2.

Interviev1 key officials within the divisionro:
and asBist them in their lab work.

3.

Follow the processing of a drug product through
the procedures involved in the testing f'or
certification.

§:!illQ.;y~if::;r-;.lll~

1.

Delineate the organization of Pharmaceutical
liesearch and Testing to include the branches
of the divisions.

2.

Describe the functions of Pharmaceutical Research
and Testing and their relation to those of New
TJru.g :tvaluat;ion, Compliance, and :E.xecuti ve
Director for Field Operations in FDA's mission
to assure quality drug products.

:?. Outline the procedures followed in the receipt

of drugs, their testing and subsequent reporting
of results in ·t;he certification processes.
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BIOMETRICS AND EPIDEl'liOLOGY (minimum 1 week)

A. .Qbjectives
1.

IJ<:plain the organiz.ation of Biometrics and
Epidemiology and the functions of its divisions.

2.

Specify the importance of the statistical evaluation of the protocols imd data in INTI's, NDA's,
and laboratory work; and the interrelationship of
Biometrics with New Drug Evaluation and
Pharmaceutical Research and Testing.

3. Describe the contents of the adverse drug

reaction reporting form FD-1639. Explain the
categorization, computerization, and evaluation
of the contents by the Division for Drug
Experience.

4.

B•

· C.

Discuss the function of the Division of Poison
Control in compiling the poison incidence reports
and their work with the poison control throughout
the nation.

~\QQ.Ql.Q.ZZ

1.

notation within the Divisions of Biometrics,
Pqison Control, and Drug Expe:r.ience to include
interviews with the key personnel in the Ili visiom1.

2.

Review a statistics~ analysis of
laboratory work.

3.

Accompany a statistician on assignment to the
laboratories "and participate in discussions of
the preparation of study'protocols that will
generate data which can be analyzed statistically.

4.

Do a search for adverse drug reactions for an
assign.ed. drug or drug category.

ptud;y;

nm, NDA, or

Asst,gn!!l~~

1.

Prepac"ate written reports relating to some aspect
of .adverse drug reaction reporting OI> poison
control.

2.

Describe the functions and responsibilities of
the divisions of Biometrics and Epidemiology with
emphasis on their relationship to the other areas
or the Bureau of Drugs.
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COMPI,IANCE (minimum 2 weeks)
A.

9_b;jecti ves
1.

Identify the organization, functions, and
responsibilities of the divisions of Compliance.

2.

Specify the prohibited acts defined in the Food,
Drug, and Cosmetic Act and the actions •~hich can
be taken by the agency to enforce them.

3• Describe the relationship of Compliance with the

other areas of the Bureau of Druss, the Executive
Director for Regional Operations,· and General
Counsel.

4.

B.

c.

Discuss the Complia.TJce programs designed to
assure drug product quality with emphasis on
good manufacturing practices, drug product defect
reporting system, drug efficacy study implementation, and drug quality assurance.

k,Je,t]lpd.olog:r
1.

Reviei.,r case files of past and pending actions.

2.

Interview key persopnel in the various divisions.

:?.

Assist in the revievl of a case sent from the field.
recommending legal action.

4.

Read the sections of the :b'ederal Food, Drug, and
Cosmetic Act pertaining to the regulation of drugs.

§tl!,gy__*ssip.;nment.:.<1.

1.

2.

Identify the principle subdivisions of Compliance
and describe their roles in programs designed to
assur.e drug product quality.
Describe the Drug Efficacy Study Implementation
and compare it with the program for the
enf'orceDJent of the drug monographs published from
the over-the-counter drug review panel reports.

progr8lll

;;.

Delineate those sections of the Federal Food, Drug,
ru1d Cosmetic Act that at'e frequently cited when
legal action is taken.

4.

Define seizure, injunction, and prosecution in
terms of their use in drug regulation.
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EXECUTIVE DIRECTOR FOR REGIONAL 01-"'ERATIONS (minimum 1 week)
A.

Objective..§.
1.

Outline the organization of the ~xecutive
Director for Regional Operations (EDRO) and
compare the structure of the home office with
the field.

2.

Define EDRO's responsibilities and understand
its relationship with the Bureaus.

3.

Identify the types of drug inspections and
understand the procedures involved in their
implementation.
··
·

4.

Explain the relation of EDRO <ri th the state
drug regulatory agencies.·

5. Describe EDRO's role in the regulation of imports.

C.

1.

Visit one of the field offices and i.nterv:i.ew.its
key personnel.

2.

Accompany an experienced drug investigator on a
Gl1P inspection of a drug firm.

3.

Intervie>1 key officials in the main office.

Stuq;z, A?..:-"8-.z.nmen t §.
1.

Ilescribe the relationship of EDRO with the FDA
Bureaus, with emphasis on t;he Bureau of Drugs.

2,,

Delineate the functions and responsibilities of
each of the divisions in EDRO.
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NEW DRUG EVALUATION (minimum 2 l-meka)
A.

Qbjectives
l.

Outline the organization and functions of the
divisions in Ne~' Drug Evaluation.

2.

Describe the process by which new drugs are
approved for marketing to include the I'equirements listed in Form 1571 (IND) ru1d Form 356H
(NDA).

3. Identify the reviewers of the IND's, NDA's, and
supplements and learn their responsibilities.

4.
B.

Discuss the methods used by the Division of Drug
Advertising to execute its responsibilities.

~thodolo©:

1. · \vork assignment within New Drug Evaluation.

2.

Assist in the review of IND's ru1d NDA's as
assigned by the staff.

3. ·Attend advisory
pru1el meetings
11
Drugs nrounds

4.

''llld

Buree.u

()f. ·

for the di visio.r:..s assig11e(Ly

Intervi.ei'i' l'l'i th the personnel in the d.i visionrs,
and include all those involved in the review
process.

5. Read portions of Title

21 Code of Federal
· ReE,''Ulations pertaining to the regulation of
new. drugs, and Section 505 of the FDC Act.

1.

llelineate the groups of drugs assigned to each
of the divisions of New Drug Evaluation.

2.

Describe the essentials of a well designed
protocol.

3.

Describe the effect of Ne\·1 Drug :E-valuation on
the steps and procedures which must be followed
in the taking a new compound from the "lab bench"
to its final approval for use as a new drug.

4·.

Specify the role of the official compendia in
the I~ID/NDA procedures.
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5.

Describe the regulatory actions that fall
wj.thin the aegis of New Drug Evaluation.

6.

Define "new drug", and determine who is
responsible for making the decision ~1hether
a substance is a new drug.
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DRUG
A.

B.

MONOt~RAPHS

(minimum 1 week)

.Qp__.iecti ve.§_
1.

Outline the organization and functions of
Drug Monographs and its relation to the
enforcement of the FDC Act.

2.

Discuss the Over-the-Counter Drug Evaluation
program and its implementation.

3.

Contrast the procedure required for approval
of an Abbreviated New Drug Application with
that of a New Drug Application.

4.

Specify the bioavailability requirements for
NDA's and ANJJA's and the involvement of
Biopharmaceutics in theirreview.

Metho§.Q;to,g;y:
1.

Attend various over-the-colmter drug revie1v
panel meetings~

2.

Il\terview key officials ~lithin each of the
Drug Monograph divisions.

3.

Study a bioavailabilit-.t review of either an
ANJJA or NDA.

I~.

Head the requirements in 21CFR:314.1(f.) for the
submission of an ANDA.

1.

Revievl the objectives and current status of' the
b'i.oavaiJ.abili ty program.

2.

Describe the process by which over-the-counter
drugs.are reviewed for safety and efficacy.
Contrast this process \vi th the one used in the
NAS/NRC review.

3. Define the differences between the ANDA and NDA •.
In addition,.describe the effect of the proposed
"old drug monographs" on the regulation of drugs.

CHAPTER VI

Sill'JMARY

There exists an apparent lack of understanding of the
functions and responsibilities of the Food and Drug
Administration (FDA), the drug regulatory, by the pharmacist, the drug dispenser.

In that the common goal of both

is to assure that safe, effective, and good quality medications reach the patient, an interface between the FDA and
the pharmacy profession should be created.

A study established

to develop a course in FDA drug regulatory proc:edu:ves for
implementation in pharmacy school was complet.ed.

Specifically,

th$ objnctiv<> of the study vms to expand educational progr'itms
for pha1:macy students througl'). the development of a c<l.I'ric·(1lar
component in drug regulatory.procedures for pharmacy.

The

intent of this project was to design a formal course or
CO'tl.I'Ses which may be offered for on-campus study and, because
it; is predicted to be a necessity .for comprehensive

understand~

ing of application and implications, to make recommendations
for a period of residency within the agency.
The study was accomplished by a graduate student's
appointment to the FDA as a temporary employee for a period
not to exceed one year in August 1974.

The specific assign-

ment was within the Bureau of Drugs, New Drug Evaluation,
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Division of Surgical-Dental Drug Products.

Under the

guidance of the supervisory chemist in the division, a
working knowledge of the organh;ation, functions, and
regulations of the agency was obtained through participation
in the division's .responsibility for reviewing data submitted
on new drugs to prove their safety and efficacy.

Additionally,

rotations to other areas within the Bureau of Drugs and the
Executive Director for Regional Operations served to provid.e
the studen-t; with a comprehensive understanding of all of the
various facets of drug regulations by the FDA.
Throughout the residency experience at the FDA,.the areas
of cooperation between the phax·macist and the agency

1~ere

0·

emphasized.

The FDA, as the drug regulator, does not have

the capabilities to assure absolute quality of drugs, but
rather works to control the quality bY setting standards and
monito:dng .compliance to these standards.

Therefore, the

pharmacist, as the drug dispenser, ·must recognize his responsibility to ::>upport the agency in its protection of the consumer from substandard or hazardous remedies.
Based upon the knowledge gained and the experience
acqui:L'ed

while >Jerking at the FDA, the author recommends

that t:he pharmacy school curriculum· should include a course
on

l!')JJi.

drug regulatory prpcedures.

The methods utilized by

the FDA to promulgate and enforce the regulations written
m1der the Federal Food, Drug and Cosmetic Act should be provided in such a course with emphasis on the responsibility of
the pharmacist in supporting the actions of the FDA.
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.Specifically, the course should conta:i.n information on the
programs of d1.'Ug production quality assurance, biopharmaeeutics, drug application evaluation, antibiotic and insulin
certification, methadone monitoring, OTC drug evaluation,
and the drug efficacy study implementation handled by the
agency.

For those students wishing to specialize in FDA

drug regulation, the residency program at the agency is
recommen.ded.
The full significance of this study can only be appreciated after several studies at the agency have been achieved.
Addi tion.al data gathered from the experienced of graduate
students engaged in research i11 other areas of drug regulation at.the agency will provide a broad base for evaluation
of the importance of the residency program.

J:!'ee•dback froiD

the stucl.E.HJts errr·olled in the course in FDA drug reg>.1latory
prOC'fdU!.'es vill a::i.d in determini11g the usefulness of such a
course.

ADDEIID Uti!

The course described :i_n this thesis was ·!;aught to 21
upper division plHJrmacy students in the fall of the academic
year 1975-76.

The information presented in the course was

that included in Chapters I and III of this thesis.
exmos

t~ere

Three

administered to the students to measure the

aehievement of the course objectives (Appendices H, I,
The average scores of the class for the exams

#2--89.15'6, and

!1'3-·-8l~.~·~6.
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& J).

#l··-89.1>%,
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Preface

•

This syllabus represents guidelines for study in a
proposed program designed to train graduate pharmacists
for specializ·ation in governmental drug regulatory procedures.

The proposed program utilizes the work-study

technique, as it applies to the development of a graduate
study in preparation of a thesis for the l'iaster of Science
degree.

Tt is designed with the intention of developing a

continuing program that others might follow in pursuing
this area of specialization.
Specifically, the objectives of this program are:
l.

to provide background re;3earch material as par-t;
of a graduate degree program~

2.

to develop an efficient and meaningful program
which may be utilized on a continuing basis for
seriicr or grad:uat;e pharmacy students.

3.

to create a resource pool of professionals trained
j_n governmental drug regulatory procedures.

It :i.s anticipated that the program shall be of four to
3ix months' duration, during which time the participating
students will hold an appointment with the Food and Drug
Administration.

\vhile they shall be salaried by that Agency,

it is the responsibility of the student arJd/or the University
of the Pacific to furnish transportation and living arrangements.
Students assigned to this program shall be screened by the

(2)
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Program Director of the School of Pharmacy, University of
the Pacific, and shall be subject to review by the Bureau
of Drugs.

The assigned students are expected to comply

\'lith the rules and regulations of the Bureau and will respect
the confidentiality of matters being handled by that Agency.
Because this program will be implemented most effectively
through the work-study technique, working assignments should
be made by

~cea

supervisors to supply study examples. which

furnish models of genuine situations and problems.

Assignments

outlined in this syllabus ro.·e desi.gn.ed to direct the student's
course of study.

However, flexibility should be maintained

to accommodate cha.nging needs and emphasis.
are ma.de should

b~)

J..:ny changes which

cleared through the Program Coordinator

and Liaison Officer of the Bureau, as well as the Program
Director.

Assignments will be evaluated by appropriate

representatives of the Bureau and the University, but the
responsibility for academic compliance will be -assumed by
the Program Director.
The position of Program Coordinator should be assumed.
by one of the keyof'ficers within the Bureau of Drugs.

He

shall assist in maldng administra.tive provisions for the
induction of the student and his assignment to the various
offices of the Bureau.

A Liaison Officer is appointed to

provide scheduling of rotations throughout the Bureau and
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to assist in directing the student to specific activities
trithin his term of residence.

Further, the Program

Coordinator or Liaison Officer may "'rish to designate
,.

staff members. to serve as preceptors during the periods
;-rhi.ch the student is studying within the various subdivisions.
Designation of individuals to fill these two principal positions \'li thin the program shall emanate from within the B1.rr·eau
of Drugs.
The student is expected to submit reports of his study

at the completion of the work in each unit, as·· delineated
within this syllabus.

(4)
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UNIT I.
A.

B.

c.

ORGANIZATION AND FUNCTIONS (1 week)

9b.jectives
1.

Learn the organization of the total Food and
Drug Administration.

2.

Identify the functions of the organization ru1d
its subdivisions with special emphasis on the
Bureau of Drugs.

3.

Identify the key persoxmel responsible for the
operation of each of the subdivisions.

NethodQlQ&.

1.

Interviews with administrative officers of the
several principal div-isions within the Agency.

2.

Attend orientation sessions for net:1l;r assigned
personnel.

___
.
Assir.:nments

,...,._......,_, __..

1.

\llhat is the charge given to the F.D.A. by the
legislation which created it?

2.

Prepare an organizational chart of the Food and
Drug Administration, indicating chief officers
of the various subdivisions.

3. Describe the functions of each of the components
which contribute to the accomplishment of the
mission of the Agency.

4.

Review the interrelationships the Assistant
Commissioners for Administration, Planning and
Evaluation, Program Coordination and Public
Mfairs with the Administration and its Bureaus.

(5)
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UNIT II.
A.

B.

BURF~U

OF DRUGS (1 week)

Objecti ve,'i
1.

Acquire a ~10rking knowledge of the functions
and responsibilities of the Bureau of Drugs.

2.

Understand the methods of implementation o:f
drug regulation as it relates to the safeguarding of public health.

,t"~;thpdolog;z

1.

Review Title 21 Code of Federal Regulations,
Part 130-146e.

2.

Interview key personnel responsible for
administration of the Bureau of DFugs.

1.

Delineate the organization of the J3ur<3au indicating the responsibilities of its adminitrative
officers.

2.

Briefly, but concisely, describe the ro.•eas of
responsibilit-y and activities delegated to the
several Offices forming the Bureau of Drugs.

3.

Describe any special proj.ects or programs >vhich
fall \1i thin the Bureau of Drugs and not included
within the responsibility of the Offices.

l)..

Review the various communications issued by the
Bul.'eau, identifying those responsible for their
preparation and distribution.

c.

(6)
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UNIT III. ·OFFICE OF COMPLIANCE (1 week)
A.

Objectiv~

1.

Identify completely the organization,.functions,
m1d responsibilities of the Office of Compliance.

2.

Determine resources available for accomplishment
of the mission of the Office of Compliance.

1.

Study organizational charts representing current
organization of the Office.

2.

Review procedm.'es manusals and regulations tmder
which the Office of Compliartee vlOrks.

:;.

Intervie1r1 key perfJonnel \1i th the Office.

4.

Review case files of past actions.

5. Assist in preparation of the current sta:ff action

f'or completion, summarization and recommendai;ions.

c. Assiggments.
1.

Identify the principal subdivisions and perso1mel
of the Office. and their areas of responsibility.

2.

Describe the major functions and specific activities of the Office in implementing provisions of
compliance.

:;.

Review actions vlhich may be required in cases of
noncompliance, p:roc:edures normally followed, and
pro-visions for enforcement.

4.

Prepare a resume' of a completed action taken by
this office (to be assigned by supervising
officer). See Methodology No. 5.

5.

By ~~hom and on what basis is the decision made
for "legend" or "no11legend" status of drugs? ·

(7)
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UNIT IV.

A.

B.

OF]'IGE OF PHARMACEU'l'ICAL RESEARCH AND TESTING (time TBA)

pbject~§.

1.

Determine functions and specific responsibilities
of the Office of Pharmaceutical Research and
Testing.

2.

Und.erst:and the procedm·es followed by this Office
in the fulfillment of its mission.

fle1hoQ,QlQ&
1.

Visit the Office of Pharmaceutical Research arJd
Testing.

2.

Visit .the National Center for Antibi.otic Analysis.

3 •. Follo~l the processing of a product <m1;Jmitted to

the Office throughout its ter:;ting and certj_fic:ation procedures.

1.

2.

Delineate the organization of the Office of.
Pharmaceutical Research and Testing and its
subdivisions.
Describe the functions of the Office o·f
Research and Testing.

~uarmaceutical

3.

Outline the Procedures followed in approving
products handled by this Office.

(8)
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UNIT V.
A.

B.

OFI!'ICE OF SCIENTIFIC COORDINATION (1-2 weeks)

Objectives
1.

Familiarization with organization of the Office
of Scientific Coordination.

2.

Learn the functions and responsibilities of the

Office of Scientific Coordination and the procedures by which these are accomplished.

Methodolog;z
1.

Work assignmen-t; within the Office of Scientific
Coordination.

2.

Participate in the evaluation of statistical
data submitted to the Division of_Btatistics.

1.

Prepare written reports rolat:i.ng to (a) some
a. s:pect of adverse drug reaction reporting.
and/or
(b) drug manufacturing Emd usage studies •.

2.

Revie~l the objectives and current status of the
bioavailability program.

c.

Prepare statistical evaluation of data suhm:L tted
on an NDA or HID. (Specific assignment to be
made by Director of Division of Statistics.)

4.

Describe the program for the establishment and
implementation of National Drug Code.

(9)
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UNIVT VI.
A.

B.

OFFICE OF SCIENTIFIC EVALUATION (4 months)

Objectl.,~

1.

Gain thorough understanding of the organization,
functions, and procedural sequence followed by
the Office of Scientific Evaluation in the execution of its responsibilities.

2.

Acquire working knowledge of FDA's responsibility
for drugs, beginning with their early development
and continuing through their clinical trials and
marketing.

l"letho.dology
1.

\~ork assignment with the Office of Scien'l;ific
Evaluation.

2. · Utilize

•~orlcin:;
1~arning tools,

a;.1d NDA 1 s as

transactions 11Jithin Office as
i.e. assist in

assign<>d by

revie~J'

of IND'-s

s'~af'f.

3. Prepare reports as required in completing reviews
abmre.

C.

}>s §ig)lmen:!i.§.

1.

Delineate the groups of drugs assigned to each
of the divisions of the Office.

2.

Describe actions and studies falling within the
aegis of this Office •

. 3. Describe, in detail, the essential components of
a well designed protocol.

4.

Describe, in detail, the steps and procedures
which must be followed in taking a new compound
from the "laboratory bench" to its final approval
for use as a new drug. What aspects of this continuum fall within the scope of the Office of
Scientific Evaluation.

(10)
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5. What provisions are made·for continuing
evaluation of drugs on the market?

6.

Who is responsible for making the decision
whether a substance is a new drug under
definition by the Food and Drug Administration?
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STATEMENT OF DUTIES AND RESPONSIBILITIES
OF THE PHARMACY GRADUATE STUDENT
,IID'R9DUC'riON

Incumbent serves as Assistant to the Assistant Director for
Chemical Review providing him with the scientific and technical expertise in the pharmacy area necessary to accomplish
the program's mission.
DUTIES P.JID RESPONSIBILITIES
Perform special studies relating to manufacturing techniques,
drug distribution and utilization in r·etail and hospital
pharru.ac:Les.

Assigned projects are s.elected to represent ··

overaJ.l functions of OSE in reviewing

nm' s and

NDA' s.

After

assi.gnm<!lnt of broad project, prepares work plans, time
schedules, and performs the routine steps of eve.luating the
safety and efficacy information as to use of the drug product
in humans. · Following completion of this evaluation, prepare
a c.ri tique of .the process and evaluates the degree to
education a11d experience apply to the fw1ction.

~:hich

Prepares

suggestions for curriculum modification based on practical
expe:c·ience.

Prepares suggestions and recommendations to the

Bureau on meeting, selecting, training and utilization of
undergraduates and recent graduates of Schools of Pharmacy.
Attends professional and administrative meetings to develop
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kno\1ledge of the interdisciplinary approach of the Bureau
of drug regulations.

Develops project presentations .for ·

these meetings as assigned.

__

_...,
SUPtJRVISION

P~CEIVED

The incumbent works under the direct

supe!~ision

Assistant Director for Chemical Review.

of the

Supervisor assists

in identification of the problems and is available to assist
with unusual developments.

Work is evaluated on the basis

of demonstrated ability to develop professional competence
in the field of pharmacy.
\ti th

Periodical r(;ports are discussed

the incumbentand with the incumbent's college advisor.

uc:.r-'•1"11 M!:.N 1

•..rr-

Mt'-AI... Itt; l:.UUCATIOtl, P.NO'WELFAR:E

PU£1llC HEALTH SERVICFFOOf-1 AND DRUG AOMINISTRATION

APPENDIX D

p-orm Apprt:.ved
OJ,fB Nc, .57-R0030

NOTICE OF
CLAIMED INVESTIGATim'IAL EXEMPTION

/

FOR A NEW DRUG

'·

Name of Sponsor__
Address
Date

Name of Investlg.ati.onal Drug
Commissioner
Food and Drug Administration
Bureau of Drugs ( BD-26)
5600 Fishers Lane
Rockville, Maryland 20852

Dear Sir:

The sponsor,-::-.,---:--:---:-----,---,------:-.,---:---:· - - - - - - - - - - - - , submits

this notice of claimed. investigational exemption for a new drUg under the proviswns of section 505(1) of the
Federal Food, Drug, and Cosmetic Act and !130.3 of Title 21 of the Code of Federal Regulations.
Attached heretc, in triplicate, are:
1. The best available descriptive aame of the drug,
including to the extem known the chemical name and
structure of any new-drug substance~ and a statement of
how it is to be administered. (If the drug has only a c-ode
name, enough information sho!Jld b~. supplied to identify
the <kug.)
2. Complete ll$t of components ·of the drug, including
any re:e..sona~le altern:..'.tes for ir.activ-.e components.
3. Complete .stv.teulent of quanti.t;:ltive composition of
d!'ug, ill.clud.ir.g rea!"~cnab.le variation~; that may be exrected
during tt.~ .luv~.cttigatiomtl :Hage.
4. Description oi source and pxe:fJaration oft any new\drug sub~~tan.ce~; u;.;':':d as c.l':lmp{m~i1ts. including the name
and acldn:·ss of ·.!.'1.::S. s~~r:Plier or pro:::"essor,· other than the
spons.or;,··of Cl\ch h~;w;.Jrug·subStance:
5. A .;natem~nt of the mcrhods, facilities, and controls
used for the manufaCrm:ing, processing," a:nd packing of the
new drug to establish a.nd maintain appropriate staridards
of identity, strength, quality, and purity as needed for
safety and to give significance to -clinical investigations
made with the drug.
6. A" statement covering all information available to
the spo.nsor derived from J?teclini.cal investigations and
·any clinical studies and experience with the drug as .follows:
a •.Adequate information about the preclinical investigations, i;tcluding stHd.ies made on laboratory animals, on
the basis of which the ;l".ponsor has c&nduded that. it is
1eascn~bly :Hlft::. to initiate clinlca1. investigations .with
the drug: Such information shQ.uld indude identification
of the person who conduc~ed each investigation; iden[ificatiod nod qu'l.li.fic~nion.s of the individm1.l" who_evnluated
--the -resufts-an-d-CoUC.:lUd"t;Ji1_a_t_1t__ is ~e-.ason:...b-iy sate to
initiate clinic:ll investigati,Jns with the drug and a statement of whue the investigations were conducted and where
the records arc available for inspection; and enough details about the investigations to permit scientific review.
The preclinica t investigations shall ·not be considered
adc::quat•.! to justify clinical testing unless they give proper
attention to the conditions of the proposed clinical testing.
When this information, the outline of the plan of
clinical pharma"colo~y .. or any progress report on the clinical pha_rmacology, imli<.,Hes a need for full review of the
FD FORM 1571 (5/71)

preclinical data before a clinical trial is undertak('n, the
Department \"\!ill notify the sponsor to submit the complete
prt~cl.bi.cai data and to withhold clinical t!ials until the
re·rie-·;<.' is completed and the ·sponsor notified. The Food
s.nd D~ug Administ;~tion will be prepared to conf~.r with
the sponsor concerning this aC"tion.
b. H the d~·ug has been marketed \-vmmt:rcially or inve~Higared (.;-.. g. oucside
the Unit<;:d States}. complete
info~m~tion ~'bnut such distribution ~r inve~:i,gution shall
be submitted.: along with a com.r,ine bi.bli.o.graphy of a·ny
publications about the drug.
c. If the dn;..g'· !:;; a ccmbin<ltion of pceJ.•ioli!':!~' inVestig<!ted or market(:;d ·drugs, an 3.dequ;.,.tt: summary of pre-·
existinG" infgrrnu_1;1on from pre_clinic:al. and. ·ci:inic:aLin.vesti.~
gation-s and· experience with its components, inc.luding
all reports available to the spOnsor suggesting side-effects, contra"indications, and ineffectiveness in uo.e Of
such components: Such summary should include an adequa~e bibliography of public.ations abo\a the components
~.nd. <may incorporate by refetence any informati<Hl concernin,g such c-omponents previously submitcc-d by the StJOnsor
to the Food and "Drug'"Administration: IOclude a :;t-,~·ti--fneO.t
·of the exPected pharmacological effecr.s of the .:ombi.o.a~
don.
7. A total of three copies of all informational material,
including label and labeling, which is to be supplied to
each investigator; This shall in~lude :~.o accurate description of the prior investigations and experience and their
results pertinent to the safety ·and possible usefulness of
the drug-under the conditions of r.he investigation. It shall
not represent chat the safety or usefulness of the drug has
been established for the ,purposes to be· investigated •. lt
shall describe all relevant hazards, contrn.indications,
side·effects, and precautions suggested by prior iJwestigations -itnd experience with the drug undCr investigUriOn anCf
related drugs for th,e information of clinical investigators.

8. the scientific trainin.g "and' experi~.,'ce considered
appropriate by the sponsor to qualifY the investigators as
suitable e.xperts to investigate the safety of the drug,"bearing in mind what is known about t~e pharmacological
action of tht~ drug and [he phase of the investigational
program thnt is to be undertaken.
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9. The names and a sUmm.ary of the tr<'Wlf•g and

elC~

pccience of each investigator and of the indivi(iu~d charged
wJth monitoring the progwss of the investigation and evaluating the evidence o( safety and effectiveness of the drug·
r<s it is received from the investigators, together with a
statement that the spon_sor has obtained froffl each investigatr.H a completed and signed form, as provided in sub~
paragra.;h {12) or (13) of this paragraph, and that the inves~
··dgatocts··qualificd· by scientific training and· experience
as ·an approrrir.te expert to undenakc the phase o{ the investigation outlined in section 1.0 of the "Notice of Claimed
Investigational Exemption! for a New Drug."l (In crucial
situations, phase 3 investigators may be added and this
form Supplemented by rapid cominunication -methods, and
the signed form FD 1573 shall be abtained·p.rompo:ly them~
after,) ..
10. An outline of any phase or phases of the planned
investigations and a description of the institutional review
committee, as follows~
a. Clinical ph::amacology. This is ordin11rily divided
inLo two F'hases: Phase 1 starts when the new drug is first
introduced into man--only animal and in vitro data are
available--with the purpose of determining human toxicity,
·metabolism, absorption, elimioatie>n, a-nd other pharmncologicn.! action, preferred route of administration, and safe
dosage tange; phase 2 covers the initial trials on a limited
number of patients for specific disease control or prophyiaxis purposes. A general outline of these phases
shall be submi.tt-ed, identifying the investig-ator or investigators, th~~ hospitl:lb: or research ft~c.ilitie$ whe.re the
clinicnl pharmacotogy will be undertaken, any expert com~
mittces or panels to be utilized; the maximum number· of
subjects to be involved, and the estimated duration of thes.~
early phases o£ i:wc~ti{?.Q.tion.' Mod~fic-ati-on of th~ exp-eri·
menr.al desigr, em the bes1s cf exper!ecce ga~ned O-'eed be
reporterJ only in the progress reports on thes-e early pbases 1
or in the <1evdopmer1t 0f th.e plan fo:r ~he clinical trial;
phase 3. The: first t"<;\'0 phases m~~·· overl11p and, when indio::ated, may ceqeire a!:!ditl.onal· ani!:!"laJ d;a:;a before· these
phases can he ct~mplNc1. O!: phase ':} can be und~rt:aken.
Sttch a~1i.m;:-.l tests ~hall be desi.~n.ed to t-ake into account
the expecte::d duration of A.dmin.i..stration ohhe drug to human
beings, the age grcmps and. physical statu·s, as for example,
infants, .rregnant women, premenopausal women, of those
hurnan beings to whom the drug may _beadministe.ced, unle~s
this has alceariy been doric in the origin·al animal studie.s.
b. Cltnical trial. Tbis ph:-~se 3 provide>S"·:the assessment
of the drug's sa!~~:y and eifecti·vene~;s and -optimum dosage
schedules in the d.itlgnosis, tr~Altment 1 o·r {'rophylaxis of
groups of ~ubjects involving a given di.s.ease or condition.
A .r<>~''.Se>r.?.ble }HOtccol is developed on the basis of the facts
f\Ccun·.ulated in the e;;.dier phases, inch:zdi-ng completed and
submitt~d anim;;.l studies. This r·ha.c;e is -c-on·ducted by sepafatc gtours following "the )j·a..:.~.e p.ro~ocol (wii:h reasonable
va.rlar.ions _and ~dtern:.:.tivcs r-e.-:mittcd by the plan) to produce
well~controlled dinicnldata. F:)r 'his phase, the fOllowing
c!atc sh~ll be submitted:
i.- The names :1.nd addr('SS~s of the i-ove·stigatorS. (Additional il1vestigators may be added,)
ii. The specific ·nature. of che investigations to be con~
ducted, together with ioformt\tion or case 'teport forms to
show the scope and detail of the planned clinical observations and the clinical laboratory tests to be ·made and reportelt
.. iii. The approximate· number of subjects (a reasonable
range of subjects is permissible and additions may be
made), and criteria propos-ed for subject selec-tion by o\ge,
sex, and conditinn,

iv. The t•siimated ·duratiOn of the clinical trial and the
interv11ls 1 not exceeding .1 ·year, lit whi.ch prog:ess reports
showing the results of the investigations will be submined
·tO the Food and Drug Administration,
(The notice of. cl~imed investigational exemption may be
limited to any one or more phases, prov.ided the outline of
the additional phase or phases is submitted before such additional phases begin. This does not preclude ·continuing
a Subject on the drug from phase 2 to phase 3 withou~ int.er·
rupdon while the plan for phase 3 is being devCloped,)
Ordinarily, a plan for clinical trial w!ll.not .. be regarded
as reas.onable unless, among other things, it. provides for
more than -onC independent competent investigator to maiP,tain adCquate Case histories of an adequate number of sub~
jcct.s, designed to_ record observations and permit evalua~
tion of any and all discerO.ible effects attributable to the
·drug in each individual treated, and comparable records on
any individuals employed as controls. These records shall
be individual cecwds for each subject maintained to include
adequate in-formation pertaining to each, including age, sex:,
conditions treated, dosage, frequency of administration of
the drug, results of all relevant clinical observations and
laboratory examinee ions made, adequate_ 'information con~
coerning any other treatment given and a full statement of
any adverse effect"> and useful results observed, togf:ther
with an opinion ~~s to W1;etner such effects or results are
attributable to the drug under investi.gation.
· c, lnstitutional.!eview committee. If the phases of clinical· study as described-under lOa and b above are conducted
on institutionalized subje<rts or are conducted by an ind!~
vidual affiliated With an institmlon which a_.gre~"'s to :assmne
responsibility for the stud_y, o..ssurac.tte rl\<J-i.;t be giv;:n that
an inst\n:tional revit:·r·J C~!'.'lmittet: i~ resr-onsibl.~ hr L~icid
-aud continuingrevie~.v and -appWYal C)f rhe propcsedc1i,:-:.ica!
study. "!he membership must bf.: campoL:·e-d o1 sufficient
members of varyingb~\ckr;ro'.lnd, that is, la'XYf::s, clergy.n~!:'!l,
or l<O.ymen a$ well <<s sci.e.ntists, to ·«.s~uH.: CO\npi.::tt· und
adequ:He review of the re:search project. The rneml:>crship
mu.-:;t possess not oniy br':'ad competence ta compt·-::h~r.d (he
nature of' the pro fe"ct-,. b\it also other competencies nec!:'!ssary
to judge the acceptability of the projector llCtivity in terms
of institutional regulations, relevant law, standards nf pro;.
fessional practice, and community acceptilnce. Assurance
must. be I>resented that neither the sponsor npr the investigator has participated in selection of co~mittec ·members';
that the reyiew committee does not allow participation in
its review and conclusions by any individual invoived in
the cotiduct of the research 11ctivity under review (cxce:pt
to provide information to the committee); that the investigator wil_l report to the committee for review any emerger.t
problems, serious advt:rse reactions, or proposeci procedurB.l
changes whi~h may -affect the status of the investigation
and that no such change will be rnade without committee
approval except where necessary to eliminate apparent immediate hazards; that reviews of thP. study will-be conducted
by the review committee at intervals appropriate to the degtee Of risk, but not exceeding 1 year, to assure that the
research project is being conduded in compliance with the
committee's understa-nding and recommendations: that rhe
review committee is provided all the information on the resea~ch project necessary for its complete review of the
project; and that the revie·w committee maintains adequate
documentation of its activities and devebps adequate pro~
cedures for reporting its findings to the institution. The
documents maintained by the committee are to include the
names and qualifications of committee members,:. tccords of
info:·mauoo provided to subjects in obtaining informed con~ent, committee discussion on substantive issues and their
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tions in institutions periodically to determine whether th~
~ommittees are operating in accord with the assurances
given by the sponsor.)

resol1,1tion, cQmmittr.e recommendations, and dated report$
of successiyc reviews as they a.re performed. Copies of all
doa.,~ments are to be retained for a period of 3 years past
the completion or discontinuailce of the_ study and are to be
rtlflde available upon request to duly authorized represen~
tatives of the Food ~nd Drug ~dministradon, (Favorable
recommendations by the committee are subject to further
appropriate review and rejection by ins~itucion O:fficia_ls.
Unfavorable recommendation-s, t(:Strictions, or conditions
may Rot be 01(erruled by the institution offiCials.) -._Procedures for the organization and operation of institutional
review committeeS are contained in guidelines isSued pursuant to Chapter 1~40 of the Grants. Admini~;ttation Manual
of the U.S. Department· of Health, Educatiott 1 and Welfare,
available from the- U.S. Government Printing Office. It is
recommended that these 'guidelines be followed in estab~
lishing insti:utional review committees and that the committees function according to the procedures described
therein. A signing of the· Form FD .1571 will be regarded
as providing the above necessary assurances. If the insti~
turion, however, has on file with the Department of Health,
Education, and Welfare, Division of Research Grants, Na. tional Institutes of Health, an naccepted general assurance, 11 and the same committee is to review the proposed
s~udy using the same piocedures, this is acceptable in lieu
~of the above assurances and a statement to this effect
should be provided with the signed FD- 1571. (In addition
to sponsor's- continuing respor.sibility to mOnitor the study,
the Food and Drug Administration will u~dectake inv~stiga-

11. !tis understood that the sponsor willootify d.e Food.
and Drug Administration if the investigation is discontinued, and the reason therefor.
·l2. ltis understood-that the sponsur will notify each in~
vestigatoi if a oew~drug. appli.catlon is approved, or if the
·investigation is dis<;:ontin11ed.
13. If the drug is to be soid, a full cx:plunation why sale
is required and- should not be regarded a::-: the commercialization of a new drug for which an application is not ap~
proved.
14. A statement that the sponsor assures thor clinical
studies i.n humans will not be init-iated prior to 30 days
after the date of receipt of the riot ice by the Food and Drug
Administration and thm he will condnue to witi"wld or to
restrict clinical studies if requested to do so by the Food
and Drug Adminisuation prior to the exPiration of such 30 ·
days. If such request is made, the sponsor' wiil be provided sp~ci.fic information as to the deficiencies and will
be afforded a c.onference on request. The_30-day delay may
be waived by ;he Food and Drug Administration upon a
showing of good reason for such Waiver; and for investigati"(;ms subject to institutional review committee approval
·as- described in item lOc ~hove, an additional statement
assuring that che investigation will not be initiated prior
to approval o( the study by such committee.

Very truly yours,

--------~'

iNDtc~Tui~~~7TY------···-·---·-~·---

-------......:-"---··-- -

-------------

....

(This notice may be amended or supplemented from time to time on the bosis o.f the experience gained with
the new drug. Progress rep~rts may be used to update the noti.:e.)

ALL NOTICES AND CORRESPONDENCE SHOULD llE SUBMITTED IN TRIPLICATE.
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APPENDIX E

Form Approved
OMB No. 57 -R0003

HEW DRUG APPLICATION (DRUGS F0£1 HUMAN USE)
(Title 21, Code of Federal Re_gulatiom,•, 'V130.4)

Name of applicant
Address
Date

---------------------------------------~---------------------------------------------------

Name of new drug ______________________________

0

Original application (regulation § 130.4).

0
D.

Amendment to origin~l. unapproved application
(regulatbn § 130.7).
Abbreviated appiication (regulation § 13Q.4(f) ).

0

Amendment to abbreviated, unapproved application
(regulation § 130.7).

D Supplement to an approved application (regulation· §'130.9).
:0 Amendment to supplement to an approved application.

·The undersigned submits this application for _a new drug pursuant to section· SOS(b) of the Federal Food,
Drug, and Cosmetic Act. It is understood that when this application is approved, the labeling and advertising for
the drug will- prescribe, recommend, or suggest its use only under the conditions stated in the labeling which is
part of this application; and .if the article is a prescription drug, it is understood that any 1 abe 1in g whlch
furnishes or purpmts to furnish information for use or which prescribes, recommends, or suggests a. dosage for
u~e of the drug- will contain the s·ame information -for its use, including indications, effects, dosages, routes,
methods, and frequency and duration of administration, any relevant warnings, hnzards 1 contraindications, side
_~ffects 1 and pr~cautions, as that contained in the labeling Whi-ch is- part of this application in accOrd with § 1.106(b)
(21 CFR 1.106(b)). It is uil_derstood that all representations in this applicrJ.tio:-t e~pp-1.y to ·the: drug prcduced L~nti1
.an approved supplement. to the application p:.-ovides fnr a change or the ch~,:Ige is made i_n confotmance VJith ot}1er
provis~ons·of §130.9 of the new-drug regulations.
Attached he!"eto, submit·~ed in the form described in § 130.4(e) of the uew·-dmg ree;t.:ia:ions, and- constituting

a part of this appli·:at.ion are the following:
1. Table of coments.

The -t_able- of contents should

spec-i-fY""""the::v~IuiD;n.~~~b~r---and---the----paf,e--number-in whic-h
.the comp!ete and de~g,il,"!d item is located and che volume
number and the page number in which the- summary of th<lt
item is located (if any).

2. Summary. A summary demonstrating that the aPplica~
tion is well-o~ganized, ;:tdequa~ely tabulated, statis.tical1y
analyzed (where appropriate), and coherent and that it
presents a sound basis for the approval requested. The
summary should include the following informacion: (In
lieu of the outline described below .and the_ evaluation
described in 1tem 3, im expanded summary and eva!uacion
as outlined in § 130.4(d) of the new-drug regulations may
be submined to faciiitare 1 the teview of this application.)
a. Ch~mistry.
· '
i. Chemical struct,.lral fo!mub· or descripLion for any
.new-drug suhstanc~t
ii. Re1ati_c·nshi_r} to other chemically or pharmacologi··
cally related d:ugs.
iii. Description of dosage fotm and quantitative composition.
b. Scientific rationale and purpose the drug is to serve.
c. Reference number of the investigational drug nocice(s) under which this drug was investigated and of any
notice, new-drug application, m: master file of whic-h any
contents are being incorporated by reference co support
this applicatiori.
d. Preclinical studies, (Present all findings including
all adverse experiences which may be interpreted as
incidental or not drug•related.
Refer to dace and page
number of the investigational drug notice(tl) or the volume
and page number o( this application where complete data
and reports appear.)
i. Pharmacology (pharmacodynamics, en<,locrinology,.
· Inetnbolism, etc.).

ii., Toxicology,and pathology: Acute tox1c1ty st,..:dit:cj
_subacut-e_. ar...d chr.onic_toxicity st.udies; ___ reproduction ... and __
teratology studies; miscellaneous scudies .
e. Clinical studies. (All m·aterial should refer spedfi·
cally to each clinical investigator and to the volume and
_page number -in the application· and any documents i.nu
corporated by reference where the complet.e data and reports may be found.)
i. Special studies not described elsewhere.
ii. Dose-range studies.
iii. Controlled clinical studies.
iv. Other clinical studies (for example, un·controlled or
incompletely controlled studies).
v . . Clinical I laboratory studies related to effectiveness.
vi. Clinical.laboratory studies related to .safety.
vdi. Summary of literature and unpublished reports available_t_o the applican_t.
3. Evahtation cf safety and effec!_~~ess.
a. Summarize sep::t:-ately the favorable and unhntorable evidem.e
for each claim in the P<-1ckage labeling. Include references
ro the volume and paEe number in the appli~ation :>.nd in
any documents incorporated by reference where the com..:
plete data and reports may be found.
b. Include tabulation of all side effects or adverse
experience, by age, sex, and dosage formulation, whether
or not coO.sidered to be significant, showing whether ad-·
m·inistration of the drug was stopped and showing .the
investigator's' name with a reference to the volume and
· pilge number in the application and any documents in"
corporatcd by reference ·where the complete data and ~e·
ports may be found. Indicate those side effects or adverse
expcrit:ncet: considered to be drug"'[elated.
4; Copies of the label and all othe-r labelinp: to be used
for thC drup (a total of 12 copies 1{ in final printed form,
4 copies if in draft form):

···c:ut5
!h_~·full_Jescriptioh of the methods U!Wd in, and the

a. Each· b'bci, or other iabelin"g, should be dcao:ly
identified to show .its position on, or the manner io which

f~tciEties

it accompanies, the aia.rket packa_ge.
b. lf the drug is to be offered OV(!f the counter, labeling
on or within the retail package should include adequ~te
directions for use by the laymt:~.n under all the conditions
for which the drUg is intended ior "la.y use or is w t.e
prescribed, re(.ommended, or suggested in any labding or
ad\>ertising sponso!ed by or on behalf of the applicant
and directed to the layman. !f ::h!O' d[ug_ is intended or
offered- for uses under the profe.s.siOnal supervision of a.
practitioner licerised by la·N to administer. it, the applica ..
tion should also contain labe.iing that includes adequate
infprmation for all such uses, including all the purposes
for which the over-the·counter drug is to be advertised to,
or represented for use by, physicians.
c. lf the drug is limited in its labeling ~o use under
the professional 5l1}'ervision of i practitione.t licensed by
law to administer it, its labeling should bear information
for usc under which such practitioners can use the drug
for the purposes for which i"' is intended, including all
the purposes for which ii: is to be advertised or representod, in acco.d with §1.106(b) (n CFR l.lOG(b)). The
application should_ include "2-0Y l-abeling for the drug
i.ntcnded to be made available to the layman.
d• . If no- established name exists 'for a new-drug substance, the applicP.don shall propose a ._nonproprietary
name for usC aS the established name for the subste.nce.
e. Tyl-'ewrittcn or other draft labeling copy may be submitted for preliminary consideration of an application. An
application will not ordinari-l;r be approved prior to the
submission ·of the final printed label and labeling _of the
drug.
··
/. No application may be approved if the labeling is
. false or misleading in any particular.
(When mailing pieces, any other lab-::ling, -Ot ~dv~1tis in.g
cOpy are devi.sed for p:omocio:1 of th{! ne-w drug, samples
shall be -su.br'lliH~·d v.t the ~itne of ioitl:,,.l dissemination cf
silch labdir.:g t:~-nd. a~ the ;;in::.c of .i.c!!i~"l ?lacement of a.l::J
such ~dvettjsit;g fot a prescription drug (see §130.13 -of
the new-...{.:;:-ug .tegw.latior.s).-- Apptc>v_al of a :supplemcn:nl
new-drug il,_-ppli.c:ation i~ r~quited prior to use of r,ny :pic•sn.otionr-.1 dahl~ oct covered \.;y the -approved application.)
5. A stn<:t::ffi{~nt £S to whether the d.rue; is {or is fi()t)
!§~j~;dTni~·s kbeli:_ljL_~d by this apPlication tO u·se
l!flder the vrofessiona.l supervision of a practitioner
ficensecfby i;,; to ad~1T;i1>ter it.
-6:1\Tul.IlGt-;,t the ar-ticles us-ed as components of
!_l.l_':_ __ §~.- This--list should include all substances used
in the syn~hesis, e:rtrection, or other method of preparmiou
of any ocw.J.ru13 subst~\ncc, and in the preparatio-n of the
fiJ,ished- do& age fo.nn, rt::ga.rclle-ss of whether they undergo
chemical ~~ang-:! or are r~~rooved .i.a the P,HH':ess.
Each
suh:~tance should be identified by its cstabli~hed name,
H any, or complet-e c:her11.ical £lame, usin.g structural
fonnvlas wht!n n.e~;:eggary for specific identifice.tion. If
any pro1rrietar'y pn:po.:c~tion is used as a component, ·the
proptietary oa'lne should be !fJllow.~d by a complete qusntitfltiv~ s,tatement of composition. Reasonable a.lt_ernativcs
for nny~listed substanCe may be specified.
7. A full statement of the composition of th-e dr~g.
ThT~~Sharf-sC"t-forth the narue and ~mount of
ca:ch ingredient, whether active or ·not, contained in a
stated quantity of the drug .in the form in which it is to be
distrib\•.ted (for example, amount per· tablet· ot per milliliter)- and t.\ batch formula representative of that to be
employed fo-e the manufacture of the _finished dosage form.
AU components should be included in the batch formula
regardless of whether they appear in the finished product.
Any calculated excess of an ingredient over the label
declaration should be designated as such and percent
excess shown. Reasonable vai:i~tions may be spe_cified.

l
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and con.trols used for, the mar:ufacture, procesS•
ft~l"r~~cking o( the drug. lnclud,:d iil thts descripti-;;-;1
should be full information with respect to any n~w-drUg
~ubstancc and to the new-drug do~age form, as follows,
in sulfident detail to permit evaluation of the adequacy
oi the descl:ibed methods of manufacture, processing, and
packing and the described facilities and controls to
determine -and pxeserve the idend,ty, strength, qunlity,
and purity of the drug:
a. A descrip_tion of the· physical facilitic~ including
building and equipment used in manufacturi1~g. processing,
packaging-, labeling, storage, and control operations.
b. A description of the qualificatiOns, including educa:tional background and experience, of the technical and
professional personnel who are responsible for assuring
that the drug has the safety, identity, strength, _quality,
and purity it purports or is repre.sented to possess·, and a
statement of theit responsibilities.
c. The methods use:d in the synthesis 1 extraction,
isolai:ion, or purification of any "new--drug substance. When
the specifications and controls applied to such substance
are inadequate in themselveS to determine its identity,
strength, quality-, and purity-, the methods should be.
described in sufficient detail, ·including quantities used,
times, ter.-lperatures, pH, solvents, e!c., to determine
these ch:itactedstics. Alternative rriethods or variations
in- methods witl;in reasonable limits that do not affect
such characteristics of the substance rilay be specified.
d. :Precautions_. to assure proper. identity, strength,
quality, and pmity ~f the raw mate"rials, whether acti-ve or
not, including the speclfications. for acceptance ~wd
methods of testing for eac:h lot of raw material.
e. Whether O! not each lot of raw materials is given a
seria~ number to identify it, and the us•:: made of sucj_l
nwnbf:rs -io subscq_UC!lt plant crpemt!cns.
-f.-· H the .appli::ant- does not himself r-edonn. ~J_l th~
m~.nufacturiug, ._;1HH:essing, rackagins, ir>.bding, and cont.::ol o:pcn1tions ft.';: ~ny hevt..J:ug substnncoe or th~ nev.f-·.,Jn:s
dosnge foiro, his stut~ment id~:ntifyinR. esch person -who
will pedorro any part of Su~b oper:1ticus and deaignating
the part; &nd a sign~4 st_:iterne;:ct from -f:ach such p-erson
fully desc1·ibin:g, directly or- by --refe{eD.ce, tht:: "methods,
facilities~ and contrOls in his par~ of the· operativn.
g. Method- of prceparation of the mas ret forro.ula records
.and individ11al batch records and nta.nner in which thes~
reCords ate used.
h. "'fhe instr_uctions used in'the manU:fac:turing, proc..;->:ss~
.!ng, pa<::l..::aging, :and labding of each dosage form· of the
new drug, including ·any Special precautions observed in
the operations.
i. Adequate infor.m..'1.tion with respect to the char.:<\ctc·l"~·
i:;;tics of and the test aiethods employed for the coo.ta.in.er,
dosure; or other compone-.u· parts of i:he drug pac.~age to
essure t~eir. suitability fot the intended use.
f. Numbe~;· of individuals checking weight or volume of
er.ch individual ingredient entering into each batch of the

dn'S·
~. W'nether or not. the total weight or volume of each
b.e.~ch is determined at any stage of the man~tacturing
process subse-quent to making up n batch according to the
formula card acd, if so, at what stage and by whom it ·is
done.
1. Precautions to check the actual package yield produced from a batch of the drug with che theoretical yield.
This should include a description of the accounting for
oUch items as discards, breakage, etc., and the criteria
used in accepting or rejecting batches Of drugs i.n the
event rJ. an unexplained discrepancy~
m. Pr-eca~tions to assure that each- lo"t of the drug is
~a-ckaged With th"e proper label and labeling, including
provisions for labeling storage and inv~ntory control.

2

~IJ':J

n. The analytical

con~wlS

used during the vadous
stages of the manufactt.ting,' processing, packaging, and
lab~ ling of thr;> drflg, including a detaill!d -dc:;cription of
the collection o.f sampl(!s and the analytical procedures to
which they are subjected.
The analytical procedures
should be capable of d,'!terminin·g the active component~
within a reasonable degree of accuracy and of assuring
the identit.}"· of Su-ch components. lf the article is one that
is repres~nted to be sterile, .the same information with
regard to. the m~oufacturing, processing, packagir.g, and
the cc•llec::don of samples· of the drug shOuld be given for
sterility C;}ntml.s.
include the standards used for acCP.pta!ACe _nf each !ot of the finished drug.
o. An explana[ion o£ the exact signifiCance of the
ba.tch control nttmbers used. in the "manufacturing, proCess·
ing, packaging, and· labeling of the drug, including the
control numbers that appear -on the label of the finished
article. Sta.te whether these numbers enable determination "of the complete manufacturing history of the prqduct.
Descri_be any methods •.\sed to _permit dct(~tmination of the
distribution of any batch if its recall is required,
p. A complete dcRcription of, and data derived from,
studies of the stability of the drug, including i"nformation
showing the suitability of the analytical methods used.
Descdbe any additioaal stab~lity studies underway or
contemplated. StabiHty data should be submiti:ed for any
new.J:rug substance, for the finished_ dosage form of the
drug in the container in which it is to be marketed,: including any proposed muitiple-dose: container, and if it is
to be put. into soh\:i.on at the time of -dispensing,_ for t\1~
solution prepared as directed. State the expiratioa" date(s)
that will be used on the label to preserve the identity,
strength, quality, and purity of the drug until it iS used.·
(lf no expiratioD. dat_e is ·proposed, the !lpplicant must
justify its ~b.sence.)
· q, Addit).(mai procedures employed which are designed
to ptc"J"ent conte;minat;.on ?>lld otherwis·e assure proper
contwl o: the 1•::.:.:-do.ct.
{A.rl a p p 1 i i..~ at i. f' 11 mn.y be tf:.'ftlsf·d. !tnles.a it in~ludes
adequme ·ir.fMmation .'3'howing that dlf! methods used in,
ftn.d -the f?.~ilities and controls used.for, the:_ manufacturir1g,
P.roccssi.ll_g,. and p.<J.ckilglng of th\~ drug ~ttc ·l1d;qui.te tO
r·resetve i.u- ide:ntity, strl!tlStb, •:~,uality, and· puri_ty in conformity with good manufacturiny, practice and identihe.s
each ·establishment; showing the location of the plant
_conducting. these. operations.)_
9. Sa§2.1!'.~.L~~!_l-~ug "<'.n~ articles used as cpmp~
!!.:.nts, a~__i:~llow.'?.: ,,._ T11e -following samples shall be subd
miued wirh thP. -application or as. soon thereafter :as.they
bec-ome ev~ilablc.
Each sample shall consist of !Our
identical, sepr..rcttc ly pac.bged subdivisions, each containing <:\t least three time-s "th-e a.roount required to perform the ·taboral:o.ry tes-t. 11rocedures described in the ap·
plication to duerrr.iae compl.iaoce with its control speciflcfl.tions fcc id·~ntity and ~.s<;;t.y.s:
i. A repres~o·<... tati·<e s<Wlf-te or sumJlles ct th~ finish-ed
dosage f;:mu(s) pL"op.:>sed in t\lf~ application and ernployed
in tLe: di\1ka.l i1WI"'stigations ~od a representative sample
or snmples of each o.ew~~~ru,; substance,_ as defined in
§130.l{g), f:~a1 thE bar.ch(es) employed in the prOduction
of such closo:\ge fotm(s).
ii, A re1·uesentative sample or samples of finished
111arket p;;;·ckages of each dos~ge form of the drug prepared
for initial marketing and, if any such sample is not from a
commercial...scale production batch, such a sample from a
reptesenr.ative commercial•scale production batch; and a
representl:'.tive sample or samples of each new-drug substance as defined- in §130.l(g), from the batch(es) em...
played in the production of such dosage form(s.).
iii. A sample or samples of any reference standard and
blank used in the procedures described iil the application
for assaying _each new-drug substance and -other assayed

components of the finished drug: Provt"dt~d, b-uwever, "That
samples of iderence standards recognized in.· the official
U.S. -Phamw.copcia cr The National I~ormulary' need ·nor.
be submitted unless requested.
b. Additional samples shall be submiti:ed on r·equcst.
c. Each of the _samples submitted shall be appropri ..
ately packaged and labeled to preserve it~> Characteristics,
to identify the ·material and the quantity in each subdivision of the sample, and to identify each subdivision
with th~ q,ame of the applicant and the new.-<:lwg applica ..
tion to which it relates..
d. There shall be included a full list of the samples
submitted pursuant to Item 9a; 'l statement of the additional samples that ·will be submitted as soon as available; and, -~:ith respect to ea(.:h sample Submitted, full
information with respect to it~ identity, the origin of any
new-drug st1bstance contained therein O.ncluding in the
case of new-..d.rug substances, a statement whether it was
produced on a laboratory, pilot-plant, or full-production
scale) and detailed results of all laboratory tests made to
determ.ine the identity, strength,· quality, and purity of
the batch lepresented by the sample, including assays.
Inc-lude for any reference standard a complete description
o£ its preparation and the res).llts of all laboratory tests
on it. If the test rn.ethods used differed from those described in the application, full details Of the methods
employed in obt?.ining the reported results shall be submitted.
e·. The ·reqllirements ·of Item 9a may be waived in
whole or in pe.!t on request of the "applicant" or otherwisewhen.an.y such samples are not neces-sarY.
f.- If samples of the drug are setH under separate
cover, they should be addressed to the ?.._ttentioo of the
Bureau of- Medicine and identified on the outside of the
shippip.g C<lftt:li'. w.ith the naffie of the_ "'"ppHcu.nt !lnd th>!':
·na.tne of the drug a$ .!'lh:own on the appLkadon;
--10 •.. Full-tepo!t~> of-D:ecliuicul in•n::stip,~'l.tions thM -hat•e
be ec·roa de t0$hO:.VV:·l~nero?n-O'~tr;~:;-~;l,:-:-·r;-;:;e·· to{ us;;;;ddfer:t0~:;-·;;:;-use. a. An appti~:atF:rt;;;_y~-:;:~l•.;;;;
uplmitc;;;;:i:.,~.in.~-full repeort£ of ndeq<.~ate predi.nical
te.';-ts by all methc,ds teasan!t"oly a-ppEc~.b\c tc a determlna·
tion--of- ~he _safety and- eff~c'.:i~·~nes.> of tbe dn~g undc[ the
conditior1s of use suggested (:"• che PWI'Osed· labeling.
b~ Detailed reports of th:~ - ·;·clini·cal investigations,
including· all studies mad-""
:~~!5oratory animals, the
met~ods used, ~nd the result~
·ined, should" be clead.y
set forth. Such information .:;~,:· .. \d include. identification
of the person who -conducted ~'~~~..:h investigation, a statement of where· i:he investipt.i.l)ns were cond\;cted; and
where the=·unde!lying data are t'\:vailable for inspection.
The anilr.al studies may rtot, bt~ considered ad·equatc unless
t~e_y give proper attention. to the c.onditions of use tccom~
mended in the ptoposed lab!.>ling, for the drug such as, for
example, ·whether the drug is fot· sho.rt- or longptenn ad~·
m.inisuation or wherher it is to be used in infants., childr-en, .pregnant women, or women of chiid·bearing potential.
c. Detailed reports of any pertinent microbiologi.cal
P.nd ·in vitro studieS.
d. Summa.t".ize and provide- a list of literature references (ii available) to all other preclinical information
known [Q the applicant, whether published or unpublished,
that "i~ pertinent to a.n evaluation of the safety or effectiveness cl.. the drug.
11. List of investigators. a. A complete list 0£ all
investigators supplied with the drug including the name
and post office address o[ each.investigator and, following
ea~h nar!l.e, the volume and page referenCes to the investigator's _teport(s) in this application 'and in any docu•
ments i~cor.por-ated by reference, or the _explanation of the
omission o( any reports.
b. The unex:plnincd omission of any reports of investigations made with· the new drug by the·applicant, o.:;:
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submitted :o him by ~n investigator, or the t:ncxpi-aincd
om iss ion of any pertinent reports of investigations or
clinjcal c.Y.pericnce received or otherwise obtaincJ by the
ap!-'licant from published literature or other sourc:ce 1
whether or not it would bias an evaluation of the safety
of the drug cr its effectiveness in use, may constitute
grounds for the refusal or withdiawal of the approval of
an application.
12. Full reports of clinical investigations that_~
~~-made to shm'.'_ whether or not_ the drus is safe for_ use
and effective in use. a. An application may be refused
unless it contains full reports of adequate tests by all
methods reasonably applica blc to show whethe.r or not the
drug is safe and effectiv~ for use as suggested in the
labeling.
b. An application may be -refused unless it includes
substantial e~lidcnce consisting of adequate and well~
colltrolled investigations, including clinical investigations, by experts qualified by scientific training and expedence to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have
the effect it purports cr is represented to have under the
conditions of use prescribed, recommended, or suggested
in the proposed la-beling.
c. Reports of all clinical tests sponsored by the applicant or received or otherwise obtained by. the applicant
should he attached. These repor.ts should include· ade~
quate information concerning each subject· treated with
the drug or employed as a control, including age, sex,
conditions treated, dosage, frequency of admini:HraLion
of the drug, :esults of all relevant dinical observ:!tions
and laboratory e-xar.1inations made, fuJi information conccrni:c\g_ :::ny other treatmcn~ given previously or cor.cur.r.;:l>dy1 :ilnd :.1 f11H stgtemem of arboerse effects and use-ful
results o~~s·NveG, t\)gecber with an opinion as to whe~he.r
such effects o.-:- results are <_ttribntable to the drug under
investig-3.t.i . :m anr:('a Statement of where .the undcr_!yi:ng ·
data are a.v:aibble for inspection. O~:dinarily, the teports
of clinical studi';~S will nut. be regarded as adequde
unless they inch<de reports -from more than one independent, competent investigator who maintains adequate
case histories of an adequate number of subjects, designed to record observations ~nd per.ffiit evaluation of
any and all d.i.scernible efbcts attributable to the drug in
e~ch individual t:eated and comparable records on any
individuals er<1ployed a,; controls. An application for a
combination drug mn.y be refused unless there is 5ub-·
stantial e-vidence that each ingredient designated as
active makes a contribution to the total effect claimed
for the drug cllmhinai:it'n. Except when the disease for
which the drug is being te.sted occw:s with such infrequent y in the ll!lit~d States · a.s to make testing impractkal, some of th!.! investigations should be oerformed
by C<..'ffi!=Jeteut investigators with!n the United Stat~s.
1

d. Attach as a separate section a completed Form
FJ)-!.639, Drug Experience Report (obtainable 1 with

i~~

;str:Jctions, on request from the Department of HEW. Foo-d
and Drug Administration. Bureau of Drugs (BD-200) Rockville, Maryland 20852), for each adverse experience or, if
feasible, for each· sub.ject or patient- experiencing one or

more adverse· effects, described in Item 12c·, whether or
not full information is available. Form FD~l639 should
be prepared by the applicant if the adverse experience
was not reported in such form by the investigator. The
Drug Experience Report should be cross-refercn-::ed to
any narrative description included in Item 12c. ln lieu of a
FD Form 1639, a computer-generated report may be submitted if equivalent in all_ elements of information with the
identical enumerated sequence of events and methods o(
completion; aU-formats proposed for such use will require
initial review and approval by the Food aP.d Drug Administra Hone. All information pertinent to· an evaluation of the
safety and effectiveness o£ the drug received or otherwise
obtained by rhe applicant from any source, including
information derived from other investigations or commerical marketing (for example 1 outside the United_ States),
or reports in the scientific literature, involving the drug
that is the subject of the application and related drngs.
An adeq:1ate summary m3.y be acceptable in lieu of a
reprint of. a published report which only supports other
data snbmitted. Reprints are not required of reports in
designatE;cl journals, listed in §130.38 of the new-drug
regulntions 1 about related drugs; a bib.\iography will
suffice. Include -!:!ny ;;;,-va1Uat£on of tbe saie;:y or f:ffe-=tiveness •Jf the dntg that h•lS be!!n made by the a.ppiico.ni.'s
medic-al department, expert Com!nitt~e, (l: consultarH:.',
/. H _t'ne drug is a combination d previously in\'esti~
gated oi· marketed t-ltogs, an adeqtu;H(~ summary nf preexistia; informati0n frortt. precli.nic<'d ;:.n-1 cli.nicai i.wt~sti·
gatic,.n and ~xp~ri,:-nc,._; with i<:s- ccmyon.:or.ts, i.:1duding. all
reports re~:eived or ot))crwise vinaitwJ br th0 f<.pplicant
sLtggestiO.g side -ei£eclS, c·ontraindications;- and ineffC!c-·
tivelless in use- of such components. Such summary should
include an adequa.te bibliography of publicatioris about
the· components and may iO.corporne by reference infonnn ..
tion concerning such components previously- submitted
by the a.pplicant to the Food and, Drug Adrninisuafion.
g. The complete composition and/or method of manufacture of the new drug used in each submitted report of
investigation should be shown to the extent necessary to
-establish its identity, strength, quality, and purity if it
differs from the description in Item 6, 7, or 8 of the application.
13. 1f this is a supplemental appli.catio·n, full. informatioc on each ptopos,;d ch~e cOnc;:_rniog any statem~;t
ma~!: in tl!_~f£!.9_ved .£-_p.2!j_cation.
Observe the provisions Of §130.9 of the new~drug regul-ations concerning supplemental applicat.ioos.

(Applicant)

Per --·-~-:c---=--=--,..,,-----;,---
(Responsible official or agent)
(Indicate authority)
(Warning: A willfully false statement is a criminal offense. U.S-.CoTitle 18, sec. lOOL)
NOTE: This i!.pplication must be signed by the applicant or by an authorized attorney·, agent, or official. If the applicant
or such authorized rt.!presentativc_ does not cc s i d c or have u. place o{ business within the United States, the n.pplication must
also furnish the uamc and p.:>st office address of nnd must be countersigned by an authorized attorney, agent, or official residing or maintaining a pluce of business wilhin the United St,\tes,
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-------~~------~--------- ~------~----~------------·-·
1---'-"-'-"C.'"c;'_:.!~fJprvv.,d: (l,\1F~_!f.u. 57-JWO~~
J---_;0~0<-f!fi:QJc..!!'E HilS SP.ACE
DATE RECEIVED

COMMUNITY PHARMACIST'S DRUG DEFECT REPORT

~~~~~~----·--------
REFEf!ENCE NO.

1, TRADE NAME, DOSAGE fORM, STRENGTH

2. LOT NUM9ER (s)

3, DATE PURCHASED (If known)·

4. SOURCE OF P-RODUCT

(IYbetP. purch<ner!, il knoWn)

5. NAME AND ADDRESS OF DRUG MANUFACTURER

6. REPORTING PHARMACIST'S NAME:

7. NAME ANO ADC!P.E~:S QF PH'ARMACY Unclude ZIP Code)jj

8, PHONE NUMSE.H -(!w::Jude Arua Code)

.

.

9.- DEFECTS NOT~D AND SUS~-ECTED

I

.l

l/

Addith>11nl form.s and po-"tll#IB·[lt:id l'tJvelopo.s will be rnt~llud to rou nutomtHict~lty at thi~ atldrcss wlwn t1Jis report Is reco/ved,

RETURN TO

United States Pharmacopeia
12601 Twinbrook Parkway
Rockvil\e, Maryland 20852
Attention: llr. joseph G. Valentino

'------~-------;__..:,_

______________________
,

,

I

~~------~----~------~=---~-.------~----~---------------CE:PARTME:NT o.F
H~~~1H;..~6'~~~6'c;.~·~~~~;~EALft~;;e
W.ASHJNGiON, D.C.

20204
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Ol!ict! ol Msna,gt.tment end Dud~or No. 57 ..R0004
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1:fl 1~-<ITIAL REPORT
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....._,

l
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ldoy

a!c)(i".;am~
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CAUC
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I

CESCMISE SUSPECTED ADVERSE RE.ACTI0~4(&) "AND ANY POSSiBLE ASSOCIATION

WJTH

1

Stete,

,.. o

·

OTHER

and

Zip Coda.)

---...-J.-,---
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DATE
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l

jI

D

D

. "'<''

.>

(f'IJ•1r1tJ!£J~~Utcr,o

LIST ALL THERAPY IN ORDER OP' SUSPICION

!~ME

OF ORUGS

M"ANUFA,."""URI::"RC: !DOSAGE
'-'I

"R.ADE (Generic)

-

FORM

-

j\
.,

\

I

I

,, ,, ,, '''""' "'"''''.,_¥'',:: '''''"''

SUBSTANTIATING

DOSE
OAII~Y

,

ROUTE

I

WURATION
/
I

".'·"-,.,..

'lI

.,.,·•

.;':I. .

.··:\:

,·"1\
•OATES OF

DIED (Glvo date and cause)

~

14.

§

0\SOROER OR REASON FOR USE OF DRUG

":O:I~:~~·~J--:.:....·:A~D~M~~·N~·~S~T~R:..__A~T~·~O~N---l----,--------,---------------~

N

l

I

COl
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I
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LAB·~~,;. TORY STUDI~cv;;;;;j"'L~~'i;;;;atory, Aulopsy, X-R.~y, etc:) . -~-

CLINICAL

~A,B:

BIOPSY/AUTOPSY:

LIST PO TEN Tl ALL. V NOX 10US 0-R.

STILL. UNDER TREATMENT

'>,

iv ofc),
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APPENDIX H

FDA Dr.ug Re~1latory Procedures
#1
October 9, 1975

l!.'xam

MULTIPLE CHOICE.

1.

a.

c.

d.

3.

(30 points)

1938
1898
1906
1902

This first federal food and d.rug lm·r established which
of the following:
a.

premarket clearance. of new drugs for seSety.

b.

definitions of food and drugs.

c.

c.urrent good

d,

standards for food.s and drugs through the
definit·ions of adulteration and rnisbr•ru:tdint!;.

E:.

drug factory inspections ever·y two

me.nui'r~cd;uring

prttctices.

;years~

\lhat legal mechanisms are defined in the Federal I!'ood,
Drug, and Cosmetic Act to serve as the tools for its
enforcement?
a~<

b.
c.
d.
4.

Circle All correct answers.

When was the first federal food and drug law passed by
Congress?
b.

2.

--

-_,...--,--·- . -----·"·---

seizure, recall, injunc-,;~on.
proseeution, recall.
seizure, prosecution, injunction.
sEd.zure, pros0cv.tion, recall, injunction.

The Federal i!'ood, Drug, and. Cosmetic Act, in the form
passed in 1938, provided for whieh of the follov1ing:
a.

adverse drug reactions must be reported to the
FDA by the firms.

b.

premarket clearance for the safety of new drugs.

c.

all antibiotics must be batch tested and certified.

d.

premarket clearance for the safety and efficacy
of new drugs.

e.

increased labeling requirements for drugs to .
include directions for use and warnings against
unsafe use.
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5. The 1962 Kefauver-Harris Drug Amendments added several

significant requirements With respect to the regulation
of drugs. These included:
a.

informed consent of patients prior to the use
of an investigational new drug.

b.

all antibiotics must be batch tested and certified prior to marketing.

c.

premarket clearance for the safet-y and effica.cy
of new drugs.

d.

drug factory inspections required every 2 years.

e.

current good
established •

ma~ufacturing

practices for

dr~gs

.SHORT .ANSWER.
1.

(2 pts.)

2.

(3 pta.)

;. (7

4.,

ptso)

What incident stimulated the passage of the
Federal }!'ood, Drug-, and Cosmetic~. Act of 1938?

1Tie FDA rec.eiv,?B its enforcemen-t; renponsibili-

ties from what tbree pieces of legisiat:i.on?

The FDA has jurisdictj.on over What products?
(7 categories)

(2 pts.)

What event, in 1962, turned the Kefauver committee from its study of the economics of the
drug industry to the stud;7 of the safety of
investigational new drugs?

(2 pts.)

How does the concept of "person" ~1i th regard to
violations of the Federal Food, Drug, and Cosmetic
Act differ from other legal concepts of liability?

(3)
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6.

(2 pts.)

\fuat is the "government ne•11spaper"?

7.

(2 pts.)

Define 21 CFR.
the FD.il.?

8.

(8 pts.)

Draw the orga~izational chart of the FDA to
include the 8 major areas.

MATCHING~

1.

\rlhat is its relationship to

(2 points ea.cb.)

!1atch the Bureau of Drugs a1:'9a with its fu:nci;ion.
A. . Revie;,rs INL' s m1d

Compliance
Information Systems

Biometrics
---"""'

"r'">

•

•

•

·B.

r,aboratory analysis of drug
produc·~s, to include the
testing of a11tibiotics and
insulin for certification.

C.

Enforcement of the la',rs
th:.cough seizure, inj1mction,
and prosecutions.

D.

Statistical support for the
Bureau's ac"!:;ivities; includes
monitoring of adverse drug
reactions and poisonings.

E.

Support for the Bureau •lith
library and library research
i'acili ties.

F.

HHndles OTC drug inrsredient
review panels, biophm:·rnaceutics data, and abbreviated
new drug applications.

&~
___-,

J',pJ.<l.eiDJ.OLOgy

.;.,.__ Drug Monographs
---·· New Drug Evaluation
Pha:r·mac~eutical

& Testing

Research
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2.

Match the Project Management System Program with its
description.

- · - Drug Application Evaluation
Drug Efficacy Study
Implementation

A. ·Post-market monitoring
of the effects of (lrugs
in an Ul1Controlled setting.
B.

Supplies drug information
to health professionals
through the "Drug
Bulletin" and "Dear Dr.
letters".

C.

Implementation o.f the NAS/
NRC recommendt',tioml on the
safety & efficaey of the
new drugs marketed between
1938-1962 •

D.

Monitor new drug investigations, evaluate data.
from these investigations,
and make recommenda.tions
as to the safety and
efficacy of new drugs.

E.

Provides data base on

---··- OTC Drug Evaluation
___ Drug Pharmaceu·!;ics and
l'lethodology
______ Drug Experience Information
_ _ Drug Abuse and Methadone
Monitoring
..._.,___ Drug Inventory
· - - - Poison Control
•. ~. , .• Prescription Drug
Advertising
~,,..

..,.,....

l'!iedical Communication &
Drug Abuse i'rends
Analynis

poisonings ar1d dissemi...,.
nates informEltion to poison
co11trol centf.::rs across the

nation.
F.

~brough the surveillance
of medical publications,
prescription dru.g advertisements are monitored.

G.

Implementation of the Drug
Listing Act of 1972.

H.

Analysis and evaluation of
drugs in the la.b, and
develops methodology.

I.

Monitoring o:f studies on
drugs with abuse potential
and the limited distribution of methadone.

J.

Coordination of the evaluation for over-the-counter
drug ingredients for safety
and efficacy.

(5)
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?.

Match the level of regulation with an example.
I.
II.

___._

Inspector at all plants.

A.

Certification batch by
batch of the products
produced.

New drugs: Ne\~
Drug Application.

B.

Large volume
parenterals:
· Specific Good
Manui'acturing .
Practices.

c.

Most drug produc·i:;s.

D.

USDA meat inspection.

E.

Antibiotics and
Insul:i.n.

III.

Certification of the firm
to make a particular
product.

IV.

Certification of the firm
for.a type of production.

V.

Collection of samples on
the marketplace and
analysis for violations.
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FllA Drug Regulatory Procedures
l!~am

#2

November

L~,

19?5

MULTIPLE CHOICE.
1.

c.
d.
e.

\~hich

of

indication.
combination.
duration of administration.
dosage form.
route of administration.

90 days.

60 da,.ys.
2 years.
l yea:r.
180 days.

FToper prescription
a.
b.
c.
d.
e.

.· 4...

(55 points)

The statutory time limit on the FDA for the review of a
new drug application is:
a.
b.

3.

Circle All correct answers.

A drug may be considered "new" for changes in
the following:

a.
b.
c.
d.
e.

2.

-------------------------·---

dr1~

labeling should:

predict TtJhat might occur w:L th the use of a drug.
reflect all significant date. about a drug.
be prompt in accomodation of changes in knowledge
about a drug.
provide prescriber with the essential information
to use the drug safely and effectively.
contain adequate information on the side effects
m1d contraindications •

There are various types and forms of labeling. After
reevaJ.uating the objectives of prescription drug labeling,
the J:i'DA has decided to utilize a more effect:i ve means of
providing health professionals \vith information to use the
drug safely and effectively. This method will be:
a.
b.
c.
d.
e.

package insert vii t;h unique labeling.
package insert with generic labeling.
national drug coropend.ia with class labeling.
national drug compendia with generic labeling.
national drug compendia with unique labeline;.

(2)
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5. Class labeling can be defined as:
a.
b.
c.
d.
e.
6.

Corrective measures that may be taken when a firm violates
prescription drug advertising regulations include:
a.

b.

c.
d.
e.

7.

deletion of the ad from further use.
fine of $10,000.
·
sending "Dear Doctor" letters to physicians
across the nation to explain that the advertisement was false and misleading.
publishing retraction in the magazine in •1hicli
the original ad was run to explain wh,_y the ad
\'/as false <md misleading.
at least one year in prison.

'I'he NAS/NRC evaluaticm of drugs reviewed:
a.
. b.
c.
. d.
e.

8.

one document for the same basic drug from
different manufacturers.
one document accounting for all members of
a given therapeutic class or subclass.
one document for each individual drug product.
several documellts for the· same basic drue~ from
different manu_facturers.
several documents for an individual drug product.

~'he

all drugs on the market at the time •
drugs put on the mm·ket pi•ior to 1938.
drugs which has new drug applications app:coved
between 1938-1962 •
prescription drug ingredients that were used
prior to 1962.
OTC drug ingredients.

NAB/NRC review was criticized because:
a.
b.
c.
d.
e.

reports were too lengthy and ambiguous.
panels met in secret.
panels supposedly composed mainly of "academic
experts" that lacked clinical eJ.);erience.
panels contained too many FDA personnel.
reports were frequently one or two sentences
long.

(?)
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9.

Several issues were raised by the JITAS/NRC revie\>1 that
led to changes in policy within the agency. These
issues included:
a.
b.
c.
d.
e.

10.

A drug is considered adulterated for which of the
folloVIing reasons:
a.

d~

methods used in manufacture do not conform
to Current Good t1anu:facturing Practices.
does not meet compendial standards.
contains ru1y filtb.y substance.
held under ins ani ta:r.y condi t:i.on.s e

·9o

col.Qr additiVe is unsa.fes

b.
c.

11.

the presentation of an unusual hazard with
combination drug products.
the difficulty in the regulation of "generic"
or "me-too's" of approved new drug products.
the need for the restructure of.the Bureau of
Drugs.
the lack of efficacy of about three-fourths
of all over-the-counter drugs reviewed.
the fact that most drugs that were reviewed
were effective.

A dJ~ug is cor1sidered misbre.r;.decl for \vhich of the
following reasons:
a.
b.
c.

if prepared in an urn~eg:i.stered. esi;ab1ishrrwnt<
.the label is false and misleading.
if the drug is dangerous when used in t;he
dosage on the label.
d •. if the drug is an antibiotic or insulin and
has not been certified.
e. if the drug is pr·escription, and the advertising
does not contain the established name, quantit:a.tive ingrediE-•nts, a...'1d a st1mmary of the side
effects, contraindications, and effectivenes$.

(1+).
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A050LUleL~ !RUE! •·
UNDE.~IAilL~ FALSE! .
VNQUE:>110NA6L~ TRUE! •;

;··!'

RSASONA6l.~

----

1RUE!

.

\RREFVTABUI""TRUE' !·'·

UNDSR5i,~NOASL~ FAL5Ef
INTRIN-5iCI\LL~ FAL5Ef
INHERE~TL~ F.~LSE!
CKAR,\\INGL~ TRUE! ·

1.

The FDA has the authority to cite violations of the
ne\'1 drug section of the FDC Act af'ter the drug has
legally come to rest following interstate commerce;
i.e. a physician can be cited bythe FDA for violations of the FDC Act for prescribing a drug for an
indication not included in the labeling.

2.

Prescription drug advertising must be approved by
the FDA prior to publication.

3•. OTC drug advertising is regulated
-·~

. 4.

by

the FDA.

One way in vlhich the OTC drug revie"l-'1 cU.ffers fro:n
the NAS/NRC r·evie>l is that; drug :i.ngredi>mts rather·
th<m drug products are b-:d.ng reviewed.,
DESI is defined as Drug Efficacy Study Implementation
tmd ·is a program designed to impJ.emr~nt the I'(:Womt\\en-·
dations of the OTC drug reviel'l :panels.

6.

- - - 7e
B.

The o~ec drug revi.e\v \vas initiated because· the NAB/NRC
revie\'1 revealed that many OTC drug products v1ere not
effective •
.A double-blind study refers to one in v1hich both the

the patient and the physician do not know wha:t; medi··
cation i.s being administered.
The primary review team for the .review of the informa-.
tion in IND's ~~d riDA's consists of the chemist, medical officer, and microbiologist.
The last step in the approval process for a new drug
application is the approval of the final printed
labeling.

--

10.

If the sponsor of an IND has not received word from
FDA 30 days following the receipt of the IND by the
agency, then the sponsor may begin clinical investigations.
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SHORT ANS\IJER (P.5 points)

1.

Define new drug.

(4 points)

2.

Wb,at is the purpose of the IND?

(3 points)

Describe the three phases involved in the investigation
of a new drug. (6 points)

4.

The r.·esults of a clinical trial should bo <:onrpe.:t.·ed wi.th
a t:;ont:r.ol. Define the following types of control compa:d.sons. (6 points)
placebo:

active treatment:

historical:

5. Define what is considered to be the "drug lag".

(3 points)

(6)
APPENDIX I

6.

FDA has been accused of both overregulation end
unde=eg~.llation.
After reading the article "FDA,
Politics, and the Public", and from '\<ihat you have
learned in class, what, in your opinion, wouldbe
the best description of the agency's performance?
(3 points)
·
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FDA Drug Regulatory Procedu.-res
Exam #3
December 12, 1975
MULTIPLE CHOICE.

· 1.

b.
c.
d.
e.

is a priority situation which may be immediate
or long-range.
is a routine situation with a remote possibil:i.ty
of a threat to life.
is an emergency situation with imminent danger.
example would be defective heart valve. or pacemaker.
example would be broken tablets or leaking capsules.

'l'he dept:t, of the monitoring by the FDA of recalls t
a.
b.
c.
d.
e.
'l~e

can be to distributors, pharmacies and even to
the consmuer level.
depends upon the severit7 of the problem.
is elassifiecl in le·vels to effe{)tively utilize
FDA field personneL
is the same for all classes of recalls.
j_s 100% for Class III recall<.,.

criminal prosecution:
a.
b.
c.
d.
e.

4.

(50 points)

A Class I recall:
a.

2.

Circle All correct answers.

involves prohibiting the firm from manufacturing
its goods.
is a lengthy procedure which is initiated based
upon a firm's record of faulty past performances.
can be instituted against those persons in control
of the firm, e.g. the president, the vicepresident, or the head of quality control.
can be either a misdemeanor or felony depending
upon the severity of the violations.
is the seizing of' adulterated or misbranded goods.

In its survey of marketed drugs, the FDA 1r1ill collect random samples end analyze certain categories. The categories
are determined based upon the following:
a.
b.
c.
d.
e.

impact. of the drug, e.g. low dose-high potency
drugs.
wide use.
therapeutic significance, i.e. life-saving.
date of approval of the NDA.
documented production problem.

(2)
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As defined in the FDA's bioequivalence regulations, the
best (one answer) determination of the bioavailability
o:f'a' drug product is:
a.
b.

c.
d.

6.

measurement of an acute pharmacologic effect
as a f~~ction of time.
measurement of concentration in blood, plasma,
or other body fluid as a function of time.
measurement of safety and efficacy from wellcontrolled clinical trials.
measurement of the in vitro dissolution rates.

I
I

The r1a-x:imum Allowable Cost (MAC) regulations promulgated
by HE\1/:
a.

b.
c.
d.

e\J

designates the price for r-eimbursing products
d:i.spensed under Hedica:i.d and r-~edicare as being
the.i; currently paid by providers in a package
sb;e most frequently purchased.
are ceilings imposedby the federal government
on reimbursement to the pharmacist for produr;ts
dispensed under Hedicaid I:'Xld l'ledicare.
rely upon. the :B'DA to assure that drugs to be
r;i VEoll1 a "filA en e.re b:i.oe,qui valfmt.
contains provisions for single Bom~ce drug
products to have e.n estimated. acqui.s.i tion •:::est.

I
I
I

des:l.gnate ·the prict:; r:;ett;:i.ng structure to be a
conunittee composed of members of l'NA, Al?hA, and.
HAim.

7.

'l:he Freedom of Ini·ormation Act of 1972 was passed by
Congress to "open up" government files to release more
ir.cformation to the public. The· regulations promulgated
by the FDA specify information which can be held as confidentia.l. These include:
a.
b.
c.
d.
e.

manufacturing and quality control procedures in
an approved NDA.
commercial or financia.l information about a firm.
existence of an IND.
personnel or medical files.
summary of safety and effectiveness data in an
approved NilA.

I
1

I
I

(3)
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B.

FDA's Drug Abuse Staff in the Division of
Neuropharmacologic Drug Products works closely with
the Drug Enforcement Agency in the enforcement of
the Controlled Substances Act in which of the follm·ling areas:
a.
b.
c.

restrictions on dispensing.
registration of handlers.
record-keeping.
d.. manufacturing quotas.
e •. determination of what substances should be
controlled.

9.

The Bureau of Biologics differs in its regulation of
b:\.ologics from the Bureau of Drugs' regulation of drugs
in that:
·
a.
b.
c.
d.
e.

10.

biologicals are regulated solely on the basis
of misbranding and adulteration violations.
each of its prQ(lucts mus-e be licensed prior
to marketing.
no prema:rketing clearance is req1.1ired for any
biologic.
all of its products must be ce:Pt:i.fied.
inspections of firms are every tvro years.

Th•,;; FDA's bioequivalence regulations :Cave been criticized
in Congressional hem.'ings in v1hich of the following ways:
a.
b.
·c.

d..

the regulations are worded in such a wa:y so that
it \'Iould appea-r that a large number of' drug
products on the max·ket a-re bioinequivalent.
the regulations are too lenient.
the implementation of the regulations could
lead to the elimination of some of the smaller
i'irms that can not afford to do the tests.
the listing of' the 193 drugs \~ith potential
problems has put doubt into the advisabilit-y
of the repeal of antisubstii..~tion laws.

(4·)
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TRUE-FALSE (3 points ee.ch)

--·

.

1.

The :fi'DA can r.ecall products fi-om the market as
one of the regulatory mechanisms defined in the
Food, Drug 9 and Cosmetic Act.

2.

The procedure of sending regulatory letters l'llas
i:o.i tiated because O'ier 909& of the seizm·e actions

never went to court and the cost of regulation
could thus be decreased.

-- . ·--

A seizure is a civil action taken against the goods,
rather than the firm of personnel.
LJ..

- ....._ 5.
____
:.

.,.......

All antibiotics e.nd insulin must be batch certified

by the FDA prior to marketing.

6.

Only a.bout 1% of 1;he batcbes of antibiotics teiJted
are rejected.

7c

·The FDA handles th0 support of the activities of
poiso11 control ce:ti.ters through its national
Clearinghouse for Poison Control.

'

---

The injunction action is t:olll:en ~1hen inspe.ctionul
reports indicate the firm has a history o:f v:i.ols.tions of the F.D.&C. Act.

8.

Prior to 1972, the FDA did not have the authority
to require producers of cb:·ugs to supply the agency
with a J.ist of those drugs ma.nillactured.
!"lethadone is the first drug. to have a limited distribution requirement set by the FDA.
The l~f.cx:imum Allovmble Cost regulations allow each
state to determil1B the dispensing fee for Medicaid
and Medicare drugs based upon periodic surveys of
pha-rmacy operating costs.

___ 11.

12.

_ _ 13.

~~e average time interval between FDA inspections of
.food firms, according to om' guest speaker, is about
five yee.J~s.

The regulations o:f medical devices and diagnostic
products is based upon the adulteration, misbranding,
and premarlcet cleara~ce provisions of the F.D.&C. Act.
Biological products are regulated by FDA under the
authority of the Public Health Service Act.

I

i

(5)
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SHO..Ti.T ANSWF-R

1. Define injunction.

(3 points)

2.

Describe the drug product defect reporting system.
(5 points)

:;.

Senator Kennedy has introduced legislation that ,,muld
split the I!'DA :i.nto t11lo separate agencies: Drugs and
Devices, and Food and Cosmetics. With all of the regu·latory respon.sibilities of the agency (i.e. jurisdj_ction
over biologicals, radiologicalst foodr:;, drugs, cosmeticr:;,
medical devices and diagnostics), do you feel this is a
good recommendation?
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